
Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Vaccine Utilisation and Prioritisation Sub Group #1 Teleconference 9:30 – 10:30am

15 September 2020

Outcomes



4. Brief Introductions

Members:

NOTED introductions

5. Brief overview of support from NCIRS

Members:

• NOTED NCIRS continued contribution to Sub Group

6. Prioritisation matrix and preliminary advice document

Action:		
Action	Responsible officer/s	Progress
6.1 Update and finalise ATAGI	* Sub Group Members	Complete
COVID Vaccine Preliminary	* NCIRS	
Advice document and	* Co-chairs	
Prioritisation Matrix in line		
with the Preliminary COVID-19		
vaccination priority groups		
Review and edit preliminary		
advice document		
List prioritisation principles		
with no reference to		
ranking		
Remove colour coding.		
Map cohorts to the		
prioritisation principles		
 Insert caveat for all 		
principles where		
information is not available		

7. Meeting Closed: 10.45am

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Vaccine Utilisation and Prioritisation Sub Group Meeting #2

Teleconference 9:00 - 10:00am 22 September 2020 Outcomes

In attendance: Members

Katie Flanagan Bette Lieu Chris Blyth **Tom Snelling** Jodie McVernon Angus Dawson Kanta Subbarao

NCIRS Technical staff s11C

Department of Health representatives

s47Ė(c), s47F

1. Meeting Opened

- Members:

2. Welcome and Apologies General committee business

- Members:
- ...ed Acknowledgement of Country Apologies/General committer DED attendees aport CLARED confile TED christ NOTED Christine Selvey would join the Subgroup subject to confidentiality form

3. Prioritisation matrix and preliminary advice document - summary and future planning

Members:

- DISCUSSED the prioritisation and preliminary advice document •
- DISCUSSED the Subgroup's overarching strategy and planning for different scenarios
- NOTED the need for further expertise such as data modelling

Action	Responsible of	fficer/s	Progress
3.1 Gather data on numbers of	NCIRS		In progress
aged care workers, health care			
workers and people in at-risk			
occupations in states/territories			
to guide decision making			
3.2 Develop a request for	s47F	in consultation	In progress
consideration by the Taskforce	with members		

outlining key input and	
expertise required by this	
Subgroup	

4. Information needed from NCIRS

Members:

- NOTED NCIRS is gathering information on at-risk groups, including local data •
- NOTED the National Incident Room (NIR) has useful state and territory data •

Action	Responsible officer/s	Progress
4.1 Circulate data on at-risk groups to members	NCIRS	In progress
4.2 Gather data on specific populations to understand the landscape	NCIRS	In progress
4.3 Contact NIR and request presentation on latest data eg NSW data on health care workers and VIC data	Secretariat in consultation with s47F	In progress

5. Astra Zeneca ChAdOx1/AZD1222 and UQ Molecular Clamp vaccines

Members:

•

- NOTED AstraZeneca will be meeting with the Working Group Executive shortly •
 - NOTED a list of questions for AstraZeneca has been developed by NCIRS $\mathcal{O} \cdot \mathcal{O}$.

Action	Responsible officer/s	Progress	
5.1 Circulate questions for AstraZeneca to members for	Secretariat	Completed	
comment			

6. Other Business

Action	Responsible officer/s	Progress
5.1 Prepare a su	ummary/list of \$11C	In progress
documents und	er development	
by NCIRS for th	e sharepoint site	
to assist with tr		
identifying gaps		

7. Meeting frequency / times

Members:

- NOTED meetings to be held weekly on Tuesday at 3.30pm (no meeting next week) •
- NOTED videoconferences would be arranged for future meetings

8. Meeting Closed: 10.00am approx

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Vaccine Utilisation and Prioritisation Sub Group Meeting #3

Teleconference 3.30-4.30pm 6 October 2020 Outcomes

In attendance: Members Katie Flanagan (Lead) Chris Blyth Jodie McVernon Angus Dawson Kanta Subbarao s11C res released under care David Durrheim Christine Selvey (part meeting) **NCIRS** Technical staff s11C **Department of Health representatives** s47E(c), s47F Secretariat s22 1. Meeting Opened Members: NOTED the Acknowledgement to Country 2. Welcome and Apologies General committee business Members:

- NOTED attendees and apologies (Bette Lieu, Tom Snelling, Penny Burns, Christopher Etherton-Beer, James Wood)
- DECLARED conflicts of interest Nil

3. Outcomes from previous meeting

Members:

- ENDORSED outcomes from the previous meeting on 22 September 2020
- NOTED the meeting to be held with AstraZeneca on 20 October 2020 involving ATAGI members, NCIRS and Departmental staff

4. Update from Executive Team meeting

Members:

- NOTED the Executive Team would consider and endorse Subgroup papers
- DISCUSSED a proposal to publish names of Subgroup members for transparency and to demonstrate diversity and expertise in informing decisions, with any objections to be raised through the Secretariat or Subgroup Lead

5. National data on COVID-19 infections

Members:

- NOTED a presentation on the *Epidemiology of COVID-19 in Australia* by Dr Martyn Kirk, Senior Epidemiologist, National Incident Room (NIR) including question and answer session
- DISCUSSED key issues and need for further data from the NIR going forward

Action	Responsible officer/s	Progress
5 Provide further questions and	Members/Martyn Kirk	Completed
answers following meeting		

6. Prioritisation framework and ATAGI preliminary advice-revisions

Members:

- DISCUSSED further work undertaken by NCIRS using the US National Academy of Sciences approach to revise the prioritisation matrix (adaptation of tables):
 - Table1 Allocating priority phases using risk-based criteria
 - Table 2 Application to potential scenarios
- AGREED this provides an improved framework, roting further work is needed
- AGREED that the overarching aims/objectives/goals of the COVID-19 vaccination program need to be defined to assist with scenario based planning and modelling
- AGREED to continue Subgroup discussions by email
- NOTED this work needs to be finalised for the Taskforce by the end of October 2020

			Progress
6.1 Further discussion to define	Secretariat		Completed – on Executive
aims of program			meeting agenda for 9/10
6.2 Summarise issues and	s47F	and members	In progress
continue discussion by email			
6.3 Complete prioritisation	Members and	NCIRS	In progress
framework by 30 October			

7. Other Business

Action	Responsible officer/s	Progress
7 Place all Subgroup agenda	Secretariat	In progress
papers on Sharepoint		

8. Meeting Closed: 4.55pm

ATAGI COVID Working Group Subgroup 1, Meeting No. 4 Tuesday 13 October 2020, 3.30pm- 4.30pm

In attendance:

Members	NCIRS Technical Staff	Department of Health
Katie Flanagan - Lead	s11C	s47E(c), s47F
Bette Lieu		
Chris Blyth		
Tom Snelling		Secretariat
Jodie McVernon		\sim
David Durrheim		s22
Angus Dawson		
Kanta Subbarao		
James Wood		
Christine Selvey		
James Ward		
s11C		
SharePoint Link		

1. Welcome and apologies / general committee business Members:

- NOTED acknowledgement to country •
- NOTED attendees and apologies (Penny Burns, Christopher Etherton-Beer) •
- Introductions (new members James Wood, James Ward) • stic
- Declared no conflicts of interest •

2. Outcomes and actions from previous meeting

ENDORSED outcomes and actions from previous meeting with no amendments •

3. Update from Executive Team meeting Members:

- pagreed to publish member names on the website subject to NOTED the Executive Gro • written consent
- ion sharing meeting for ATAGI subgroups will be held in early NOTED a half day informat • November 2020

Action	Responsible officer/s	Progress
3 Seek confirmation from members to	Secretariat	Completed
publish names on website		

4. Program Aims and Objectives

Members:

ENDORSED the following program goal: The Australian COVID-19 vaccination program has the overarching goal of protecting all people in Australia from the harm caused by the novel coronavirus SARS-CoV-2

5. Decision Framework

Members:

DISCUSSED s47F presentation on a quantitative approach to decision making • to underpin transparency and equity and noted the role of values in decision making

ATAGI COVID Working Group Subgroup 1, Meeting No. 4 Tuesday 13 October 2020, 3.30pm- 4.30pm

6. Prioritisation framework and ATAGI preliminary advice - revisions

Members:

- NOTED the initial preliminary advice on priority populations prepared shortly after establishment of Subgroup 1 requires further work and needs to be finalised to the satisfaction of members (noting a version of this may be published at a later date)
- DISCUSSED the revised prioritisation framework, in particular the aims/objectives and the priority population tables
- AGREED to focus on refining aims and provide comments on both documents for endorsement as a package at the next meeting

Action	Responsible of	ficer/s	Progress
6.1 Provide comments via email or	Members		In progress
Sharepoint on preliminary advice			
document by Friday 16/9 and prioritisation			
framework by Monday 19/10		4	
6.2 Collate comments and provide revised	s47F	and	In progress
documents for next meeting	s47F		
framework by Monday 19/10 6.2 Collate comments and provide revised documents for next meeting No other business Meeting closed at 4.40pm Meeting closed at 4.40pm		ed	Sed Co
Meeting closed at 4.40pm	200	46 3	
		2 allo	
	ee' ilo'	Nr.	
_0			
NS.	KON KY		
	10, 40,		
ne. of	offic .		
CUI M X	n		
90° 90° 31	~		
is to over			
He He			
6			
\$ *			

ATAGI COVID Working Group Subgroup 1, Meeting No. 5 Tuesday 20 October 2020, 2-3pm

In attendance:

Members	NCIRS Technical Staff	Department of Health
Katie Flanagan - Lead	s11C	Secretariat
Bette Lieu		
Chris Blyth		s22
Tom Snelling		
Jodie McVernon		
David Durrheim		
Angus Dawson		
James Wood		
James Ward		
s11C		
Penny Burns		
SharePoint Link		

- 1. Welcome and apologies / general committee business
 - Members:
 - NOTED acknowledgement to country
- NOTED attendees and apologies (Kanta Subbarao, Christopher Etherton-Beer, Christine Selvey)
 Introductions (new members Penny Burns)
 Declared no conflicts of interest

 2. Outcomes and actions from previous meeting at the selver of the selver

comes and actions from previous meeting ENDORSED outcomes and actions from previous meeting with no amendments •

3. Update from Executive Team meeting

Members:

- NOTED a half day information sharing meeting for ATAGI subgroups will be held on • 10 November 2020 from 1-5pm ?
- NOTED the Executive ream agreed to invite a health economist to join this group • (Professor Kirsten Howard)
- NOTED the Executive Team will meet with AstraZeneca on 20 October and Seqirus on • 22 October

4. Preliminary advice on vaccine priority groups - revisions

Members:

- DISCUSSED proposed revisions to the ATAGI Preliminary advice COVID vaccine priority • groups including:
 - Amend language around prioritisation of health care workers
 - Remove 'phases' and 'mitigating factors' from the table at this stage
 - Split age groups with further refinement possible in future 0
 - Insert caveat around low, medium and high risk definitions 0
 - o Add Aboriginal and Torres Strait Islander peoples in remote areas to the text
 - Add Aboriginal and Torres Strait Islander children to the table 0
 - Include low socioeconomic status and culturally and linguistically diverse 0 communities given association with increased risk of adverse outcomes
 - Remove appendix and provide link instead 0

ATAGI COVID Working Group Subgroup 1, Meeting No. 5 Tuesday 20 October 2020, 2-3pm

- AGREED that NCIRS and **s47F** would make changes to the document as discussed and finalise within 24 hours
- ENDORSED the document with agreed changes

Action	Responsible officer/s	Progress
4.1 Amend and finalise preliminary advice	NCIRS and s47F	Completed 21/10/20
document		
4.2 Submit to Taskforce following Co-Chair	Secretariat	Completed 21/10/20
Executive endorsement		

5. Revised preliminary advice on suitability of the AstraZeneca vaccine for possible priority populations

Members:

• ENDORSED the document with no changes

Action	Responsible officer/s	Progress
5 Submit to Taskforce following	Secretariat	In progress
endorsement by Executive		

6. Next steps

Members:

- DISCUSSED the need for further information to inform decision making and development of epidemiological scenarios
- AGREED to invite a representative from the Department's data modelling team to present at the next meeting
- AGREED to use the next meeting as a brainstorming session to identify data and information needed and scenarios

Action	Responsible officer/s	Progress
Invite Department's data modellers to provide a half hour presentation on data modelling relevant to this group	Secretariat	In progress

7. Other business

Members:

- AGREED to invite a representative from the TGA to present at a high level on the provisional registration approval pathway
- NOTED that a presentation by S47F on ethical considerations would be useful at a future meeting
- DISCUSSED confidentiality arrangements associated with membership of this Subgroup and interactions with other committees

Action		Responsible officer/s	Progress
Invite TGA representati	ive to present on	Secretariat	In progress
TGA approval process			
Liaise with S47F	regarding sharing	Secretariat	Completed
of information with the COVID-19			
Aboriginal Taskforce			

Meeting closed at approx. 3pm

ATAGI COVID Working Group Subgroup 1, Meeting No. 6 Tuesday, 27 October 2020, 3:30 – 4:30pm

In attendance:

Members	NCIRS Technical Staff	Department of Health
Katie Flanagan – Lead	s11C	s47E(c), s47F
Chris Blyth		Sarah Sinclair
Jodie McVernon		s47E(c), s47F
Angus Dawson		
Kanta Subbarao		
s11C		
Tom Snelling		Secretariat
Bette Lieu		$\sim \sim $
James Wood		S22
Penny Burns		-
Kirsten Howard		
SharePoint Link	·	•

1. Welcome and apologies / general committee business

Members:

- NOTED acknowledgement to country •
- NOTED attendees and apologies (Christopher Etherton-Beer and David Durrheim)
 Introductions (new member Kirsten Howard)
 Declared no conflicts of interest

 2. Outcomes and Actions from previous meeting

Members ENDORSED outcomes and actions from previous meeting with no amendments •

3. Update from Executive Team meeting

Members:

- 0 NOTED that the Executive Team encorsed two papers developed by Subgroup 1:
 - Preliminary advice on vaccine priority groups; 0
 - Revised preliminary advice on suitability of AZ vaccine for possible priority 0 populations

4. Data modelling

- Allyson Essex (Health Economics & Modelling Branch) presented on economic modelling • work undertaken by the Department's Health Economics and Research Division (HERD). Members:
- NOTED key points including:
 - Two models: economic cost model and vaccine distribution model;
 - The models are designed to "talk to each other" and inform each other's inputs and outputs;
 - The models allow selection of various efficacy scenarios as data becomes available; 0
 - An epidemiological model has not yet been developed, however could be built; and 0
 - Additional materials may be provided including specifications and metadata. 0
- NOTED it would be useful for Allyson to review this Subgroup's advice on priority populations.

ATAGI COVID Working Group Subgroup 1, Meeting No. 6 Tuesday, 27 October 2020, 3:30 – 4:30pm

Action	Responsible officer/s	Progress
4.1 Allyson Essex to consider further	Allyson Essex	In progress
information to be provided to Subgroup 1		
and liaise with members on data modelling		
work, including feasibility of sandpit		
approach		

5. Data modelling and scenarios

Members

- DISCUSSED:
 - Gaps and concerns about the current models, particularly the lack of health outcomes data and transmission data incorporated in the current models, epidemiological parameters and equity issues;
 - Models developed early in the pandemic by other Government departments that may be worth considering;
 - o Overarching program objectives and how these are defined; and
 - The importance of shared objectives and working with Departmental modellers to achieve the best outcome for the program.
- AGREED to:
 - Offer to review the models (S47F
 -) and provide feedback to Subgroup 1
 - Discuss again at the next Subgroup 1 meeting;
 - Prepare a brief paper on gaps and recommendations for further modelling work.

Action	Responsible officer/s	Progress
5.1 Email Allyson Essex outlining	s47F	Completed
Subgroup's thinking and offering to	40 4X	
collaborate and provide input	10, *0,	
5.2 Continue discussions at Executive	Secretariat	In progress
meeting and Subgroup 1 meetings		
5.3 Prepare brief paper on data modelling	Subgroup 1/ NCIRS	To progress
requirements		
	-	•

6. Other business

Members:

• NOTED meetings held with AstraZeneca and Seqirus.

Meeting closed at 4:33pm.

ATAGI COVID Working Group Subgroup 1, Meeting No. 7 Tuesday, 3 November 2020, 3:30 – 4:30pm

In attendance:

Members	NCIRS Technical Staff	Department of Health
Katie Flanagan – Lead	s11C	s47E(c), s47F
Chris Blyth		
Angus Dawson		
Kanta Subbarao		Secretariat
s11C		-
Tom Snelling		s22
Bette Liu		
James Wood		
Penny Burns		
Kirsten Howard		
Christopher Etherton-Beer		
SharePoint Link		

- 1. Welcome and apologies / general committee business
 - Members:
 - NOTED acknowledgement to country •
 - NOTED attendees and apologies (James Ward, Jodie McVernon and Christine Selvey) •
 - Declared no conflicts of interest •

2. Outcomes and Actions from previous meeting

- actions from previous meeting with no amendments Members ENDORSED outcomes and actions
- 3. Update from Executive Team meeting?

Members

- NOTED: •
 - Two papers (Multidose vials and AIR issues) developed by Subgroup 2 endorsed by 0 the Executive Team;
 - Discussion about the addition of a chapter on COVID-19 vaccination in the Australian 0 Immunisation Handbook;
 - Commonwealth's preference for centralised approach on the vaccine rollout. 0

4. NCIRS update

- provided update on the progress of documents NCIRS s47F and s47 are working on:
 - Comparison table: Key findings of reactogenicity and safety results;
 - Comparison table: Key findings of immunogenicity results;
 - Table (spreadsheet) of major inclusion and exclusion criteria of clinical trials; 0
 - Template for summarising key characteristics and clinical trials of an individual 0 COVID-19 vaccine candidate; and
 - Analysis and technical summaries of at-risk groups. 0
- NCIRS are in the process of securing four key COVID-19 data sets to inform their work.

5. Review of data modelling and scenarios

- Members
- NOTED:
 - Ongoing liaison with Allyson Essex on data modelling;

ATAGI COVID Working Group Subgroup 1, Meeting No. 7 Tuesday, 3 November 2020, 3:30 – 4:30pm

- Meeting on 5 November 2020 with representatives of Subgroup 1 to discuss COVID-19 data modelling with Allyson Essex and team.
- DISCUSSED SAGE modelling and its relevance to the group's work and strategy
- DISCUSSED the need for a transmission data model with health outcomes developed by experienced infectious diseases health outcomes modellers
- AGREED to:
 - Send modellers' "wish list" to S47F by 9 November 2020, for discussion at the next meeting;
 - Organise a modelling sandpit session with Allyson Essex;
 - Provide modelling requirements and advice to SG Lead, to help inform the brief paper on data modelling.

Action	Responsible officer/s	Progress
5.1 Provide Allyson Essex with the group's	Secretariat	Completed
prioritisation document as pre-meeting		
reading	~	
5.2 Organise modelling sandpit session	Secretariat	To progress
with Allyson Essex		$\mathcal{C}^{\mathcal{D}}$
6. Other business Nil.	elegeed of	Sec.
5.2 Organise modelling sandpit session with Allyson Essex 6. Other business Nil. Meeting closed at 4:37pm. Meeting closed at 4:37pm.	been ion that are	

ATAGI COVID Working Group Subgroup 1, Meeting No. 8 Tuesday, 17 November 2020, 3:30 – 4:30pm

In attendance:

Members	NCIRS Technical Staff	Department of Health
Katie Flanagan – Lead	s11C	Secretariat
Angus Dawson		s22
Kanta Subbarao		322
Tom Snelling		
Bette Liu		
James Wood		
James Ward		
Penny Burns		
Kirsten Howard		
Jodie McVernon		
David Durrheim		
Chris Blyth		
Chris Etherton-Beer		
SharePoint Link		ď
Chris Etherton-Beer		

- 1. Welcome and apologies / general committee business Members:
 - NOTED acknowledgement to country •
 - NOTED attendees and apologies \$11C •
- 1011-N982 ged Care NOTED that Christine Selvey is not able to attend meetings and a replacement CDNA ٠ ation it a representative has been arranged
 - Declared no conflicts of interest •
- Outcomes and Actions from previous meeting
 - Members ENDORSED outcomes and actions from previous meeting with no amendments

3. Update from Executive Team meeting

- Members:
- mbers: NOTED two documents recently published
 - ATAGI advice on COVID-19 vaccination prioritisation 0 https://www.wealth.gov.au/news/health-alerts/novel-coronavirus-2019-ncovhealth-alert vaccines-and-treatments/covid-19-vaccination-prioritisation
 - Australia's COVID-19 Vaccination Policy https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncovhealth-alert/vaccines-and-treatments/australias-covid-19-vaccination-policy

Katie Flanagan thanked members for their contribution to the prioritisation work which will need to be refined as more information becomes available

Members:

NOTED TGA had provided an update to the Executive Team and would be invited to attend the next Subgroup 1 meeting

Action	Responsible officer/s	Progress
Invite TGA to update at next SG1 meeting	Secretariat	Complete

ATAGI COVID Working Group Subgroup 1, Meeting No. 8 Tuesday, 17 November 2020, 3:30 – 4:30pm

4. NCIRS update

s47F provided an update from NCIRS including work in progress to summarise vaccine data and to identify data modelling requirements.

5. Issues from information session 10 November

Members:

- AGREED the session was critical for information sharing to identify gaps and avoid duplication
- NOTED the next information sharing session is scheduled for 15 December •

6. Review of data modelling and scenarios

Members NOTED:

- relevant Subgroup 1 members met with the Department's data modelling branch this week • and are working collaboratively on data modelling issues and recommendations
- the Department's existing data models do not address transmission or various • epidemiological scenarios to assist with determining priorities and are too simplistic in terms of risk groups and vaccine coverage
- input from Subgroups 2 (implementation) and 3 (vaccine acceptance) would be valuable •
- a paper with Advice to the Department of Health on recommended additional • modelling relating to the COVID-19 vaccination program strategy has been prepared for consideration at this week's Executive Team meeting

Action	Responsible officer/s	Progress
All interested SG1 members to review modelling advice and provide edits and comments by Wednesday morning	SG1er of all all all all all all all all all al	Complete
Submit data modelling recommendations	NCIRS/Secretariat	In progress
to Executive Group for consideration	(C, [*] O,	
7. Other business Nil Meeting closed approx. 4pm the Depart	mei	

ATAGI COVID Working Group Subgroup 1, Meeting No. 9 Tuesday, 24 November 2020, 3:30 - 4:30pm

In attendance:

Members	NCIRS Technical Staff	ff Department of Health	
Katie Flanagan – Lead	s11C	s47E(c), s47F	
Chris Blyth			
Angus Dawson		Secretariat	
s11C		s22	
Tom Snelling		322	
Bette Liu			
James Wood			
James Ward			
Penny Burns			
Kirsten Howard			
Jodie McVernon			
David Durrheim			
SharePoint Link			

1. Welcome and apologies / general committee business Members:

- NOTED acknowledgement to country •
- NOTED attendees and apologies (Kanta Subbarao and Christopher Etherton-Beer)
 New member (S11C)
 Declared no conflicts of interest
 Outcomes and Actions from previous meeting in the formation of the second secon

comes and Actions from previous meeting Members ENDORSED outcomes and actions from previous meeting with no amendments

3. TGA update

- (TGA) provided an update including: s47E(c), s47F
 - provisional registration approval process 0
 - provisional determination approvals to Janssen, AstraZeneca and Pfizer 0
 - close liaison with international regulatory authorities such as Access Consortium, 0 including considerations around using an international harmonised label
 - evaluation process for applications including risk/benefit analysis 0

Members NOTED:

- challenges in determining timelines for granting full registration •
- complexities in evaluation processes
- fortnightly TGA update at Executive Team meeting

4. Update from Executive Team meeting

Members:

- NOTED that the advice on data modelling has been provided to the Taskforce for • consideration
- AGREED to continue to advocate for data modelling requirements

5. Key Vaccine Scoping Progress and WG1 Future Directions

Members:

- NOTED three documents that NCIRS are currently working on: •
 - Immunogenicity comparison table for AZD1222, BNT162b2 & NVX-CoV2373 0

ATAGI COVID Working Group Subgroup 1, Meeting No. 9 Tuesday, 24 November 2020, 3:30 - 4:30pm

- Reactogenicity & safety comparison table for AZD1222, BNT162b2 & NVX-CoV2373 0
- Summary of major inclusion and exclusion criteria of clinical trials for COVID-19 vaccine candidates
- AGREED to review the documents and discuss again at the next meeting •
- DISCUSSED what the subgroup's priorities should be and considered:
 - prioritisation matrix 0
 - decision tree influenced by practical aspects (equitable, acceptable, ethical and robust) 0
 - o scenario planning
 - o importance of understanding what end products the subgroup is producing
 - identifying outward-facing documents
 - a package/strategy or playbook approach

6. NCIRS Update

s47F provided an update on current work including comparing the three key vaccine candidates.

Members AGREED that NCIRS could prepare a 'deep dive' into the Oxford vaccine for discussion at the next meeting.

Action	Responsible officer/s	Progress		
Prepare a detailed presentation on the Oxford Vaccine for discussion at the next meeting	NCIRS CONTRACTOR	To progress		

7. Other business

Members:

- mbers: DISCUSSED whether ATAGI needs to make formal advice on vaccination requirements when • travelling
- NOTED the Vaccination Policy statement that there may be circumstances where the • Australian Government and other governments may introduce border entry or re-entry requirements that are conditional on proof of vaccination

Meeting closed approx. 4:40pm

ATAGI COVID Working Group Subgroup 1, Meeting No. 10 Tuesday, 1 December 2020, 4-5pm

In attendance:

Members	NCIRS Technical Staff	Department of Health
Katie Flanagan – Lead	s11C	Secretariat
Angus Dawson		~ 0.0
s11C		s22
Tom Snelling		-
Bette Liu		
James Wood		
Penny Burns		
Jodie McVernon		
David Durrheim		
s11C		
Kanta Subbarao		
SharePoint Link		

- 1. Welcome and apologies / general committee business Members:
 - NOTED acknowledgement to country •
 - NOTED attendees, apologies (Kirsten Howard, Christopher Etherton-Beer, Chris Blyth) and welcomed new member (S11C) Declared no conflicts of interest tcomes and Actions from previous meeting Members ENDORSED outcomes and actions from previous meeting with no amendments •

2. Outcomes and Actions from previous meeting

3. Update from Executive Team meeting

Members NOTED:

- er. Subgroup 1's advice on data modelling is being considered by the Department •
- useful documents available on Sharepoint •
- recent meeting with Jurisdictional Immunisation Coordinators and ATAGI Subgroup leads •
- Dr Richard Kidd to join Subgroup 1 due to his expertise (not as a representative of the Australian Medical Association)

4. Prioritisation

Members DISCUSSED:

- correspondence from the Australian and New Zealand Transplantation Society •
- laboratory staff working with COVID-19 •
- essential workers identifying who they are and numbers, noting that NCIRS has done some • preliminary work on this
- the level of granularity required for priority population groups, which is dependent on the • level of evidence available

Members AGREED to consider further prioritisation subject to advice from the Executive Team.

Action	Responsible	Status
Upload NCIRS draft document re critical	NCIRS	In progress
workers on Sharepoint		

ATAGI COVID Working Group Subgroup 1, Meeting No. 10 Tuesday, 1 December 2020, 4-5pm

5. Ring fencing

Members DISCUSSED ring fencing, noting that:

- information is needed to establish whether or not the vaccine blocks infection •
- community expectations will need to be managed regarding vaccine availability

6. Meeting with Seqirus

Members were advised that the Executive Team had met with representatives from Segirus today to receive feedback on phase 1 data and noted confidentiality requirements of these meetings.

7. Vaccine deep dive - Oxford/AstraZeneca

NCIRS provided an overview of the Oxford vaccine deep dive, noting:

- it provides a summary of the study protocols
- this is a living document and will be revised when more data becomes available •
- published data is expected shortly
- the Subgroup will consider the Oxford vaccine again at the next meeting along with the • Pfizer vaccine

8. Other business

Members discussed meeting arrangements over the December/Japuary holiday period, noting that

and Christopher Etherton-Beer)

ATAGI COVID Working Group Subgroup 1, Meeting No. 11 Tuesday, 8 December 2020, 3:30-4:30pm

In attendance:

Members	NCIRS Technical S	taff	Department of Health
Katie Flanagan – Lead	s11C		s47E(c), s47F
Chris Blyth			
Kirsten Howard			
Angus Dawson			Secretariat
s11C			s22
Tom Snelling			322
Bette Liu			
James Wood			
Penny Burns			
Jodie McVernon			
David Durrheim			
Kanta Subbarao			
SharePoint Link			

1. Welcome and apologies / general committee business Members:

- NOTED acknowledgement to country •
- NOTED attendees and apologies (s11C •
- Declared no conflicts of interest

2. Outcomes and Actions from previous meeting

- tcomes and Actions from previous meeting Members ENDORSED outcomes and actions from previous meeting with no amendments inforr
- 3. Update from Executive Team meeting Members NOTED:
 - Further discussions on data modelling underway within the Department **Drity populations** More granulative mhers DISCUSSED •

4. Priority populations X

- Members DISCUSSED
- Strategies to reduce risk and protect the vulnerable in the absence of community • transmission, including border protection (ports of entry and border workers) alongside hospitals and health workers
- Vaccination as part of a package of risk mitigation strategies and interventions, including • testing
- An holistic approach covering people with multiple jobs or interactions eg aged care and • border protection
- High mortality rate in aged care settings •
- Advice from the Taskforce about further granularity required for priority populations •
- The need to define principals to assist with categorising essential workers and provide • examples for each category

Action	Responsible	Status
Provide a more detailed breakdown of priority	NCIRS/Subgroup 1	In progress
populations and staged rollout by month or quarter		
according to predicted vaccine doses available		

ATAGI COVID Working Group Subgroup 1, Meeting No. 11 Tuesday, 8 December 2020, 3:30-4:30pm

5. COVID-19 and flu vaccines

Members DISCUSSED:

- Preference for COVID-19 and flu vaccines to be administered separately and logistical • difficulties of implementing two programs
- The need for clear advice and directives for Government on what is safe and effective
 - Documenting different scenarios and core recommendations
 - Intersection between the three ATAGI subgroups, including communications
- Theoretical risk of vaccine co-administration including: •
 - Reduced immunogenicity
 - Potential higher rate of adverse events 0
- Suggested two week gap between Pfizer and flu vaccines and the need to validate this administration interval
- Systems already in place for flu vaccination and changes underway to introduce mandatory • reporting to the AIR
- Maximising the AIR to check vaccination history and send reminders for the second dose Members AGREED:
- To document different scenarios that could arise from vaccine co-administration and recommendations 0 20

Action	Responsible	Status
Recommend how next year's flu vaccine program	NCIRS	To progress
will interface with COVID vaccine rollout	ar all	

6. Vaccine deep dive

Vaccine deep dive • Oxford/AstraZeneca • Pfizer Members NOTED overview of the Pfizer vaccine including:

• Storage requirements, adverse reactions and contraindications

Action	Responsible	Status
Add questions for meeting with Pfizer on:	NCIRS/ Secretariat	To progress
 One dose efficacy, confidence levels and 		
correlates of protection		
 Any emerging data on people who have had 		
COVID-19		

7. Other business

- Next meeting 14 December at 4pm •
- Half day information session 15 December, with James Wood to lead for Subgroup 1

Meeting closed 4:40pm

ATAGI COVID Working Group Subgroup 1, Meeting No. 12 Monday, 14 December 2020, 4:00-5:00pm

In attendance:

Members	NCIRS Technical St	aff	Department of Health
Katie Flanagan – Lead	s11C		s47E(c), s47F
Chris Blyth			
Jodie McVernon			Darius Everett
Angus Dawson			s47E(c), s47F
Kanta Subbarao			
s11C			Secretariat
James Ward			s22
Bette Liu			322
James Wood			
Kirsten Howard			
Christopher Etherton-Beer			
s11C			
Richard Kidd			
SharePoint Link			4

- Welcome and apologies / general committee business Members NOTED:

 Acknowledgement to country
 Apologies (Tom Snelling)
 New member (Dr Richard Kidd)
 Declared no conflicts of interest

 Outcomes and Actions from previous meeting

 Members ENDORSED outcomes and actions from previous meeting with no amendments
- 3. Update from ATAGI 78th meeting Members NOTED:
 - mbers NOTED: That the subgroup leads provide an update at the ATAGI 78th meeting on • 11 December 2020
- 4. Priority populations further granularity
 - More granularity •

Members DISCUSSED the draft supplementary advice on the phased allocation of vaccine doses to priority groups. Key points NOTED:

- The quarterly phases of the vaccination rollout may be too long and a shorter time frame • such as a month by month phase then working through different age groups may be more suitable
- The need to define who is first among the first with overlay of practicality
- Who will get lower efficacy vaccines?
- The need to further nuance the age groups specifically the 18 to 64 year old individuals with certain underlying conditions
- As a whole, adult Aboriginal and Torres Strait Islander people will be considered a priority population
- Concerns for cleaners and maritime and flight crews and whether they should be considered as priority populations

ATAGI COVID Working Group Subgroup 1, Meeting No. 12 Monday, 14 December 2020, 4:00-5:00pm

- The need to consider data (from Melbourne) to rationalise addition of general practitioners ٠ to the priority population groups
- South Australia has data on number of quarantined people and can serve as a case study •
- Addition of children in phase three of rollout and the need for more data to support this ٠
- Explore evidence behind clinical risk group, severe mental illness •
- The need to discuss logistics and delivery issues with subgroup 2 •
- Department to provide jurisdictional data on priority population numbers to subgroup 1 •

Action	Responsible	Status
Provide a more nuanced prioritisation and month by	Subgroup 1/NCIRS	In progress
month phase by number of available doses		
Discuss logistics and delivery issues with subgroup 2	Subgroup 1	In progress
Finalise documents that detail/map at risk groups	NCIRS	In progress
Provide jurisdictional data on priority population	s47E(c) . s47F	In progress
numbers to subgroup 1	/Secretariat	
 5. Flu and COVID-19 vaccine co-administration Members AGREED: That advice will be provided at a later date whi 6. NCIRS update Nil. Meeting closed 5pm This document of the provided at a later date whi The the provided at a later date whi 	le group is focused on pri	oritisation
6. NCIRS update	P no	
Nil.		
De ati		
Meeting closed 5pm	NO.	
Ine or cert		

5. Flu and COVID-19 vaccine co-administration Members AGREED:

6. NCIRS update

ATAGI COVID Working Group Subgroup 1, Meeting No. 13 Monday, 22 December 2020, 3.30-4:30pm

In attendance:

Members	NCIRS Technical St	taff	Department of	Health
Katie Flanagan – Lead	s11C		s47E(c), s47F	
Allen Cheng			Darius Everett	
Jodie McVernon			s47E(c), s47F	
Kanta Subbarao				
s11C				
David Durrheim			Secretariat	
Bette Liu			s22	
Penny Burns				
Kirsten Howard				
Tom Snelling				
Richard Kidd				
SharePoint Link				

- 1. Welcome and apologies / general committee business
 - Members NOTED:
 - Acknowledgement to country
 - Apologies (Chris Blyth, James Ward, James Wood, s11C
 - Christopher Etherton-Beer is unable to attend meetings in 2021
 - Declared no conflicts of interest

2. Outcomes and Actions from previous meeting (14 December)

- Members ENDORSED outcomes from the previous meeting with no amendments
- Members NOTED:
 - Model of the second seco
 - A smaller group has met to progress the prioritisation work
- 3. Priority populations further granularity

Members DISCUSSED the graft documents on SharePoint:

- ATAGI priority vaccine allocation supplementary advice v5.2 21Dec2020
- COVID-19 vaccine allocation prioritisation worksheet v2.2 21Dec2020

Members NOTED key points including:

- Principles and aims are important to re-state
- The epidemiological scenario can change and impact on the strategy
- Groups should be shown in priority order
- Advice to be categorical but not too prescriptive, allowing some flexibility for jurisdictions
- Discussion of risk levels for GPs, nurses and other staff
- Focus needs to be on settings rather than roles/professions
- Exposure at borders/ports (maritime and air) and who has responsibility
- Stratify elderly adults, starting at over 80 years and working down by decade
- Risk factors for co-morbidities can be further explored in the new year
- Very limited doses will be available initially and need to be targeted, with priority advice to be further refined over time

ATAGI COVID Working Group Subgroup 1, Meeting No. 13 Monday, 22 December 2020, 3.30-4:30pm

- No need for a percentage of vaccine doses to be reserved initially ٠
- Delivery of vaccines to all adults in Aboriginal and Torres Strait Islander communities is • pragmatic due to logistical and other issues
- Advice needs to be implementable at a program level
- Remove table on recommended allocation and retain excel spreadsheet which better • outlines priorities

Action	Responsible	Status
Provide further feedback on draft prioritisation	Members	Completed
advice in next 24 hours		
Provide input in relation to GPs and prioritisation	s47F	Completed
Incorporate member comments to enable revised	NCIRS/S47F	Completed 23/12
version to be circulated to Subgroup 1		
Provide prioritisation advice to Executive Group	Secretariat	In progress
for endorsement by 24 December		

Katie Flanagan thanked participants for their contribution to this important work.

4. NCIRS update

Nil due to time constraints.

Meeting closed 5.20pm

e de sin de la comparte de la compar

ATAGI COVID Working Group Subgroup 1, Meeting No. 14 Monday, 5 January 2020, 3.30-4:30pm

In attendance:

Members	NCIRS Technical St	aff	Department of Health
Katie Flanagan – Lead	s11C		s47E(c), s47F
Chris Blyth			
Jodie McVernon			
Kanta Subbarao			
David Durrheim			Secretariat
Bette Liu			s22
Penny Burns			522
Kirsten Howard			
James Wood			
SharePoint Link			

1. Welcome and apologies / general committee business Members NOTED:

- Acknowledgement to country •
- Apologies (s11C Tom Snelling, James Ward •
- Declared no conflicts of interest •

2. Outcomes and Actions from previous meeting (22 December)

- Members ENDORSED outcomes from the previous meeting with no amendments
- Members NOTED that actions from the last meeting have been completed •

3. Priority populations – further granularity

Members NOTED that updated proritisation advice from Subgroup 1 was forwarded to the • Taskforce on 24 December 2020 on the basis that further refinement is required as more information becomes available

4. Single versus two dose regimen

- Members DISCUSSED single versus two doses of the COVID-19 vaccine, noting that:
 - There are conflicting international opinions (UK is advocating a single dose to 0 vaccinate more people while US FDA is advocating a double dose regimen)
 - Where there is low/no transmission (currently in Australia), the focus is protection 0 and a second dose is likely to reinforce this
 - Data to date shows good results when the vaccines are tested in a two dose regimen 0
 - Some countries (eg Germany) are experiencing slower than expected rollout due to complexities of administering vaccines
- Members AGREED that a two dose regimen is the correct approach at this time, noting that epidemiological and other information will continue to be monitored and advice may change accordingly

5. Clinical Advice Statement on COVID-19 Vaccines

- Members DISCUSSED the draft Clinical Advice Statement, intended as a public facing document, and raised the following points for consideration in the next draft:
 - Messaging needs to be succinct and unambiguous 0
 - 0 Ensure efficacy is separated from logistical issues when discussing vaccine preferences

ATAGI COVID Working Group Subgroup 1, Meeting No. 14 Monday, 5 January 2020, 3.30-4:30pm

- Comparison of vaccines or recommendation of one vaccine over another not supported (with exception of those with allergy) due to differences in clinical trials & situations
- Interchangeability of different vaccines generally not supported due to lack of clinical evidence
- Further consideration required in relation to pregnant and breastfeeding women but statement needs to be made
- Apply general rules / normal contraindications in relation to not proceeding with vaccination if unwell, with individuals and providers to make decisions around this
- Published data indicate that past infection is not a contraindication
- Refer adverse event reporting content to Subgroup 3
- o Insert concise information on nature of disease and clinical features at beginning
- o Align this advice with ATAGI priority population advice eg age recommendations
- Align with product information regarding dosing schedule and make further recommendations as evidence emerges
- Unable to comment on factors related to effects on disease transmission due to lack of data
- Provide clear advice about facilities required to administer vaccine eg anaphylaxis kit
- Align with Immunisation Handbook advice regarding acute care
- Add information relating to efficacy and effects on severe disease, as well as coadministration with flu vaccine
- Members NOTED gaps in the Clinical Advice Statement and that further information may be provided by AstraZeneca at a meeting next week

Action	Responsible	Status
Incorporate Subgroup 1 comments and put revised	NGIRS	In progress
draft Clinical Advice Statement on sharepoint	No.	
Refer revised version of Clinical Advice Statement to	s47F	In progress
Subgroups 2 and 3 for input/comment		
Finalise revised Clinical Advice Statement next week	All	In progress
for consideration by Exec or 15 January		
Seek Product Information for Pfizer vaccine	Secretariat	In progress

6. Flu and COVID-19 vaccine co-administration

 Members NOTED a draft document on influenza and COVID-19 vaccine administration on sharepoint for comment to be discussed at the next meeting

Action	Responsible	Status
Provide comment on draft flu document for	All	In progress
discussion at next SG1 meeting on 12 January and		
finalise for consideration by Exec on 15 January		

7. Other business - Data modelling

• Members NOTED a meeting will be held next week with the Executive Team to discuss data modelling work being undertaken within the Department

8. Next meeting

- Tuesday 12 January and Tuesday 19 January, 3:30-4:30pm
- 26 January no meeting (public holiday)

Meeting closed approx. 4.35pm

ATAGI COVID Working Group Subgroup 1, Meeting No. 15 Tuesday, 12 January 2020, 3.30-4:30pm

In attendance:	
----------------	--

Members	NCIRS Technical Sta	ff	Department of Health
Katie Flanagan – Lead	s11C		s47E(c), s47F
Chris Blyth			
Jodie McVernon			
Kanta Subbarao			
David Durrheim			
Penny Burns			
Tom Snelling			Secretariat
Bette Liu			$\mathbf{O}\mathbf{O}$
Kirsten Howard			S77
James Wood			SZZ
Richard Kidd			— —
James Ward			
s11C			
SharePoint Link			

Numbers NOTED: Acknowledgement to country Apologies (S11C) Declared no conflicts of interest 2. Outcomes and Actions from previous meeting 5. Jan Members ENDORSED outcomes from the previous meeting with no amendments Members NOTED action items in progress 3. Update from Executive Term

3. Update from Executive Team meeting

Members NOTED:

- mbers NOTED: Government announcement (7 January 2021) of COVID-19 Vaccination Program commencing in February 2021
- Ongoing work on logistics, training packages and IT systems
- Recent Executive Team meeting with Novavax

4. TGA update s47E(c),

s47F

provided TGA update. Members NOTED:

- Pfizer vaccine to be considered by the Advisory Committee on Vaccines (ACV) on 15 January •
- AstraZeneca vaccine expected to go to AVC in early February, depending on progress of • evaluation
- Rolling data from Janssen •
- Provisional Determination Application from Novavax
- Upcoming meeting with Moderna •

Members DISCUSSED:

Desire for ATAGI to meet with sponsors where there is currently no Advance Purchase Agreement in place

Action	Responsible	Status
Include agenda item for Exec meeting re ATAGI	Secretariat	Completed
meetings with Janssen and Moderna		

ATAGI COVID Working Group Subgroup 1, Meeting No. 15 Tuesday, 12 January 2020, 3.30-4:30pm

5. Clinical Advice Statement on COVID-19 Vaccines

Members DISCUSSED the draft Clinical Advice Statement. Key points include:

- Dosing intervals to be confirmed and will be adjusted when Product Information becomes available
- Importance of registries for pregnant women, severe reactions and heterogeneous schedule recipients
- Need for the wording of the advice to accommodate some flexibility Members AGREED:
- To provide minimal dosing intervals, and reassure that immune response is not lost if second dose is given after minimal interval period
- That in the event of adverse reaction to first dose of a vaccine, a second dose of an alternative vaccine would be sufficient (in absence of data)
- To maintain standard observation intervals of 15 minutes, and 30 minutes for individuals with history of anaphylaxis and severe drug allergies
- To re-word *Pregnant women & women who are breastfeeding* section to reflect that pregnant women can consult with their health care providers should they choose to be vaccinated
- To name the advice 'preliminary' on the understanding that it is likely to change as further information becomes available

6. Flu and COVID-19 vaccine co-administration Members DISCUSSED:

- Logistical challenges and the need for advice to be nimble as circumstances may change
- Whether a separate flu and COVID-19 vaccine administration document is needed
- Minimal intervals for live (28 days) and non-live (14 days) vaccines and the pressure to administer flu and COVID-19 vaccines at the same time
- Flu vaccine can be administered in between COVID-19 vaccine dose, if the interval period permits
- In the absence of data, the subgroup's advice is to avoid administering flu and COVID-19 vaccines together due to the possibility of increased reactogenicity
- Understanding that the fluvaccination program will not be delayed

7. NCIRS update

Members NOTED that ATAGI advice will stand in relation to Aboriginal and Torres Strait Islander priority populations

8. Other business

Members NOTED Exec team meeting with Quantium and that S47F and S47F will attend subsequent meetings.

Meeting closed approx. 4:55pm

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Subgroup 2 Meeting #1

16 September 2020

Outcomes

Outcomes
In attendance:
Members
Robyn Gibbs - Lead
, Madeline Hall
Karen Bellamy
Katherine Gibney
Nick Silberstein
Chris Blyth (ATAGI Co-Chair)
s11C
NCIPS Tachnical staff
s11C NCIPC
s11C NCIPC
- NCIRS
Denartment of Health representatives
Sarah Sinclair
s47E(c), s47F
intre or err
cui an an
Secretariat
Secretariat
Michelle Giles Nick Silberstein Chris Blyth (ATAGI Co-Chair) s11C NCIRS Technical staff s11C - NCIRS s11C - NCIRS Department of Health representatives Sarah Sinclair s47E(c), s47F Secretariat S222 the the

1. Meeting Opened

Members:

- NOTED acknowledgement of country
- NOTED attendees and apologies
- DECLARED no conflicts of interest

2. Role of the Subgroup

Members:

• NOTED the role of the subgroup is to provide technical advice on the immunisation program for COVID vaccines as they become available in Australia and identify and prioritise gaps in the immunisation landscape to improve impact and equity with the use of COVID vaccines.

3. Introductions

Members:

NOTED introductions from members. •

4. Work plan

Members:

• NOTED the key deliverables requested by the Department of Health for each sub group and the need for preliminary advice from the ATAGI COVID-19 working group by the end of September.

Action	Responsible officer/s	Progress
4.1 Prepare discussion paper on	NCIRS technical support	In progress
logistics and issues of		
distributing frozen COVID-19		
Vaccines		
4.2 Review learnings from 2009	NCIRS and ATAGI COVID-19	In progress
PanVax Program	Secretariat	
4.3 Prepare discussion paper on	NCIRS technical support	In progress
immunisation workforce-		- Alo
capacity, competencies and	2 ³ 0.	G ^o
training needs.		
4.4 Prepare discussion paper on	NCIRS technical support	In progress
information systems to track	de ci de	
distribution and coverage of		
COVID-19 vaccines	Mi Oi iO	

5. Integration with Jurisdictional Immunisation Committees

Members:

 NOTED that the work of COVID-19 Jurisdictional Immunisation Committee will link with the work being undertaken by this subgroup ps ers: AGREED to meet weekly on Wednesday 11:00am – 12:00pm.


6. Next Steps

Members:

•

7. Meeting Closed: 11:05 am

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Subgroup 2 Meeting #2 23 September 2020 Outcomes



Members:

- NOTED acknowledgement of country •
- NOTED attendees and apologies
- DECLARED no conflicts of interest .

2. Introductions

Members:

NOTED and welcomed Annaliese Van Diemen as the CDNA representative. •

Action	Responsible officer/s	Progress
2.1 Update membership list and	Secretariat	In progress
circulate		

3. Work plan

3.1 Program logistics

Members:

- DISCUSSED the NCIRS paper on distributing frozen vaccines •
- NOTED concerns regarding ability to deliver a vaccine program at -80 degrees .
- AGREED to focus on -20 degrees and consider transport issues
- NOTED challenges of delivering a program in remote areas •

vaccines following further input from members and consideration at next Subgroup meeting - include high level summary at beginning; clear recommendations and conclusions; and reference to Commonwealth Request for Tender (RFT) to review system readiness 3.1.2 Develop another piece of work incorporating different scenarios 3.1.3 Consider availability and cost of freezers and transporting of vaccines 3.1.4 Circulate public Secretariat In progress	Action	Responsible officer/s	Progress
from members and consideration at next Subgroup meeting - include high level summary at beginning; clear recommendations and conclusions; and reference to Commonwealth Request for Tender (RFT) to review system readiness 3.1.2 Develop another piece of work incorporating different scenarios 3.1.3 Consider availability and cost of freezers and transporting of vaccines 3.1.4 Circulate public Secretariat In progress	3.1.1 Finalise paper on frozen	s47F	In progress, to be completed
consideration at next Subgroup meeting - include high level summary at beginning; clear recommendations and conclusions; and reference to Commonwealth Request for Tender (RFT) to review system readinessImage: Construct of the system structure of the system structure of the system structure of the system scenariosNCIRSImage: Constructure of the system structure of the system to review system scenariosImage: Constructure of the system structure of the system scenariosNCIRSImage: Constructure of the system to review system to review system3.1.3 Consider availability and cost of freezers and transporting of vaccinesSarah SinclairIn progress3.1.4 Circulate publicSecretariatIn progress	vaccines following further input		by 30 September for advice to
meeting - include high level summary at beginning; clear recommendations and conclusions; and reference to Commonwealth Request for Tender (RFT) to review system readiness 3.1.2 Develop another piece of work incorporating different scenarios 3.1.3 Consider availability and cost of freezers and transporting of vaccines 3.1.4 Circulate public Secretariat In progress	from members and		Taskforce
summary at beginning; clear recommendations and conclusions; and reference to Commonwealth Request for Tender (RFT) to review system readiness 3.1.2 Develop another piece of work incorporating different scenarios 3.1.3 Consider availability and cost of freezers and transporting of vaccines 3.1.4 Circulate public Secretariat In progress	consideration at next Subgroup		
recommendations and conclusions; and reference to Commonwealth Request for Tender (RFT) to review system readiness 3.1.2 Develop another piece of work incorporating different scenarios 3.1.3 Consider availability and cost of freezers and transporting of vaccines 3.1.4 Circulate public Secretariat In progress	meeting - include high level		
conclusions; and reference to Commonwealth Request for Tender (RFT) to review system readiness 3.1.2 Develop another piece of work incorporating different scenarios 3.1.3 Consider availability and cost of freezers and transporting of vaccines 3.1.4 Circulate public Secretariat	summary at beginning; clear		
Commonwealth Request for Tender (RFT) to review system readiness 3.1.2 Develop another piece of work incorporating different scenarios 3.1.3 Consider availability and cost of freezers and transporting of vaccines 3.1.4 Circulate public Secretariat In progress	recommendations and		
Tender (RFT) to review system readinessNCIRS3.1.2 Develop another piece of work incorporating different scenariosNCIRS3.1.3 Consider availability and cost of freezers and transporting of vaccinesSarah Sinclair3.1.4 Circulate publicSecretariatIn progress	conclusions; and reference to		<i>.</i>
readiness 3.1.2 Develop another piece of work incorporating different scenarios 3.1.3 Consider availability and cost of freezers and transporting of vaccines 3.1.4 Circulate public Secretariat In progress In progress		~	
3.1.2 Develop another piece of work incorporating different scenarios NCIRS In progress 3.1.3 Consider availability and cost of freezers and transporting of vaccines Sarah Sinclair In progress 3.1.4 Circulate public Secretariat In progress			
work incorporating different scenarios 3.1.3 Consider availability and cost of freezers and transporting of vaccines 3.1.4 Circulate public Secretariat In progress			
scenarios 3.1.3 Consider availability and cost of freezers and transporting of vaccines 3.1.4 Circulate public Secretariat In progress In progress		NCIRS	In progress
3.1.3 Consider availability and cost of freezers and transporting of vaccines Sarah Sinclair In progress 3.1.4 Circulate public Secretariat In progress			S)
cost of freezers and transporting of vaccines 3.1.4 Circulate public Secretariat In progress	scenarios	6 0 0	
of vaccines 3.1.4 Circulate public Secretariat In progress	3.1.3 Consider availability and		In progress
3.1.4 Circulate public Secretariat In progress	cost of freezers and transporting	1/x ^O x	
	of vaccines	De St. Str.	
information on RFT to members 💦 👋 🔏	3.1.4 Circulate public	Secretariat	In progress
	information on RFT to members		

3.2 Program workforce

Members:

- n workforce •
- NOTED Jurisdictional Immunisation Coordinators (JIC) are meeting to discuss
- NOTED Advisory Committee on Vaccines is meeting and TGA input is needed

Action	Responsible officer/s	Progress
3.2.1 Finalise paper on	s47F	In progress, to be completed
workforce competencies		by 30 September for advice to
following further input from		Taskforce
members and consideration at		
next Subgroup meeting		

3.3 Information systems for vaccine distribution and coverage

Members:

AGREED to place this item on hold pending discussion by JIC •

Action	Responsible officer/s	Progress	
3.3.1 Report back to members	s47F	In progress	
at next meeting regarding JIC			
discussions, intersect with this			
Subgroup and respective roles			

4. Other priority issues for program implementation

Members:

- NOTED suggestions for further pieces of work to be undertaken by this group:
 - set of principles to embed in program rollout eg data
 - clinical administration advice eg co-administration and contra-indication
 - multidose vials program implementation and workforce training
 - innovative mechanisms for vaccine delivery

Action	Responsible officer/s	Progress
4.1 Develop list of other pieces	NCIRS	In progress
of work to be undertaken		
4.2 Update workplan in	Secretariat	In progress
Sharepoint as required		


5. Next Meeting

Members:

AGREED to meet by videoconference with a test to be held prior to next meeting

Action	Responsible officer/s Progress
5.1 Organise a test of	Secretariat In progress
videoconferencing with	
members	
leeting Closed: 12:00 noon	ent has been released and hose
	bee atile with
	25 Meyeo
	on an at
JIN	an and
5000	SO. AL.

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Subgroup 2 Meeting #3 30 September 2020 Outcomes



- NOTED and welcomed Lena Sanci as the new primary care representative .
- DECLARED no conflicts of interest

2. Outcomes and Actions from previous meeting

Members:

NOTED outcomes and actions from previous meeting with no amendments •

3. Update from Executive Team meeting

Members:

- NOTED the Executive Team will need to consider and endorse papers developed by • Subgroups
- NOTED information on the COVID-19 Working Group establishment and structure will be published on the website shortly
- DISCUSSED issues associated with possible publication of Subgroup member names on • the website, noting that consent forms would need to be completed

Action	Responsible officer/s	Progress
3 Members to send comments to	Members	In progress
Secretariat in relation to possible		
publication of names		

4. Feedback from Jurisdictional Immunisation Coordinators (JIC) COVID-19 Roundtable meeting

Members:

- NOTED feedback from the Chair on the JIC meeting and concerns in relation to program implementation issues
- NOTED that JIC COVID-19 meetings will be held weekly
- NOTED the Advisory Committee on Vaccines meeting today and the need for feedback from TGA

Action	Responsible officer/s	Progress
4 Place item on Exec agenda re possible	Secretariat	To progress
TGA rep on Subgroup 2		

5. Work plan update

5.1 Discussion paper on distributing frozen vaccines Members:

- DISCUSSED the NCIRS paper on distributing frozen vaccines, noting its high quality
- NOTED comments in relation to freezer availability, maintaining transportation cold chain, preservatives, expiry dates and remote settings
- AGREED to provide further comments to NGRS

Action	Responsible officer/s	Progress
5.1 Finalise paper on frozen vacci	nes \$47F	In progress, to be
following further input from men	bers,	completed by early
for consideration at Exec meeting	g 9/40	October

5.2 Discussion paper on workforce competencies

Members:

- DISCUSSED the NGIRS paper on workforce competencies, noting its high quality
- NOTED comments in relation to insufficient providers for previous vaccination programs, truncated/COVID-specific training (eg Ambulance Victoria rapid online training program) and record keeping as a core workforce competency
- AGREED to provide further comments to NCIRS

Action	Responsible officer/s	Progress
5.2 Finalise paper on workforce competencies following further input	s47F	In progress, to be completed by early
from members for consideration at Exec		October
meeting 9/10		

5.3 Information systems for vaccine distribution and coverage

Members:

• NOTED this paper is on hold pending discussions between Commonwealth and JICs

6. Other proposed workplan topics for program implementation

Members:

- NOTED proposed topics for further work, subject to consideration by the Executive Team • to ensure prioritisation and no duplication
- NOTED NCIRS has commenced background work on multidose vials ٠

Action	Responsible officer/s	Progress
 6. Place item on Exec agenda re Subgroup 2 proposed work including: Multidose vials 	Secretariat	To progress
 Lessons learned from H1N1 pandemic vaccination program Principles for program implementation 		
 Targets for coverage Serology post vaccination Issues related to clinical guidance Innovative approaches 	e Inder	C. alle

7. Other business

Members:

- DISCUSSED issues for providers associated with using the Australian Immunisation • Register (AIR) including passwords, authentication files, access and delegations
- NOTED the Taskforce is considering AIR case of access issues for providers and • welcomes advice from members on known barriers
- NOTED an intersection with the communications strategy in relation to messaging • around vaccine preservatives and good clinical practice, relevant to Subgroup 3's work on quality control measures and monitoring workforce compliance

8. Next Meeting

Members:

- eting ers: AGREED to move meeting time due to clash with CDNA meetings
- NOTED NCIRS to present draft work on AIR data quality and multidose vials

Action V '	Responsible officer/s	Progress
8.1 Move meeting times to Wednesdays	Secretariat	Completed
from 12-1pm		
8.2 Consolidate information already	NCIRS	In progress
gathered on AIR data quality and present		
at next meeting		
8.3 Provide draft points on multdose vials	NCIRS	In progress
at next meeting		

9. Meeting Closed: approximately 12 noon

In attendance:

Members Robyn Gibbs - Lead Madeline Hall Karen Bellamy Katherine Gibney Michelle Giles Nick Silberstein Annaliese Van Diemen s11C Lena Sanci

NCIRS Technical Staff s11C

Department of Health s47E(c), s47F

Sarah Sinclair s47E(c), s47F



1. Welcome and apologies / general committee business

Members:

- NOTED acknowledgement to country.
- NOTED attendees and apologies (Chris Blyth).
- DECLARED no conflicts of interest.

2. Outcomes from previous meeting

NOTED outcomes and actions from previous meeting ith no amendments. •

3. Actions from previous meeting

Members:

- NOTED items to be raised at Executive Working Group Meeting Friday 9 October:
 - For endorsement: Workforce and frozen vaccine discussion papers.
 - For discussion: TGA representative; publication of member names online.
- NOTED a log of all action items has been uploaded to SharePoint. •

Action	Responsible officer/s	Progress
3.1 Executive Group to discuss GA	Executive Group	In progress
representative		
3.2 Executive Group to discuss publication	Executive Group	Completed – discussed on
of member names online		9/10
3.3 Executive Group to endorse workforce	Executive Group	Completed
and frozen vaccine discussion papers		

4. Feedback from Jurisdictional Immunisation Coordinators (JIC) COVID-19 Roundtable meeting

- NOTED update on JIC discussions, including: communications; safety (including TGA setting • up a pharmacovigilance discussion); workforce; logistics, including warehousing of frozen vaccine, multidose vials (MDV) and consumables, noting some of these topics were being addressed by the Taskforce.
- DISCUSSED consumables, including update from Taskforce ^{\$47E(c), \$47F} on preliminary • purchasing arrangements.
- NOTED that the next JIC COVID-19 meeting is Thursday 8 October.

Action	Responsible officer/s	Progress
4.1 WG 2 to develop list of consumables,	NCIRS	In progress, drafts uploaded
both a 'minimum requirements' list and		to SharePoint prior to WG2
more detailed version.		meeting 14/10

5. Work plan update

Members:

- DISCUSSED the NCIRS paper on MDV. Topics discussed included:
 - Limited literature on use of MDV and anecdotal evidence of provider discomfort with the use of MDV. Issues to consider in the use of MDV include:
 - Need for very clear guidelines / protocols and communications to providers about risks and how to manage, including for example a service offering for immunisation providers to contact once a known issue arises.
 - Recommendation for a separate area for vaccine preparation and administration to help minimise some of the risks, and NCIRS will update the paper to include a section on implications for different clinical settings.
 - Consideration of informed consent: verbal acknowledgement vs. a signed form.
 - Wastage issues and instructions for how to discard unused vaccine, (particularly if GMO).
- DISCUSSED update on consumables from the Taskforce ^{s47E(c), s47F} including:
 - 1ml syringes (not as user friendly for providers) vs 2ml syringes (better, as they are shorter and offer providers better control);
 - \circ issues with coring of MDV (i.e. from repeated injections to draw up vaccine) ; and
 - the potential for increased numbers of localised / injection site reactions, due to antigen present on outside of needle (use of drawing up needles preferable).
- DISCUSSED the NCIRS paper on Australian Immunisation Register data quality, noting this paper is focused on: the limitations of AB in coverage, underreporting, software issues, reporting levels by provider types, known issues that need to be addressed.
 NOTED an update from ^{s47E(c), s47F} on current AIR work and that if needed, reports
- NOTED an update from ^{s47E(c), s47F} on current AIR work and that if needed, reports and/or demonstration from ClikSense could be provided to this group.

Action	Responsible officer/s	Progress
5.1 Members to send through any further	Members	In progress
comments or questions on MDV in writing		
5.2 NCIRS to update MDV paper following		In progress, revised version
discussion, including addition of section or	1	uploaded to SharePoint
implications for different clinical settings		prior to WG2 meeting 14/10
5.3 Discuss at Executive meeting this group	Secretariat	Completed – discussed at
developing a checklist for site		Exec meeting 9/10
requirements necessary to deliver COVID		
vaccines		
5.4 NCIRS to discuss AIR paper with \$47E(c), \$47F	NCIRS	In progress, due for
), 5471		discussion by WG2 on 21/10

6. Other proposed workplan topics for program implementation

Members:

• NOTED the item on Consent in use of MDV would be held over until the next teleconference.

7. Other business

Members:

• NOTED confidential update from the Taskforce regarding expected numbers for rollout.

8. Next meeting

• Weekly meetings - Wednesdays at 12 noon

In attendance:

Members	NCIRS Technical Staff	Department of Health
Robyn Gibbs – Lead	s11C	s47E(c), s47F
Madeline Hall		
Karen Bellamy		
Katherine Gibney		
Michelle Giles		Sarah Sinclair
Nick Silberstein		s47E(c), s47F
Lena Sanci		
Annaliese van Diemen		Secretariat
		c77
		322
SharePoint Link	·	

1. Welcome and apologies / general committee business

Members:

- NOTED acknowledgement to country.
- NOTED attendees and apologies.
- DECLARED no conflicts of interest.
- 2. Outcomes & Actions from previous meeting Members:
- dunue. 1982 ded Car NOTED outcomes and actions from previous meeting with no amendments. •
 - NOTED a TGA representative would be invited to attend meetings on an as needed basis.

3. Update from Executive Team meeting

- NOTED at the Executive Working Group Meeting on Friday 9 October the publication of ATAGI member names online was agreed, following receipt of written consent.
- NOTED a half day information sharing for ATAGI subgroups members will be scheduled, likely for November and an invitation will follow once dates have been considered.

4. Work plan update

- NOTED and DISCUSSED a summary on the updated Multidose vials (MDV) paper presented by NCIRS.
- DISCUSSED the issue of consent, including:
 - What is currently done for the National Immunisation Program and other immunisation 0 programs, e.g. workplace programs, and consent issues around MDV specifically;
 - It was agreed that this SubGroup should develop a discussion paper on consent; and 0
 - It was noted that no fault compensation / indemnity issues were being discussed at the 0 upcoming ATAGI meeting on Thursday 15 October 2020 and at SubGroup #3 on Friday 16 October 2020.
- NOTED an update from NCIRS on a discussion regarding freezer capacity for -80deg and that NCIRS is working with AIR team to understand current projects and timelines.

Action		Responsible officer/s	Progress
4.1 Invite ^{s47E(c), s47F}	from the Gene	Secretariat	In progress: s47E(c), s47E
Technology Policy Section t	o the next		unavailable 21 October;
meeting to discuss:			seeking availability for
whether the proposed	vaccines are		28 October.
considered GMO, and			
• if so, what are the disp	osal		
requirements?			
5.3 Will the vaccines have seria	l numbers?	Taskforce	In progress
5.4 Raise issue of implementation / track and		Secretariat	In progress
trace software at the Executive Working			
Group and report back.			
5.5 Develop a Discussion Paper	on consent.	NCIRS	In progress
5.6 Members to review both ch	necklists and	Members	In progress, email reminder
updated MDV paper on ShareP	oint prior to		sent from Secretariat on
seeking endorsement at the ne	xt meeting.		19 October

5. Other business

Nil

6. Next meeting

• Wednesday 21 October 2020.

This tree beatment of the the the beat theb

In atte	ndance:
---------	---------

Members	NCIRS Technical St	aff	Department of H	lealth
Robyn Gibbs – Lead	s11C		s47E(c), s47F	
Madeline Hall				
Karen Bellamy			Sarah Tyquin	
Katherine Gibney			s47E(c), s47F	
Michelle Giles				
Nick Silberstein			Secretariat	
Annaliese van Diemen			~ 22	
s11C			SZZ	
Chris Blyth				
SharePoint Link				

1. Welcome and apologies / general committee business

Members:

- NOTED acknowledgement to country.
- NOTED attendees and apologies (^{\$11C})
- DECLARED no conflicts of interest.
- 2. Outcomes & Actions from previous meeting Members:
 - NOTED outcomes and actions from previous meeting with no amendments.
 - NOTED update from the Secretariat on the AstraZeneca meeting held on Tuesday 20 October 2020 and that a meeting with Seqirus would be held on Thursday 22 October 2020.

3. Update from AZ meeting Tuesday 20 October 2020

• NOTED and DISCUSSED the update from the Secretariat regarding the meeting with AstraZeneca.

Action	Responsible officer/s	Progress
 Seek an update from the Tas the next meeting about the A & Seqirus information and implementation. 	AstraZenesa	In progress
 Executive WG meeting Frida- item for discussion (following with Sponsors this week) reg regulatory pathway timing for AstraZeneca & Seqirus and h impacts implementation time 	g meetings arding the or both ow this	In progress

4. Items for Endorsement

Members:

- DISCUSSED the MDV paper, including need for training for providers around use of multidose vials (MDVs);
- AGREED to add a recommendation to the paper around the need for provider training in the use of MDVs, nationally consistent if possible, and that the training should be appropriate forms for:
 - o regular immunisation providers as an update specific for MDVs; and
 - o a more comprehensive training item for providers who do not regularly administer vaccines.
- NOTED that the issue of training for providers has already been raised at Jurisdictional Immunisation Coordinators (JIC) as an item for further discussion / action.
- DISCUSSED the need for further coordination of efforts between the JIC and this group, and agreed that this would be discussed offline between S47F and S47F , to consider how best to

, Taskforce, ^{s47E}(c), s47F).

ensure that both expertise of the JICs is being utilised and duplication of efforts between this group and JIC is minimised.

Action	Responsible officer/s	Progress
 Secretariat to raise issue of training at JIC either Thursday 22/10 or the following week. 	Secretariat	In progress
	NCIRS, Members	In progress
 Taskforce to provide an update on PPE being purchased at the next meeting. 	Taskforce	In progress
 Work plan update Members: NOTED a chart summary on the Chasklin 	under of	Care

5. Work plan update

- Members:
- NOTED a short summary on the Checklists provided by NCIRS. •
- AGREED that Members would review and comment on the following documents via SharePoint by Monday 26 October, with a view to seeking endorsement of the documents and the next meeting on Wednesday 28 October 2020: Checklists;
 Consent discussion paper;
 AIR discussion paper; and
 Clinical guidance. ٠

Action	~~ Č	Responsible officer/s	Progress
Review	and comment on the following	Members	In progress
docum	ents on SharePoint by Monday 26		
Octobe	er, for endorsement at next		
meetin			
0	Checklists;		
0	Consent discussion paper;		
0	AIR discussion paper; and		
0	Clinical guidance.		

6. Other business

Responsible officer/s	Progress
ICIRS	In progress

7. Next meeting

• Wednesday 28 October 2020.

Members	NCIRS Technical Staff	Department of Health
Robyn Gibbs – Lead Chris Blyth s11C	s11C	s47E(c), s47F Sarah Tyquin
Karen Bellamy Katherine Gibney Michelle Giles Nick Silberstein Lena Sanci Annaliese van Diemen Scott Brown Madeline Hall		s47E(c), s47F Sarah Sinclair s47E(c), s47F
		secretariat
SharePoint Link		

1. Welcome and apologies / general committee business Members:

- .
- •

2. Update from the Taskforce

- elcome and apologies / general committee business embers: Acknowledgement to Country; Introductions for new members; Apologies; and Declarations of interest. date from the Taskforce ers: NOTED thanks from the Taskforce for the work of SG2 in developing documents to help inform the policy for COVID19 vaccination program. • policy for COVID19 vaccination program
- NOTED the personal protective equipment (PPE) requirements necessary to deliver the COVID-19 vaccination program in a COVID-sate way are currently under consideration and the Taskforce is working with the National Medical Stockpile on availability. The Taskforce will seek advice from this group as required.
- NOTED that Secretary Brendan Murphy briefed Health CEOs on the proposed approach for a COVID-19 vaccination programmand that more information will be provided shortly, following Government review and consideration, as soon as possible (hopefully a matter of weeks).
- NOTED that JICs have been advised that the Commonwealth will potentially be involved in warehousing of the vaccine (more than currently happens with NIP), including considering IT system developments to ensure line of site to the vaccine doses, particularly in context of initially having a limited supply, to minimise wastage.
- DISCUSSED that this approach was a change from current systems, potentially increasing the complexity, and questioned at what level this approach had been discussed (e.g. AHPPC).
 - The Taskforce noted that Secretary Murphy discussed with Health CEOs and it was likely 0 further conversations would occur at that level and also at AHPPC, however the Taskforce would follow up at the Executive Group meeting. s47F noted that he would also follow up on this.

Action	Responsible officer/s	Progress
Taskforce to follow up what level discussion	ons Taskforce	Completed – discussed at
have been held on the proposed		Executive Meeting 30/10
implementation approach.		
s47F to follow up discussion regarding	ng S47F	Completed – discussed at
the rationale for these decisions		Executive Meeting 30/10

3. Items for Endorsement

Members:

- ENDORSED the MDV paper and agreed it would be presented to the Executive Group on 30 October 2020.
- NOTED the Taskforce had minor feedback on the Consent paper for NCIRS to incorporate. Following this update, the Consent paper would be presented at next week's meeting on 4 November for endorsement.
- ENDORSED the AIR paper with minor edits, and agreed it would be presented to the Executive Group on 30 October 2020, following discussion of member comments provided in the AIR paper. Discussion included incorporating issues with PRODA (difficulty linking to a provider in a hospital setting) and the need for specific COVID vaccine drop downs in the AIR (not a generic option).
- NOTED that the Mandatory Reporting public consultation would be published by 2 November 2020 and would be open for two weeks, and a link would be sent to key stakeholders.

4. Items for Discussion

Members:

AGREED to review the Checklists and Clinical Guidance but of session and discuss at the next meeting. **her business** ers: •

5. Other business

- NOTED the GMO advice/update from \$47E(c), \$47F
 - The AstraZeneca and Johnson and Johnson vaccine candidates are both GMO; and 0
 - While specific details of timing and consideration by the Office of the Gene Technology 0 Regulator are currently unavailable, updates can be provided to SG#2 at future meetings as appropriate.
- DISCUSSED the issue of wastage presented in the H1N1 review paper:
 - The Taskforce noted the figure of 40% is quite high in the context of a limited stock scenario 0 and sought members' feedback on whether this figure was reasonable to expect or if there were other examples to draw on, as they are currently looking into training programs and how to minimise wastage (noting leakage is less of a concern given the prioritisation of doses).
 - NCIRS noted the 40% figure was an average of GPs and that the literature suggested rates of 0 wastage were higher when vials contained more doses.
 - Members noted BCG (which is also a MDV) could be a comparator, however this is used in 0 an appointment-based setting to minimise wastage, however the key issue in COVID setting would be the volume / demand (i.e. as demand increases, wastage increases) and an initial phased approach to COVID vaccination program would likely help with wastage. Adequate time for system preparation (in addition to training) would also be critical for implementation.
- NOTED the Outcomes & Actions from previous meetings are mostly complete.

ATAGI COVID Working Group Subgroup 2, Meeting No. 8 Wednesday 4 November 2020, 12.00-1.00pm **Meeting Outcomes**

NCIRS Technical Staff	Department of Health
s11C	s47E(c), s47F
	Secretariat
	<u>-</u>
	s22

SharePoint Link

Welcome and apologies / general committee business 1.

Members:

- NOTED acknowledgement to country. •
- NOTED attendees and apologies.
- DECLARED no conflicts of interest. •

2. Papers for Endorsement

Members:

- DISCUSSED and ENDORSED: •
- CLARED no conflicts of interest.
 for Endorsement
 CUSSED and ENDORSED:

 Consent paper, with minor edits;
 Checklist for equipment (noting that the tables estimating the numbers of consumables were being finalised); and consumables were being finalised); and Checklist for site requirements, with minor edits.
 - 0

3. Drafts for discussion

- fts for discussion ers: DISCUSSED the multidose viat (MDX) clinical guidance paper, including: •
 - issues around the size of recommended syringes;
 - o drawing up of one dose or multiple doses in succession, including the Australian Society for infectious Disease recommendations; and
 - noted that it was appropriate to include some cautionary statements for providers 0 about what not to do, with short rationale.
- NOTED during the 91N1 pandemic some documents contained RACGP branding and that the • potential for consultation with key groups should be considered.
- AGREED to hold over discussion of the H1N1 paper to the next meeting.

Action	Responsible officer/s	Progress
3.1 Seek list of consumables to be shared	Secretariat	Complete, uploaded to
with SG#2	475	SharePoint.
	s47F	Complete.
for key documents (e.g. NHMRC and other		
groups e.g. RACGP).		
3.3 Discuss H1N1 paper at next meeting	Secretariat	In progress, added to
		agenda.

ATAGI COVID Working Group Subgroup 2, Meeting No. 8 Wednesday 4 November 2020, 12.00–1.00pm Meeting Outcomes

4. Public facing documents

Members:

• DISCUSSED the list of outward facing advice/ documents developed by NCIRS and agreed to add information on aged care, outreach sites.

5. Outcomes & Actions from previous meeting

• NOTED outcomes and actions from previous meeting with no amendments.

6. Other business

Nil.



ATAGI COVID Working Group Subgroup 2, Meeting No. 9 Wednesday 11 November 2020, 12.00-1.00pm

Members	NCIRS Technical Staff	Department of Health
Robyn Gibbs – Lead	s11C	s47E(c), s47F
Chris Blyth		Sarah Sinclair
s11C		s47E(c), s47F
Madeline Hall		
Karen Bellamy		Secretariat
Michelle Giles		c77
Nick Silberstein		322
Lena Sanci		
Annaliese van Diemen		
Scott Brown		
SharePoint Link		

1. Welcome and apologies/general committee business

Members:

- NOTED acknowledgment to country
- NOTED attendees and apologies (nil)
- Declared no conflicts of interest

2. Documents for discussion


- Multi Dose Vials (MDV) Clinical Guidance
- Members DISCUSSED:
 - concerns about contamination when drawing up a vaccine
 - aspects of the clinical procedures for administering a vaccine, specifically whether two 0 staff members are required when drawing up a MDV to maintain sterile technique

Members NOTED:

- ers NOTED: that in practice, Aseptic Non-Touch Technique can be achieved by one staff member 0 (s47F offered to share materials on this subject with the group)
- early engagement with the Infection Control Expert Group (ICEG) is important 0
- consultation procedures for outward facing documents will need to be determined with \circ the Executive
- **Checklist for Equipment**

Members NOTED:

- that the Executive endorsed the Checklist for Equipment at the last meeting, subject to 0 any further comments
- that a list of consumables procured by the Taskforce had been provided to the subgroup 0 Members AGREED:
 - to revise the Checklist for Equipment and provide recommendations based on expert advice
 - to take the checklist to the next Executive meeting and raise discrepancies between recommendations and purchased consumables
- H1N1 Lessons Learned
 - Members AGREED to discuss this paper at the next meeting 0



ATAGI COVID Working Group Subgroup 2, Meeting No. 9 Wednesday 11 November 2020, 12.00–1.00pm

Action	Responsible officer/s	Progress
2.1 Revise the MDV Clinical Guidance to incorporate group comments	Subgroup 2/NCIRS	In progress
2.2 Early engagement with the Infection Control Expert Group	Subgroup 2/ <mark>S47F</mark>	Completed - raised by S47F at ICEG meeting on 11/11 and to be discussed at Exec meeting on 13/11
2.3 Consult with the Executive on consultation procedures for outward facin documents	Subgroup 2 /Secretariat g	To progress
2.4 Recall the Checklist for Equipment, make revisions, and resubmit to Executive for endorsement	NCIRS/Secretariat	Completed – for Exec meeting 13/11

3. Update from Services Australia

s47E(c), s47F from Services Australia presented on the progress of the PRODA transition. Members NOTED:

- Members NOTED:
 there is no firm cut-off date for PRODA authentication files being ceased (expected 2021)
- State and Territory Health Departments have registered their organisations
- Services Australia is working with multisite companies and the next target group is councils
- barriers and challenges faced when setting up and using PRODA in the public hospital setting
- Services Australia is open to discussing PRODA registration with private hospitals

Members AGREED:

- to track progress of PRODAC ansition and continue discussions at Executive meetings
- to encourage the Commonwealth and Services Australia to provide resources to ensure PRODA access issues are resolved

Action	Responsible officer/s	Progress
3.1 Track progress of PRODA transition and continue discussions at Executive meetings		To progress
continue discussions at Executive meetings		

4. Issues from information session 10 November

0

Members were invited to email topics/issues from the information session to the subgroup lead for discussion next week.

5. Outcomes & Actions from previous meeting

Members NOTED that actions are up to date and outcomes from last week's meeting are being finalised.

Meeting closed at 1:10pm.

ATAGI COVID Working Group Subgroup 2, Meeting No. 10 Wednesday 18 November 2020, 12.00-1.00pm

Meeting Outcomes

Members	NCIRS Technical Staff	Department of Health
Robyn Gibbs – Lead	s11C	s47E(c), s47F
Madeline Hall		
Karen Bellamy		
Katherine Gibney		
Nick Silberstein		
Lena Sanci		Secretariat
Annaliese van Diemen		- 00
Scott Brown		S//
		~ ––
SharePoint Link		

1. Welcome and apologies / general committee business

Members:

- NOTED acknowledgement to country.
- NOTED attendees and apologies. •
- DECLARED no conflicts of interest. •

2. H1N1 paper

Members NOTED:

- eleased under wing discussion in alther wing discussion that the H1N1 paper has been updated following discussion last week and is now on • SharePoint;
- the summary of the paper and recommendations provided by NCIRS, noting that it was a • well written paper; and
- that the paper should be shared with WG#3 •

Members ENDORSED the H1N1 paper, with minor edits, including addition of:

- a reference to vaccine safety concerns; and
- a recommendation about tracking uptake. •

Members DISCUSSED:

- the audience for this paper, noting that the request to share the papers prepared by this group has previously been raised at the Executive Group meetings and with the taskforce;
- that most of the papers developed are summaries of publicly available information, with the • addition of recommendations for the Commonwealth/ Taskforce and if there are concerns about recommendations or other confidential information included in these papers, an option may be to prepare a public facing version with this information removed, that could be disseminated to the jurisdictions/ more broadly.

Action	Responsible officer/s	Progress
2.1 NCIRS to update paper to include:	NCIRS	In progress.
• a statement noting need to consider		
safety; and		
 add recommendation on uptake. 		
2.2. Provide H1N1 paper to Executive	Secretariat	Complete, on agenda for
Group for endorsement Friday 20/11		Executive Group Friday 20/11.

ATAGI COVID Working Group Subgroup 2, Meeting No. 10 Wednesday 18 November 2020, 12.00-1.00pm

Meeting Outcomes

2.3 Provide a copy of the H1N1 paper to	Secretariat	In progress
WG#3 once endorsed by the Executive		
Group		
2.4 Follow up sharing of papers with JIC	Secretariat	In progress, on agenda for
and more broadly in jurisdictions		Executive Group Friday 20/11.

3. Work plan update

MDV Clinical Guidance

Members NOTED:

- that the MDV Clinical Guidance has been updated to: 0
 - remove some of the specific information (e.g. sizes of needles);
 - incorporate details regarding the no touch technique;
 - include characteristics of all four vaccines the Commonwealth has advance purchase arrangements with and;
 - the paper will continue to be updated as more information becomes available.
- that the pathway for these COVID clinical advice documents is not yet finalised, however and at the Executive Group meeting on Friday 13 November 2020, Co-Chairs S47F s47F noted the topic of MDVs had been raised at the Infection Control Expert Group (ICEG) and they agreed to provide a copy of the MDV clinical Guidance once finalised.

Members ENDORSED the MDV Clinical Guidance with these changes noting paper will be added to as e information becomes available.
Overview of mandatory vaccination policies more information becomes available.

• Overview of mandatory vaccination policies Members NOTED during a recent Executive Group meeting discussion on consent it was agreed that NCIRS would draft a paper on the current mandatory vaccine policies in each jurisdiction, e.g. influenza vaccination in aged care workers

tor session and provide any comments by Monday Members AGREED to review the 23 November 2020.

Action	Responsible officer/s	Progress
3.1. Provide updated MOV Clinical	Secretariat	Complete, on agenda for
Guidance to Executive Group for		Executive Group Friday
endorsement Friday 20/11		20/11.
3.2 Members agreed to review the	Members	In progress.
Overview of mandatory vaccination policie	s	
the paper on SharePoint and provide any		
comments by Monday 23 November 2020		

4. Workforce & Training

Members AGREED the discussion on workforce would be held over to next meeting on 25 November 2020.

ATAGI COVID Working Group Subgroup 2, Meeting No. 10 Wednesday 18 November 2020, 12.00-1.00pm

Meeting Outcomes

5. Other business

Issues from information Sharing Session, 10 November 2020

Members DISCUSSED feedback / concerns arising from the ATAGI COVID-19 Working Group information sharing session on 10 November 2020 including:

- the role of ATAGI COVID-19 working groups in data and reporting requirements, 0 including:
- consistency of data gathered and/or the development of a minimum data set, noting 0 that it is anticipated that the all levels of government are likely to want regular, clear reporting of all COVID-19 related data to occur;
- co-ordination of these efforts, noting that it may be occurring by the Taskforce (including \cap via the data / logistics RFPs) however it is not clear at this stage;
 - the Secretariat NOTED that based on advice from the Taskforce, it is likely much of the detail regarding the data would be covered by the data and logistics RFPs and that a RFP was also in progress for a Project Manager to oversee the implementation. Ø,
- the need for an understanding of the overall plan for the rollout, particularly now that 0 the COVI19 Vaccination Policy has been published. For example, it was noted that in Queensland it takes two weeks to roll out a new vaccine across the state, so for a 1 March implementation date, distribution would need to commence in mid-February, and it is this level of detail regarding the overall project planning that would be useful.
 - The Secretariat NOTED that bi-lateral discussions with the States and Territories were commencing over the next two weeks with jurisdictional representatives nominated by Health CEOs 3 80
- **Publications**

Members NOTED that following the announcements made by the Prime Minister and Minister for Health last Friday, the following publications are available on SharePoint:

- Australia's COVID-19 vaccination policy; and
- COVID-19 vaccination prioritisation. 0
- 6. Outcomes & Actions from previous meeting

Secretariat NOTED that actions are up to date.

ATAGI COVID Working Group Subgroup 2, Meeting No. 11 Wednesday 25 November 2020, 12.00–1.00pm

Members	NCIRS Technical Staff	Department of Health
Robyn Gibbs – Lead	s11C	s47Ė(c), s47F
Chris Blyth s11C		
Madeline Hall		
Karen Bellamy Lena Sanci		
Annaliese van Diemen	s47F	Secretariat
Scott Brown		~ 22
		s22
SharePoint Link		

1. Welcome and apologies/general committee business

Members:

- NOTED acknowledgment to country
- NOTED attendees and apologies
- Declared no conflicts of interest

2. Workplan update

Members DISCUSSED:

- Consent to mandatory vaccination and who may be responsible for vaccination injuries
- Whether the Commonwealth has considered mandatory COVID-19 vaccination for the
- o The importance of considering risks and benefits of implementing mandatory vaccination

Members NOTED:

Victoria is yet to implement egislative changes on mandatory vaccination for healthcare 0 workers, Although flu vaccination is not mandated for aged care facility workers, it was noted that emergency provisions may be considered, if necessary.


Members AGREED

- That the issue of return travellers and its implications are not currently imposing on the 0 subgroup's work
- To endorse Mandatory Vaccination Policies paper and take to the next Executive Team 0 meeting for endorsement, following inclusion of yellow fever vaccination for travellers as a recommendation

Gap Analysis Workforce & Training paper

Members NOTED:

- That formal training is recommended for MDV administration and clinical aspects of COVID-19 vaccines
- The need for national consistency of training programs and modules
- The importance of vaccination reporting
- o Importance of having the Commonwealth's implementation plan shared with the subgroup and jurisdiction
- That there will be discussion about the implementation plan between the Department and jurisdictions



ATAGI COVID Working Group Subgroup 2, Meeting No. 11 Wednesday 25 November 2020, 12.00–1.00pm

Members AGREED:

• to endorse the Gap Analysis Workforce & Training paper and take to the next Executive Team meeting for endorsement

3. Workforce / Training discussion

Members DISCUSSED:

- Surge workforce and explored the possibility of deploying other resources such as medical and nursing students as vaccinators and that these could also be extended to paramedics, indigenous health workers, pharmacists, and retired ambulance officers
- How to segregate roles in providing vaccines within existing vaccine provider structures
- Whether a surge plan should be developed
- Training requirements and how modules like *train the trainer* courses may be effective when training up a surge workforce

Members NOTED:

- QLD has been approached by dental associations with their interest in being vaccine providers
- That travel clinics have expressed their interest in supporting the vaccine roll out as vaccine providers. s47F
 has agreed to put the travel clinics in contact with the Department.

Action	Responsible officer/s	Progress	
3.1 Draft a surge workforce plan	NGIRS N	To progress	
	NO KON KY		
4. Other business			
Nil.			

5. Outcomes & Actions from previous meeting

Members NOTED outcomes and actions from previous meeting with no amendments.

Meeting closed at 1/10pm.

ATAGI COVID Working Group Subgroup 2, Meeting No. 12 Wednesday 13 January 2021, 12.00–1.00pm

Members	NCIRS Technica	l Staff	Department of Health	
Robyn Gibbs – Lead	s11C		s47E(c), s47F	
Madeline Hall				
Karen Bellamy				
Lena Sanci				
Annaliese van Diemen				
Chris Moy			Secretariat	
Nick Silberstein			s22	
Michelle Giles			s4/E(c),	
			\$22	
SharePoint Link				

1. Welcome and apologies/general committee business

Members:

- NOTED acknowledgment to country
- NOTED introductions, and welcomed new member, Dr Chris Moy
- NOTED attendees and apologies (Scott Brown, Katherine Gibney, Chris Blyth, S11C
- Declared no conflicts of interest

s47E(c), s47F provided Departmental update including

- Announcement of the COVID-19 vaccination program rollout commencing in February 2021
- Ongoing engagement with jurisdictions, including bilateral implementation plan discussions, plans aimed to be finalised this week
 - o link to Prime Minister and Minister for Health presentation, 7 January 2021
 - o link to Minister Hunt Media Retrase: Data and Logistics Partner, 24 December 2020

2. Work plan update

MDV Paper: Updates from the ICEG

s47E(c), s47E noted that **S47F** was a member of the Infection Control Expert Group (ICEG) and that the MDV Paper had been provided to the group for review.

s47F

provided an overview of the feedback from ICEG on the MDV paper.

Members DISCUSSED:

- Implications of house-bound individuals and other circumstances which warrant pre-drawing of the vaccine
- Whether diluent will be provided by Pfizer
- Reports of difficulties experienced by UK nurses when mixing the Pfizer vaccine, with pharmacists engaged to mix the vaccine
- Possible regulatory (i.e. immuniser should draw up vaccine) flow on effects if vaccines are drawn up and mixed by another party instead of the immuniser
- Whether separate instructions are required for the use of the solo shot mini

Members NOTED:

• In clinical practice, the Pfizer vaccine should not be any different from other MDVs

Members AGREED:

• That the Product Information (PI) will include instructions on how to reconstitute the vaccine and that immunisers should refer to this document

ATAGI COVID Working Group Subgroup 2, Meeting No. 12 Wednesday 13 January 2021, 12.00–1.00pm

- To include clinical experience of other countries, beyond what is in the PI
- That information on solo shot mini would be helpful

Action	Responsible officer/s	Progress
2.1 Finalise MDV Paper, incorporating ICEG	SG2/NCIRS	In progress
edits as agreed by members, for Executive		
endorsement on 15 January		

• Consent documents (Patient information sheet, provider information sheet and consent form)

s47E(c), s47F noted that ATAGI Executive WG would be discussing the issue of consent at their meeting on 15 January, and the purpose of today's item is to seek input on the content of the draft consent documents.

Members DISCUSSED the suite of consent documents. Key points include:

- That the draft documents have been developed to be consistent with the endorsed advice developed by this group: Advice on obtaining and recording informed consent for COVID-19 vaccines (Found in the 'Endorsed Documents' folder on SharePoint).
 - I.e. that clear, unambiguous supporting information should be provided for patients and providers to manage perceptions, but that a consent form is not a requirement for the COVID-19 vaccination program (consistent with current practice for NIP vaccines)
- Some practitioners have concerns about consent and liability (e.g. are Medical Defence Organisations being consulted?)
- Organisations being consulted?)
 Importance of practitioners leading the way to manage perceptions, but not elevating possible concerns by providing too much information / changing the consent process from existing practice (these supporting documents would assist)
- Importance of the messaging that social distancing and other COVID-19 precautions are to continue after vaccination
- Encourage adverse event reporting both by health care providers and patients

Members NOTED: 👋

- That in general practice, verbal consent is normal process for NIP
- General practices are poised for the COVID-19 vaccination program rollout however, uncertainties about logistics, requirements etc remain
- That further advice will be provided by the Executive Working Group prior to these documents being finalised

Members AGREED:

- It will be important that any materials are produced appropriately from a communications perspective (i.e. in appropriate language for general public and variety of languages)
- That verbal consent is acceptable and some jurisdictions/providers record verbal consent
- To review the content of the draft consent documents, noting further discussion to be had at Executive meeting Friday 15 January

ATAGI COVID Working Group Subgroup 2, Meeting No. 12 Wednesday 13 January 2021, 12.00–1.00pm

Action	Responsible officer/s	Progress
2.2 Finalise suite of consent documents for	SG2/NCIRS	In progress
SG2 endorsement 20 January, review by		
SG3 chair, and Executive endorsement on		
22 January		

3. Other business

Dr Robyn Gibbs noted that the subgroup is back to weekly meetings and thanked everyone for their contribution.

4. Outcomes & Actions from previous meeting Nil.

Meeting closed at approximately 1:10pm.

This document has been released under care Act 1982 ded Care the been released under the Act and Aged Care this document of the atth and Aged Care the buttle buttle beat the the atthe of the atthe a

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group <u>Vaccine Safety, Evaluation, Monitoring and Confidence Sub Group #3</u> Teleconference 1:30 – 2:30pm

18 September 2020

Outcomes
Outcomes

In att	endance:
Mem	bers
Nigel	Crawford (chair)
•	Cheng
Chris	-
Tony	Korman
Marg s47E(c	ie Danchin), s47F
Deb P	Petrys
	e Walsh
	/l Jones
NCIRS s11C	S Technical staff
Depa	rtment of Health representatives
S+7 E(C	
Saran s47E(c	Sincial
347 2(0	
	ument has pormat Healt
1 Welcome a	and Anologies General committee husiness
Members	
• NC	TED attendees and apployies
• NC	TED Acknowledgement of Country
- 110	

- DECLARED conflicts of interest Nil (noting S47F has been invited as a temporary expert on a WHO Committee with no remuneration not considered a conflict)
- NOTED introductions from members

2. Role of Sub Group

- DISCUSSED role of the Vaccine Safety, Evaluation, Monitoring and Confidence Sub Group to provide advice on safety and surveillance, monitoring system for the COVID-19 vaccine and test the communication strategy and messaging around the vaccine
- NOTED role of NCIRS in supporting Sub Group

3. Workplan

Members:

- NOTED the four elements of the Sub Group workplan, with this meeting to focus on 1 & 4:
 - 1. Vaccine safety
 - 2. Surveillance for vaccine effectiveness and impact of the Australian program
 - 3. Evaluation of the Australian COVID-19 vaccination program
 - 4. Vaccine confidence
- NOTED the NITAG Summary: COVID-19 & CDC ACIP vaccine safety presentation

4. Vaccine Safety

Members:

- NOTED an update on international regulation activities including work with the Medicines and Healthcare products Regulatory Agency (MHRA) and the International Coalition of Medicines Regulatory Authorities (ICMRA)
- NOTED the Therapeutic Goods Administration (TGA) is developing a Pharmacovigilance Plan covering:
 - Existing adverse event reporting systems
 - o Rapid early detection and validation
 - o Communications within the Department of Health
 - External communications
 - o International collaboration
- NOTED the importance of communications being developed early with a coordinated message across TGA and the broader Department of Health

Action	Responsible office /s	Progress
4.1 Sub Group 3 to review the	COVID-19 Vaccine	In progress (agenda
Communications Strategy being	Taskforce	item for next meeting
developed by the Department of	to be no	on 2/10)
Health	of the second	
	No all all	

5. Vaccine Confidence

Members:

- DISCUSSED using transparent communication and community engagement to build public confidence and trust in the vaccine and the need to develop a framework around this
- NOTED a change in terminology from vaccine 'hesitancy' to vaccine 'confidence'

Action	Responsible officer/s	Progress
5.1 Small working group to be established to develop a framework regarding 'vaccine confidence' as part of the COVID-19 readmess planning	s47F	Interested members to contact Secretariat

6. Other Business

- NOTED the confidentiality of information discussed at meetings and the requirement to seek approval prior to speaking to the media
- AGREED to contact the Chair of Sub Group 3 or Co-Chairs of the ATAGI COVID-19 Working Group or the Department for any clarification
- AGREED to meet fortnightly on Friday from 1:30 2:30pm
- NOTED the format of agenda to remain, including an update on specific topics from members as needed
- NOTED another platform for meetings to be considered (eg videoconference)

Action Responsible officer/s Progress

	101	
6.1 Schedule fortnightly meetings for	COVID19 Vaccine Support	Completed
Subgroup 3 - Friday 1.30-2.30pm using	Section	
videoconference platform.		

7. Meeting Closed: 2.30pm

This document has been released under care Act 1982 oct of the has been released under and Aged Care Act and Aged Care this document of the health and Aged Care the but he provide the pr

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group <u>Vaccine Safety, Evaluation, Monitoring and Confidence Sub Group</u> Videoconference 1:30 – 2:30pm 2 October 2020

Outcomes	
----------	--

In att	tendance:
Allen Tony Marg	i bers Crawford (lead) Cheng Korman gie Danchin :), s47F
Diane Chery Alan	
NCIR s11C	S Technical staff S Technical staff artment of Health representatives of the leased under the art of the leased to a care the art of the art
Depa Jodie s47E(c	rtment of Health representatives en in a i
Secre	22 this free Departit
1. Welcome a	and Apologies/General committee business
Members	

Members:

- NOTED attendees and apologies (Chris Blyth)
- NOTED Acknowledgement to Country
- DECLARED conflicts of interest Nil
- NOTED introductions from members
- NOTED the role of the Sub Group

2. Outcomes

- NOTED outcomes from the previous meeting on 18 September 2020
- NOTED the Subgroup's workplan

Action	Responsible officer/s	Progress
2. Send Secretariat suggested revised	s47F	In progress
wording for workplan from 'Covid		

	1 01	Decamone 20
vaccine' to 'effective and safe Covid		
vaccine'		

3. Update from Executive Team meeting

Members:

- NOTED the Executive Team will consider and endorse papers developed by Subgroups
- DISCUSSED issues associated with possible publication of member names on the website

Action	Responsible officer/s	Progress
3 Subgroup members to send comments	Members	In progress
to Secretariat in relation to possible		
publication of names		

4. Confidence and Communications

4.1 COVID-19 Communication Strategy

Members:

- NOTED a presentation by Jodie Grieve on the Commonwealth's draft COVID-19 Communication Strategy
- DISCUSSED key groups where engagement is important eg RACGP as well as providers
- AGREED Sharepoint could be used to house relevant COVID-19 information and resources
- NOTED the role of this Subgroup to develop an evidence-based framework flagging issues and gaps, rather than delivering a strategy
- NOTED the consumer perspective requiring clear key messages that are consistent, as well as addressing false statements
- NOTED the primary care perspective requiring transparency and honesty

4.2 Collaboration on Social Science and Immunisation (COSSI)

- NOTED a presentation by s47F on a framework for supporting vaccine uptake comprising:
 - engagement with key groups, understanding needs and targeting campaigns to reach everyone in communities, including those that are culturally and linguistically diverse (CALD).
 - o central repository of resources that can be accessed quickly
 - strategies to address misinformation

Action	Responsible officer/s	Progress
4.1.1 Fortnightly agenda item key	Jodie Grieve/ ^{s47E(c), s47F}	In progress
themes/updates on Commonwealth	Secretariat	
communication strategy C		
4.1.2 Use Sharepoint page as a central	Secretariat	To progress
repository for resources and		
communication pieces		
4.1.3 Agenda for next meeting to	Secretariat	In progress
include item on community resources		
that can be shared, including regional		
components		
4.2.1 Share COSSI strategy with	s47F	In progress
members		

5. Development of a Communication Framework (Vaccine Confidence)

Members:

• NOTED a small working party had been established to commence developing a confidence & communication framework

Action	Responsible officer/s	Progress
5. More information on the ATAGI	s47F	In progress
subgroup#3 Confidence &	NCIRS	

Communication framework to be	
provided for next meeting	

6. Other Business

Members:

• NOTED the importance of open communication between ATAGI and CDNA committees

7. Next Meeting


Members:

• NOTED the next meeting on 16 October will focus on safety and pharmacovigilance

This freedom of the net of the att of the perfection of the perfection of the perfection of the att of the perfection of the att and hold of the att and hold of the perfection of the att and hold of the

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Vaccine Safety, Evaluation, Monitoring and Confidence Sub Group Videoconference 1:30 – 2:30pm 16 October 2020

Outcomes



3. Update from Executive Team meeting

- NOTED the Executive Team will consider and endorse papers developed by subgroups. •
- NOTED member names will be published on the website subject to written consent.
- NOTED half day meeting for information sharing with ATAGI subgroups will be on Tuesday • 10 November 2020 from 1-5pm AEDT.

Action	Responsible officer/s	Progress
3.1 Seek written consent to publish	ATAGI COVID-19 Working	Completed
member names on website.	Group Secretariat	

3.2 Half day information sharing	ATAGI COVID-19 Working	Invitations to be sent next
meeting for Subgroups: 1-5pm AEDT,	Group Secretariat	week
Tuesday 10 November 2020.		

4. Confidence and Communications

Members:

- NOTED the communication activities that have recently been undertaken
 - o GP webinar
 - o GP newsletter
 - Web content uploaded
 - o Met with Culturally and Linguistically Diverse team in the Department
 - Discussion with Therapeutics Goods Administration (TGA) and Office of the Gene Technology Regulator regarding the vaccine announcements.
- NOTED the working paper developed by the Collaboration on Social Science and Immunisation (COSSI)

Action	Responsible officer/s	Progress
4.1 Draft high level list of	COVID-19 Taskforce	To progress
communication activities to be placed		
on SharePoint		

5. TGA vaccine safety-pharmacovigilance plan

Members:

- NOTED the objectives of the COVID-19 Vaccine Pharmacovigilance Plan:
 - Timely collection and management of COVID-19 vaccine adverse event reports
 - Timely detection and investigation of COVID-19 vaccine safety signals
 - Timely regulatory and programmatic actions for addressing COVID-19 vaccine safety concerns
 - Timely communications for addressing emerging COVID-19 vaccine safety concerns to inform and ensure public confidence
 - Close collaboration and coordination of effort with government agencies and stakeholder organisations with an interest in vaccine safety

Action 60 00	Responsible officer/s	Progress
5.1 TGA to establish COVID Standing	TGA	
Committee and draft Terms of		
Reference		

6. Adverse Events of Special Interest (AESI)

- NOTED the discussion paper on the Adverse Events of Special Interest (AESI): COVID-19 Vaccines
- NOTED the presentation and discussion paper on SARS/ MERS Vaccine Disease Enhancement

Action	Responsible officer/s	Progress
6.1 Members to provide feedback on AESI discussion paper	Subgroup 3 Members	Add feedback in track changes to document on SharePoint
6.2 Members to provide feedback on the SARS-CoV-1 / MERS-CoV Vaccine- associated Enhanced Disease discussion paper.	Subgroup 3 Members	Add feedback in track changes to document on SharePoint

7. No fault Compensation scheme

Members:

• NOTED rather than a no fault compensation scheme, the advanced market agreements for COVID19 vaccines include an indemnity clause for the manufacturer.

8. Other Business


• Nil

9. Next Meeting

Members:

 NOTED the next meeting on 30 October 2020 will focus on Evaluation (AIR and other programs).

10. Meeting Close: 14:36



Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group <u>Vaccine Safety, Evaluation, Monitoring and Confidence Sub Group</u> Videoconference 1:30 – 2:30pm 30 October 2020

Outcomes

In attendance:
Members
Nigel Crawford (lead)
Chris Blyth
Tony Korman
Margie Danchin s47E(c), s47F
Diane Walsh
Cheryl Jones
Alan Leeb
s11C
Paul Effler
Bette Liu
Tom Snelling
NCIRS Technical staff
s11C
60 964 0
ro pono
et ion ion
be all all
est the sec
Department of Health representatives
s47E(c), s47F
Sarah Tyquin
s47E(c), s47F
Secretariat
Paul Effler Bette Liu Tom Snelling NCIRS Technical staff s11C NCIRS Technical staff s11C Department of Health representatives S47E(c), s47F Sarah Tyquin s47E(c), s47F Sarah Tyquin s47E(c), s47F Sarah Tyquin s47E(c), s47F Sarah Tyquin s47E(c), s47F
Icome and Analogie General committee business

1. Welcome and Apologies/General committee business

Members:

- NOTED Acknowledgement to Country
- NOTED attendees and apologies (Allen Cheng, John Kaldor, Deb Petrys)
- DECLARED conflicts of interest Nil

2. Outcomes from previous meeting on 16 October

- NOTED outcomes from the previous meeting on 16 October 2020
- NOTED the Adverse Events of Special Interest (AESI) discussion paper will form part of Subgroup 3's preliminary advice on safety, to be discussed/endorsed at the next meeting
- NOTED feedback on TGA's draft pharmacovigilance plan should be forwarded through the Secretariat

		FOI 2181 IC Review - Document 31
Action	Responsible officer/s	Progress
2.1 Finalise preliminary advice on safety	Subgroup 3	In progress
including AESI		

3. Program Evaluation

Members:

- DISCUSSED the Australian Immunisation Register (AIR) with Sarah Tyquin including:
 - new functionality available from 14 November, including a 'generic flag' that alerts the provider to look at their record in more detail
 - \circ $\;$ importance of linking the AIR to other data sets for safety monitoring and evaluation
 - gaps in reporting of vaccinations received in workplace settings
 - \circ $\,$ consumer consent in relation to uploading of vaccination status onto the AIR $\,$
 - separate recording of vaccine brand names
 - \circ $\;$ discussing AIR issues at the half day session for members on 10 November $\;$
- DISCUSSED elements of a COVID-19 vaccination program evaluation with s47F including:
 - o program objective
 - process for implementation
 - o vaccine uptake
 - o disease impact

Action	Responsible officer/s Progress
3.1 Invite Government agency working with	Secretariat
linked data to Subgroup 3 meeting to discuss linking to the AIR	
3.2 Prepare brief document outlining a	NCIRS (47FC In progress
range of evaluation options and timings	

4. Feedback from US FDA meeting 22 October re evaluation

Members:

• NOTED a brief update from ³⁴⁷F SO Son the US FDA meeting

5. Commonwealth Communications Activities

Members:

- NOTED an update from ^{347E(c)}^{347F} on communications activities including:
 - development of aCOVID-19 public facing resource hub
 - roll out of a social media program
 - planning for a national campaign
- NOTED Subgroup 3 advice on communications/confidence will be considered at the next meeting including:
 - material in other languages
 - o community champions
 - o informing key messages

Action	Responsible officer/s	Progress
5.1 Bring ATAGI communications advice to	NCIRS/Secretariat	In progress
next Subgroup 3 meeting for endorsement		

6. Next Meeting

Members:

• DISCUSSED changing the fortnightly meeting day from Fridays to Thursdays at 11.30am (next meeting proposed as Thursday 12 November at 11.30am)

Meeting Close: approx. 2.30pm

ATAGI COVID Working Group Subgroup 3, Meeting No. 5 26 November 2020, 11:30 – 12:30pm

In attendance:

Members	NCIRS Technical Staff	Department of Health reps
Nigel Crawford- Lead	s11C	s47E(c), s47F
Cheryl Jones		
Tony Korman		
John Kaldor		
s47E(c), s47F		Secretariat
Alan Leeb		s22
Deb Petrys		
Paul Effler		

1. Welcome and apologies / general committee business Members:

- NOTED acknowledgement to country
- NOTED attendees and apologies (Allen Cheng, Diane Walsh and Margie Danchin)
- Declared no conflicts of interest

2. Outcomes and Actions from previous meeting on 30 October

• Members ENDORSED outcomes and actions from previous meeting with no amendments

3. Update from Executive Team Meeting

Members NOTED that the priority populations and vaccine policy have been published

4. Communications and confidence advice

- ATAGI COVID19 WG3 Comms Strategy Preliminary advice DRAFT v2.1
- Attachment C Australian Immunisation stakeholder draft v1.5 23Nov2020

Members DISCUSSED:

- The purpose of the communications and confidence advice
- The role of Subgroups in providing advice to the Department and identifying gaps
- Minor refinement to the paragraph: Develop additional messages for specific target groups
- Suggestions for Attachment C (which is a living document) including category headings

Members ENDORSED both documents for consideration by the Working Group Executive.

Action	Responsible officer/s	Progress
Forward Comms advice to Executive for	Secretariat	Completed
endorsement		

5. Safety advice

- ATAGI COVID19 WG3 Vaccine Safety preliminary advice DRAFT v1.2
- AESI for COVID19 vaccines 12112020 v3
- SARS MERS Vaccine Enhanced Disease Summary V2

Members AGREED to continue to refine the documents and incorporate inputs including:

 Revision of no-fault compensation scheme wording to make the subgroup's recommendation clearer

ATAGI COVID Working Group Subgroup 3, Meeting No. 5 26 November 2020, 11:30 - 12:30pm

- Clinical management of adverse reactions
- Review of patients prior to receiving a second dose
- o Stronger communications on safety and the need to report adverse events
- Inclusion of an executive summary to capture clear recommendations 0

Action	Responsible officer/s	Progress
Incorporate changes to draft safety advice	NCIRS/Secretariat/Members	In progress
and circulate to members for comment by		
next week		

6. Evaluation framework & advice

ATAGI COVID 19 WG3 Evaluation Preliminary advice DRAFT v2

Members NOTED:

- The critical role of evaluation in relation to the National Immunisation Program
- Overview and purpose of the evaluation advice which is a work in progress
- Aspects of the advice including multi-phased evaluation balancing real time monitoring with 6-12 months evaluation
- o That Communicable Diseases Network Australia supports the modelling advice developed by Subgroup 1

Members DISCUSSED:

- The need for greater clarity around ownership implementing components of the Data sources that should be highlighted
- 0

7. Incident management strategy

Members AGREED to conduct scenario planning at the next meeting

Action Responsil	ole officer/s Progress
Conduct scenario planning next week, Subgroup	3 To progress
3 December 2020	

8. Commonwealth communications activities update

s47E(c), s47F provided an update on communications activities.

Members NOTED:

- Importance of advice from the subgroup to ensure the Department is briefing the public well
- The Minister and Prime Minister's Offices receive regular communications updates

s47E(c), will provide an update on sentiment monitoring at the next meeting c/7

9. Other business

Nil

Meeting closed approx. 12:40pm

ATAGI COVID Working Group Subgroup 3, Meeting No. 6 3 December 2020, 11:30 – 12:30pm

In attendance:

Members	NCIRS Technical Staff		Department of Health reps	
Nigel Crawford- Lead	s11C		s47E(c), s47F	
Cheryl Jones				
Tony Korman			Leanne Ringwood s47E(c), s47F	
John Kaldor				
s47E(c), s47F				
Alan Leeb				
Paul Effler				
Diane Walsh			Secretariat	
Margie Danchin			s22	
Katie Attwell				

1. Welcome and apologies / general committee business Members:

- NOTED acknowledgement to country
- NOTED attendees (welcoming Katie Attwell from the communications working group of Subgroup 3) and apologies (Allen Cheng and Debra Petrys)
- Declared no conflicts of interest

2. Outcomes and Actions from previous meeting on 26 November

• Members ENDORSED outcomes and actions from previous meeting with no amendments

3. Update from Executive Team Meeting Members NOTED that the Executive Team endorsed the Subgroup 3 communications advice

4. Safety advice

- ATAGI COVID19 WG3 Vaccine Safety preliminary advice DRAFT v1.4
- Attachment A_AESI for COVID19 vaccines 12112020 v3
- Attachment D_SARS MERS VaccineEnhancedDiseaseSummary V2

Members DISCUSSED:

- Encouraging reporting of adverse events and the interplay between communications and safety
- Reporting to the Australian Immunisation Register and the importance of 'active surveillance'
- \circ The structure of the document

TGA thanked Subgroup 3 members for this work which will be a helpful resource for pharmacovigilance activities.

Members ENDORSED the safety advice documents for consideration by the Working Group Executive, subject to incorporation of further input by NCIRS. It is anticipated that the safety advice will be provided to the Taskforce and TGA.

Action	Responsible officer/s	Progress
Forward safety advice to Executive for	Secretariat	Completed
endorsement		

ATAGI COVID Working Group Subgroup 3, Meeting No. 6 3 December 2020, 11:30 – 12:30pm

5. Communication issues/planning

List of likely scenarios

s47E(c), s47F from Corona Comms provided an update including:

- Request for feedback from members on the draft COVID-19 vaccine scenario register 0 and any significant events warranting a comms response
- Article in The Conversation by Chris Blyth and Allen Cheng
- Media briefings being undertaken by the Department
- Development of a COVID-19 hub for publishing on the Department's website
- Spokespeople to be deployed depending on the scenario and domain

Members NOTED

- the National Aboriginal Community Controlled Health Organisation is an important stakeholder organisation
- o developments in the United Kingdom in coming weeks will have implications for vaccine confidence
- the department is working towards identifying spokespeople at a local level
- o some jurisdictions are setting up teams for COVID-19 rollout, including communications activities

communications activities Members AGREED to hold a scenario testing session at the next meeting on 10 December Members AGREED to hold a scenario testing session active next meeting on 10 December covering an adverse event in Australia, with a future scenario to have an international context. Other business Nil eting closed at 12:10pm This document in the future scenario to have an international context.

6. Other business

Meeting closed at 12:10pm

Page 2 of 2

ATAGI COVID Working Group Subgroup 3, Meeting No. 7 10 December 2020, 11:30 - 12:30pm

In attendance:

NCIRS Technical Staff	Department of Health reps
s11C	s47E(c), s47F
	Claire Larter
	s47E(c), s47F
	Secretariat
	s22
	NOT CL

- Welcome and apologies / general committee business Members:

 NOTED acknowledgement to country
 NOTED attendees and apologies (nil)
 Declared no conflicts of interest

 Outcomes and Actions from previous meeting on 26 November

 Members ENDORSED outcomes and actions from previous meeting

 - - Members ENDORSED outcomes and actions from previous meeting with no amendments

3. Update from Executive Team Meeting

Members NOTED:

- that the Executive Team endorsed the Subgroup 3 safety advice
- evaluation advice requires further direction from Executive/Taskforce •

4. Scenario walk through (Australian context)

Members DISCUSSED how to respond to likely scenarios following vaccine roll out such as:

- Mild reactions (e.g. hives) to severe anaphylactic episodes requiring intensive care admission •
- Deaths •
- Increased media attention to Commonwealth and local health departments
- Poor vaccine sentiment and reduced uptake •

Members AGREED to the following key points:

- Clear communication channels and early dissemination of talking points to spokespeople ٠
- Accurate, transparent and consistent messaging •
- Consider cultural sensitivities and the need for emphatic messaging •
- Early public reassurance and clear advice on the process being undertaken •
- Importance of alerting and involving the Commonwealth Health Department and TGA early ٠
- Whether there is a need to document vaccine attribution and potential for causality •
- Importance of sentiment and uptake monitoring and how they complement each other

ATAGI COVID Working Group Subgroup 3, Meeting No. 7 10 December 2020, 11:30 – 12:30pm

Members NOTED:

- Daily media briefing by the Department's CMO
- Department's central news team and how it operates
- Preparation work with journalists is underway
- TGA's signal and safety processes in response to vaccine adverse events
- The need to explore vaccine indemnity further

		Progress
Circulate information on how and when to	Secretariat/s47E(c), s47F	To progress
contact the news team		

5. Other business

Nil.

Meeting closed at 12:40pm

This document has been released under Care Act 1982 ded Care the been released under Care Act 1982 ded Care the bound of the attraction and hoed Care the attraction attracti

ATAGI COVID Working Group Subgroup 3, Meeting No. 8 17 December 2020, 11:30 – 12:30pm

In attendance:

Members	NCIRS Technical Staff	Department of Health reps
Nigel Crawford - Lead	s11C	s47E(c), s47F
Allen Cheng		
Tony Korman	1	Secretariat
John Kaldor		s22
s47E(c), s47F		
Alan Leeb		
Paul Effler	1	
Diane Walsh		
Margie Danchin		
Katie Atwell		
Debra Petrys		
Tom Snelling		
 Welcome and apologies / Members: NOTED acknowledgem NOTED attendees and Declared no conflicts of 	general committee busines ent to country apologies (Bette Liu) f interest	iness 10 December om previous meeting with no amendments
	m previous meeting on outcomes and actions to on the excellent scenar	10 December om previous meeting with no amendments io planning that was undertaken

- 1. Welcome and apologies / general committee business Members:
 - NOTED acknowledgement to country •
 - NOTED attendees and apologies (Bette Liu) •
 - Declared no conflicts of interest
- 2. Outcomes and Actions from previous meeting on 10 December
 - Members ENDORSED outcomes and actions from previous meeting with no amendments and provided feedback on the excellent scenario planning that was undertaken

3. Update from ATAGI Working Group Information Sharing Session 15 Dec 2020 Members AGREED:

- Session was useful however noted the need for further clarity on issues including:
 - how safety signals are communicated to the Department 0
 - decision making in relation to prioritisation (from a consumer perspective) 0
 - how to handle media requests and the need for a clearer process 0

Members NOTED: NO

- Established mechanisms in place to communicate significant safety signals to the Department
- Need for a mechanism to share speaking points to ensure consistency in messaging •
- Corona Comms Team's intention to provide greater clarity on handling media requests •
- Overlap in issues considered across the ATAGI subgroups and opportunities to work together

4. Evaluation framework - planning

Members AGREED:

- Two aspects of the evaluation framework:
 - real-time monitoring of the rollout (data collection)
 - broader aspects of evaluation (impacts on disease burden etc)

Members DISCUSSED

- Role of Department's logistics and data partners
- Potential topics for the evaluation framework including:
 - Doses given, mandatory reporting to AIR 0
 - Vaccine safety, adverse events 0

ATAGI COVID Working Group Subgroup 3, Meeting No. 8 17 December 2020, 11:30 – 12:30pm

- Cold chain breaches
- Communications and messaging
- Vaccine sentiment, hesitancy
- Data sources and collection points
- How far back the evaluation framework will go (e.g. formation of subgroups)
- Lessons learned, what worked and any improvements
- Focus on what needs to be in place in the early days of the rollout and separating immediate and longer term requirements
- Identifying the indicators and frequency of reporting, the decisions that need to be made about rollout and the information needed to inform those decisions
- Advice on specific data fields that need to be captured
- How the national evaluation framework will link to jurisdictional processes
- Lessons learned from the CDNA HPV vaccine evaluation framework
- Role of Subgroup in giving advice on an evaluation framework rather than undertaking the evaluation
- Longer term and broader picture, such as addition of COVID-19 vaccines to the NIP
- Reputable sources of information such as the Department's vaccine hub and NCIRS FAQs

Members NOTED:

- TGA working closely with NHMRA in relation to Adverse Events Following Immunisation (AEFI) data, noting that only high level information on adverse events cases are visible on WHO database
- TGA receives adverse event reports through the Database of Adverse Event Notifications which is updated following validation of reports
- TGA considering how to report AEFL
- Mandatory reporting to AIR is well-underway

Responsible officer/s	Progress
Subgroup 3/NCIRS	In progress
Secretariat	Completed

- 5. Subgroup 3 meeting timetable 2021 Members AGREED to
 - <u>Phase 1</u>: provide feedback on the draft evaluation advice by **8 January 2021** (*Preliminary draft advice on evaluation strategies v2.1*) high level inclusions in an evaluation plan
 - NCIRS to finalise draft in week of **11 January 2021**
 - Subgroup 3 Lead, NCIRS and Secretariat to pre-meet on **11/12 January 2021**
 - Subgroup 3 to reconvene **14 January 2021** to endorse evaluation advice and provide to Executive Group for consideration on 15 January 2021
 - <u>Phase 2</u>: build on Phase 1 work via Expressions of Interest for smaller group/s to flesh out detail of evaluation plan

Action	Responsible officer/s	Progress
Seek members' availability and topic	Secretariat	Completed
interests for smaller group evaluation		
workshop		

Subgroup Lead thanked everyone for their work and support and wished everyone a restful break. Meeting closed 12:30pm

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group #1 Videoconference 4 September 2020

In attendance: Executive Members Chris Blyth (Co-Chair) Allen Cheng (Co-Chair) Lisa Schofield Nick Henderson S11C Hope Peisley Katie Flanagan Nigel Crawford Robyn Gibbs Sub group Members Karen Bellamy Katherine Gibney Michelle Giles Madeline Hall Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling S47E(e), S47F Angus Dawson Kana Subbarao Margie Danchio Heelle Holl Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling S47E(e), S47F Angus Dawson Kana Subbarao Margie Danchio Heelle Holl Cheryl Jones S47E(e), S47F Angus Dawson Kana Subbarao Heelle Holl Cheryl Jones S47E(e), S47F Angus Dawson Kana S
Chris Blyth (Co-Chair) Allen Cheng (Co-Chair) Lisa Schofield Nick Henderson
Allen Cheng (Co-Chair) Lisa Schofield Nick Henderson
Lisa Schofield Nick Henderson
Nick Henderson
s11C Hope Peisley Katie Flanagan Nigel Crawford Robyn Gibbs Sub group Members Karen Bellamy Katherine Gibney Michelle Giles Madeline Hall Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danchin Lee Depresent and Suppillance (NCIPS) consecutations (abcorver)
Hope Peisley Katie Flanagan Nigel Crawford Robyn Gibbs Sub group Members Karen Bellamy Katherine Gibney Michelle Giles Madeline Hall Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling Satter Constant of the function of th
Katie Flanagan Nigel Crawford Robyn Gibbs Sub group Members Karen Bellamy Katherine Gibney Michelle Giles Madeline Hall Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Katherine Gibney Matienel Content of the flat of
Nigel Crawford Robyn Gibbs Sub group Members Karen Bellamy Katherine Gibney Michelle Giles Madeline Hall Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao
Robyn Gibbs Sub group Members Karen Bellamy Katherine Gibney Michelle Giles Madeline Hall Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danchin Hittor Internation Percearch and Suprolilance (NCIPS) representatives (observers)
Sub group Members Karen Bellamy Katherine Gibney Michelle Giles Madeline Hall Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danchine Helen Hall Cheryl Jones Helen Hall Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danchine Helen Hall Cheryl Jones Helen Hall Cheryl Helen Hall Chery
Sub group Members Karen Bellamy Katherine Gibney Michelle Giles Madeline Hall Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danchine Herburg Jones Herburg Jon
Karen Bellamy Katherine Gibney Michelle Giles Madeline Hall Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danchine Her Hall Cheryl Jones Her H
Katherine Gibney Michelle Giles Madeline Hall Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danchin Hational Control on Percarch and Surveillance (NCIPS) representatives (observers)
Michelle Giles Madeline Hall Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danchine Hational Control for Junio Linear (NCIPS) representatives (observers)
Madeline Hall Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danchin United the performance (NCIPS) representatives (observers)
Cheryl Jones Bette Liu Debra Petrys Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danching
Debra Petrys Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danchin Under the Department and Surveillance (NCIPS) representatives (observers)
Nicholas Silberstein Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danchin Proposition Perspert and Surveillance (NCIPS) representatives (observers)
Tom Snelling s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danchin National Control for Internation Persoarch and Surveillance (NCIPS) representatives (observers)
s47E(c), s47F Angus Dawson Kanta Subbarao Margie Danchin National Control for Implunication Research and Surveillance (NCIPS) representatives (observers)
Angus Dawson Kanta Subbarao Margie Danchin National Control for Lincourisation Research and Surveillance (NCIPS) representatives (observers)
Kanta Subbarao Margie Danchin National Control for Limpunication Research and Suproillance (NCIRS) representatives (observers)
Margie Danchin Grup In Superior Research and Superillance (NCIPS) representatives (observers)
National Control for Remunication Research and Surveillance (NCIPS) representatives (observers)
National Control for Immunication Research and Sunvaillance (NCIRS) representatives (observers)
National Centrevior information research and surveindrice (NCIRS) representatives (Observers)
s11C
s11C
Department of Health representatives
Secretariat
s47E(c), s47F

1. Meeting Opened

Members:

- NOTED attendees and apologies
- DECLARED no conflicts of interest

2. Finalise Scope and Terms of Reference (ToR) for the Working Group

Members:

- DISCUSSED Working Group ToR and members asked for comments •
- NOTED sub group leads were encouraged to advise the Executive if they require representation • from a particular group
- NOTED Dr Penny Burns, Prof Lena Sanci, Dr Alan Leeb could possibly be the primary healthcare • representatives

Action:		
Action	Responsible officer/s	Progress
2.1 Review ToR and add	ATAGI Secretariat	Completed
suggested updates		
2.2 Endorse Working Group ToR	Co-Chairs	Completed
with changes	20 ¹	0
2.3 Draft mud map of COVID-19	COVID-19 Taskforce	Inprogress
Committees and how they		6
integrate with one another		
2.4 Make recommendations of	Executive members	Completed
possible Primary Care	Che Che d'	
representatives for the Working		
Group	0, til, til	

3. Working Group work streams

- Group work streams ers: NOTED NCIRS Technical Support staff will support each sub group, refer to Attachment A • Working Group Structure
- NOTED NCIRS draft work plan

Action:	in S	1.50	Jox


Action	Responsible officer/s	Progress
3.1 Review NCIRS work plan to	COVID-19 Taskforce	In progress
identify gaps and ensure key		
deliverables of each sub group		
are included.		
3.2 Taskforce to provide a list of	COVID-19 Taskforce	In progress
resources that are available.		
3.3 Approved work plan to be	ATAGI Secretariat	In progress
provided to Sub Group leads for		
comment.		
3.4 Establish new email inbox	ATAGI Secretariat	SharePoint page is Complete,
and a Working Group SharePoint		email inbox in progress
page for the ATAGI COVID		
Working Group		
3.5 Establish a team to provide	Immunisation and	In progress
support to the ATAGI COVID	Communicable Disease Branch	

Working Group and the JIC		
COVID Working Group		
3.6 Provide link to the COVID-19	COVID-19 Taskforce	Completed
Vaccines and Treatments for		
Australia Science and Industry		
Technical Advisory Group webpage		
3.7 Schedule weekly Executive	ATAGI Secretariat	Completed
Working Group meeting		completed
3.8 Schedule initial meetings for	ATAGI Secretariat	Competed
each Sub Group		
3.9 Provide the COVID-19	NCIRS	Completed
Taskforce with a list of data		
required		
3.10 Arrange CDNA	ATAGI Secretariat	In progress
representation on each		
Subgroup		<u>v</u>
Sub groups – Preliminary Discussion: Members: • NOTED introductions from M Meeting Closed: 11:15 am	CO OCLE	
This Free Der the the Der	attric	
This free Der the the Dy the Der	artific	

4. Sub groups – Preliminary Discussions

5. Meeting Closed: 11:15 am

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group #2 Videoconference 11 September 2020



2. NCIRS work plan

- NOTED the deliverables requested by the Department of Health for each sub group. Will need to
 provide Government with preliminary advice from the ATAGI COVID-19 working group by the end
 of September.
- NOTED NCIRS Technical Support staff will support each sub group.
- DISCUSSED the NCIRS work plan and agreed that it would be a useful iterative tool,

Action: Action	Responsible officer/s	Progress
2.1 Update and Finalise ATAGIs Preliminary advice on general principles to guide the prioritisation of target populations in a COVID-19 vaccination program in Australia	Subgroup 1 – Vaccine utilisation and prioritisation	In Progress (due 17/9)
2.2 First draft of ATAGIs COVID19 vaccine prioritisation matrix	Subgroup 1 – Vaccine utilisation and prioritisation	In progress (due 17/9)
2.3 Overlay priority populations with the Oxford and UQ vaccines.	Subgroup 1 – Vaccine utilisation and prioritisation	In progress (due 17/9)
2.4 Monitoring of COVID-19 vaccines	COVID-19 Taskforce	In progress
2.5 Prepare implementation plan for rollout of Oxford, UQ and RNA vaccines.	Subgroup 2 – Vaccine distribution and program implementation	(In progress (due 30/9)
2.6 Prepare advice on Workforce required for implementation of COVID-19 vaccine – determine how many and what sort of training will be required	Subgroup 2 Vaccine distribution and program implementation	In progress (due 30/9)
2.7 Plan for monitoring and tracking doses of the COVID-19 vaccine	Subgroup 2 – Vaccine distribution and program implementation	In progress (due 30/9)
2.8 Prepare advice on safety and surveillance, monitoring system to be used- how existing systems such as AusVaxSafety and AIR fit.	Subgroup 3 – Vaccine Safety, Evaluation, Monitoring and Confidence	In progress
2.9 Test the communication strategy and messaging around the COVID-19 vaccine	Subgroup 3 - Vaccine Safety, Evaluation, Monitoring and Confidence	In progress
2.10 NCIRS technical leads to be invited to Executive Group meetings	ATAGI Secretariat	Completed

3. Working Group work streams

Members:

Subgroup 1

- NOTED the prioritisation matrix needs to be updated to align with what is happening in Australia
- NOTED ring- fencing may need to be considered.

Subgroup 2

• NOTED that implementation plan for the rollout of COVID-19 Vaccines and systems to track the vaccine are a priority of this subgroup.

Subgroup 3

- NOTED a landscape analysis of global vaccine safety plans would be useful.
- NOTED the importance of linking into the communication strategy early.
- NOTED that tracking vials administered to patients is a priority for this subgroup.

Action		Responsible officer/s	Progress
3.1 ^{s47F}	to meet with	NCIRS technical leads and	Completed
NCIRS techni	ical leads prior to	Subgroup 1 Lead	
sub group1 r	neeting.		
3.2 ATAGI se	cretariat to	ATAGI Secretariat	In progress
establish pro	cess with TGA to		
share inform	ation		
3.4 Establish	new email inbox	ATAGI Secretariat	Completed-Email to Member
and a Worki	ng Group SharePoint	inc.	with SharePoint and inbox
page for the	ATAGI COVID	- D - 2	details 14/9/2020
Working Gro	up. Provide details	50° 0,0°	
to Working O	Group members	le a start	
		Che Dar 91	
3.5 AIR shou	ld be a standing	ATAGI Secretariat	Completed
item on the	Executive Meeting	10 till 1th	
Agenda			
		nas foll of the	
eeting Closed	l: 10.30am		
	D'NI	U CO.	
	C A		
	90° edu	2 ²¹	
	this tree De	221	
	This Free De	221	
	This Free De	2011	
	This Free De	2211	
	This Free De	ATAGI Secretariat ATAGI Secretariat ATAGI Secretariat ATAGI Secretariat ATAGI Secretariat ATAGI Secretariat ATAGI Secretariat	

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group #3 Videoconference 18 September 2020

n attendance: Executive Members
Chris Blyth (Co-Chair)
Allen Cheng (Co-Chair)
.isa Schofield
Nick Henderson 11C
(atie Flanagan
Nigel Crawford
Robyn Gibbs
2
NCIRS support staff
an ten te ane
Lee allo all
25 JULIO 260
All C Hope Peisley Katie Flanagan Nigel Crawford Robyn Gibbs NCIRS support staff 11C Department of Health representatives ArE(c), s47F Sarah Sinclair Secretariat 12 13 14 14 14 14 14 14 14 14 14 14
are Cinter Culture Culture Culture
Saran Sinclair
in s crooper
Secretariat
22 the the
$\langle \phi \rangle$

Outcomes

1. Meeting Opened

- NOTED acknowledgement of Country
- NOTED attendees and apologies
- DECLARED no conflicts of interest

2. Australian Immunisation Register

• No discussion

3. Communications

Members:

 NOTED that any media requests should be responded to in line with other ATAGI media requests. ATAGI members are able to respond as individual experts, however if requested to speak on behalf of ATAGI or the ATAGI COVID-19 Working Group, members are required to seek approval from the Department via the <u>ATAGI.Secretariat@health.gov.au</u>.

4. Subgroup Updates

Members:

• NOTED updates from Subgroup leads.

Action:	inder	- MO
Action	Responsible officer/s	Progress
4.1 Workshop ring-fencing and incorporate into prioritisation document.	Subgroup 1 – Vaccine	[°] To progress
4.2 Overlay priority populations with the Oxford and UQ vaccines.	Subgroup 4 – Vaccine utilisation and prioritisation	In progress
4.3 Prepare implementation plan for the rollout of each vaccine -Oxford, UQ and BNA vaccines. How would you roll out a targeted program? Provide different scenarios.	Subgroup 2 – Vaccine distribution and program implementation	In progress (preliminary draft due 30/9)
4.4 COVID 19 vaccine Taskforce to meet with F to further explore scenarios to be tested.	COVID-19 Vaccine Taskforce and Subgroup 2 Lead	To progress
4.5 Test Communication Strategy with various advisory groups including COVID-19 ATAGI working Group	COVID-19 Vaccine Taskforce and Subgroup 3 – Vaccine Safety, Evaluation, Monitoring and Confidence	To progress
4.6 Update ATAGI webpage to include information about the ATAGI COVID-19 Working Group	ATAGI Secretariat	In progress

5. Other business

Members:

6.

- NOTED the verbal update from Ms Peisley on the Astra Zeneca meeting, 16 September 2020.
- NOTED the verbal update from Ms Peisley on the NITAG meeting, 17 September 2020 (Australia, Canada, UK, US, Germany, and World Health Organisation).

Action	Responsible officer/s	Progress	
5.1 Arrange a meeting with AstraZeneca to brief the ATAGI COVID-19 Working Group	COVID-19 Vaccine Support Section	In progress	
5.2 ATAGI to provide the Department with themes/questions they would like to discuss with AstraZeneca	ATAGI Co-Chairs	In progress	
5.3 Provide overview brief of what NITAGS are doing in the COVID-19 space.	NCIRS 100 ACT 10 AO	In progress	
5.2 ATAGI to provide the Department with themes/questions they would like to discuss with AstraZeneca ATAGI Co-Chairs In progress 5.3 Provide overview brief of what NITAGS are doing in the COVID-19 space. NCIRS In progress Meeting Closed: 10.31am NCIRS In progress			
This freedom	Partime		

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group **Executive Team Meeting #4 by Videoconference** 24 September 2020, 4.30-5.30pm

Outcomes

In attendance: **Executive Members** Chris Blyth (Co-Chair) Lisa Schofield Nick Henderson s11C Hope Peisley Katie Flanagan Nigel Crawford Robyn Gibbs Department of Health representatives the action of the althouse the

- NOTED attendees and apologies (Allen Cheng) •
- DECLARED no conflicts of interest
- NOTED outcomes from previous meeting

2. Communications

Members:

NOTED presentation by Jodie Grieve on the COVID-19 Communication • Strategy and draft plan on a page summarising strategic approach, key messages, audience and activities. The communication strategy will:

- include health care workers
- align and interconnect with other strategies (eg Covid Safe)
- reflect open and transparent decision making to promote confidence

- NOTED other communication activities being undertaken in the Department:
 - o participation in a GP webinar discussing ATAGI activities
 - o web content to be expanded and used for social media
 - letters to be sent to providers
 - market research to be conducted on community attitudes, noting strong community support for COVID-19 vaccines to date
- NOTED Subgroup 3 is considering communications and connections with other groups (eg aged care and disability)
- NOTED consistent messaging and transparency around decision making processes are crucial

Action	Responsible officer/s	Progress
2.1 Upload draft communication plan on a	Secretariat	Completed
page on Sharepoint		
2.2 Provide feedback on communication	Members	In progress
plan, including suggestions to disseminate	*	
information to key groups	2 ^{CI}	.9,
2.3 Incorporate feedback and bring revised	Jodie Grieve	n progress
plan back to Working Group	6 6 A	
2.4 Update ATAGI website with information	Secretariat	In progress
about Working Group and Subgroups		
2.5 Seek advice from Subgroup members	Secretariat	In progress
regarding publication of names on website		

3. New committee members

- AGREED to the addition of new CDNA representatives:
 - o s47F ATAG(full committee
 - Dr Christine Selvey + Subgroup 1
 - Dr Annaliese van Diemen Subgroup 2
 - Prof John Kaldor Subgroup 3
- AGREED to the addition of new GP representatives:
 - Dr Penny Burns Subgroup 1
 - Prof Lena Sanci Subgroup 2
 - Dr Alan Leeb Subgroup 3
- AGREED to the addition of other representatives for Subgroup 1, noting that membership across groups will need to be agile as required:
 - Prof Dave Durrheim
 - Aboriginal and Torres Strait Islander rep (nominated through CDNA)
 - Gerontologist (preferred Prof Chris Etherton-Beer; Geriatrician and PBAC member)
 - Member with expertise in evaluation of benefit versus risk

Action	Responsible officer/s	Progress
3.1 Make necessary arrangements with	Secretariat	In progress
proposed members		

4. Subgroup Updates

Members:

- NOTED updates from Subgroup leads •
- NOTED Subgroups need to come together to share information
- AGREED Executive Team should consider and endorse documents developed by Subgroups before advice is provided to the Taskforce

Action	Responsible officer/s	Progress
4.1 Plan to bring Subgroup members together for half day information sharing (end of October)	Secretariat	To progress
4.2 Embed process to seek Executive	Secretariat and	In progress
approval of Subgroup documents	Subgroup leads	

5. Other business

Members:

- NOTED verbal update from Ms Peisley on arrangements for ext meeting •
- with AstraZeneca (likely week commencing 5 or 12 October) C;0
- AGREED no Executive Team meeting next week
- AGREED future meetings on Fridays at 12 noon (A

	N
Responsible officer/s	Progress
Secretariat	In progress
epartment of the	
	Responsible officer/s Secretariae hashortot

6. N

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group **Executive Team Meeting #5 by Videoconference** 9 October 2020, 12-1pm

Outcomes

In attendance: **Executive Members**

Chris Blyth (Co-Chair) Allen Cheng (Co-Chair) Lisa Schofield Nick Henderson s11C **Hope Peisley** Katie Flanagan **Nigel Crawford Robyn Gibbs**

NCIRS support staff

s11C

Department of Health representatives

Sarah Sinclair s47E(c), s47F

Secretariat s22

1. Meeting Opened

Members:

- Partment of Health representatives Tah Sinclair E(c), s47F Cretariat Opened ers: NOTED Acknowledgement to Country and the excellent work Aboriginal and Torres Strait Islander communities have done in relation to COVID-19 Strait Islander communities have done in relation to COVID-19
- NOTED attendees and apologies (nil) •
- DECLARED no conflicts of interest

2. Outcomes and Actions from previous meeting

- ENDORSED outcomes from the previous meeting on 24 September 2020 •
- NOTED information on the ATAGI COVID-19 Working Group was published today at • https://www.health.gov.au/committees-and-groups/australian-technical-advisory-group-onimmunisation-atagi-covid-19-working-group
- NOTED all ATAGI COVID-19 Subgroups discussed the proposal to publish member names on the website with no objections
- AGREED to proceed with publishing member names subject to completion of consent forms by members
- AGREED to bring all members together for a half day information sharing session in the first • week of November 2020

Action	Responsible officer/s	Progress
2.1 Seek written consent from all subgroup members to publish names on website	Secretariat	To progress
2.2 Organise half day session for all members in November	Secretariat	In progress

3. Overall aim of COVID-19 Vaccine Program

Members:

• NOTED the suggested aim of the program under discussion by Subgroup 1

4. Subgroup Updates

Members:

- NOTED new members appointed to all Subgroups
- NOTED updates from Subgroups, including:
 - o Subgroup 1 will bring a prioritisation matrix to the Executive meeting in a fortnight
 - Subgroup 2 has proposed further workplan topics (Executive identified top three topics as multidose vials, consent, and checklist/s relating to vaccine delivery)
 - Subgroup 3 is preparing a confidence and communication framework from a social science perspective and is working closely with the pepartment
- AGREED to invite ^{\$47F}
 to join Subgroup's due to his expertise in safety and evaluation

Action	Responsible office	r/s Progress
4.1 Advise on the process around informati	on Lisa Schofield	Discuss at next
prepared by the ATAGI COVID-19 Working	Group	meeting
and whether further input is needed	Ŏ	
4.2 Extend invitation to s47F	\$47F	Completed

5. Subgroup 2 papers for endorsement

Members:

- ENDORSED the following discussion papers, noting they will be updated when more information about the vaccine/s is available:
 - frozen vaccine logistics
 - workforce competencies
- DISCUSSED next steps in relation to this work, including whether the documents can be circulated to Jurisdictional Immunisation Coordinators

Action	Responsible officer/s	Progress
5 Advise on next steps in relation to discussion	Lisa Schofield	Discuss at next
papers on workforce competencies and frozen		meeting
logistics		

6. Meeting with AstraZeneca (20 October)

Members:

 NOTED advice from Ms Peisley that attendance at the meeting with AstraZeneca carries strict obligations and any information provided can only being used for the express purposes under which it is given (i.e. within the ATAGI structure and not beyond)

NOTED the Taskforce is anticipating a similar meeting with CSL in approximately one month •

Action	Responsible officer/s	Progress
6 Email to be sent to ATAGI members seeking confirmation regarding AstraZeneca meeting obligations	Taskforce	In progress

7. Australian Immunisation Register (AIR)

Members:

NOTED the Minister has provided approval for the Department to commence consultation • on mandatory reporting to the AIR

8. Communications

Members:

DISCUSSED the need for COVID-19 key stakeholder briefings broader than primary care • (similar to monthly flu roundtables) , di

	6	S S S S S S S S S S S S S S S S S S S
Action	Responsible officer/s	Progress
8.1 Clarify what COVID-19	Hope Peisley	in progress
stakeholder briefings have been		00-
done or are planned		
8.2 Discuss stakeholder briefings	\$47F	Completed
with Lisa Schofield		
	De all all	
Other Business	25 Millinger	

9. Other Business

Members:

- r Business mbers: NOTED NCIRS is holding a public seminar with AstraZeneca in late November •
- DISCUSSED the need for Garity in defining the safety roles of ATAGI and the TGA's Advisory • Committee on Vaccines (ACV) and whether a meeting with Chairs and the Department is needed to define where and discuss how the committees can work together

9 Organise meeting with ACV	Secretariat	To progress
and ATAGI Chairs subject to		
advice from Lisa Schofield		

10. Meeting Closed: approx. 1pm

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group **Executive Team Meeting #6 by Videoconference** 16 October 2020, 12-1pm Outcomes

s11C Hope Peisley Katie Flanagan Nigel Crawford **Robyn Gibbs**

NCIRS support staff s11C

In attendance: **Executive Members** Chris Blyth (Co-Chair) Allen Cheng (Co-Chair) Nick Henderson

Department of Health representatives

Sarah Sinclair s47E(c), s47F

Secretariat

1. Meeting Opened

s22

Members:

- Jpened ers: NOTED Acknowledgement to Country NOTED attendees and apologies (Lisa Sch-)ECLARED no conflicts of interest nd Actions from previor ED outcomes f) how f

2. Outcomes and Actions from previous meeting

- ENDORSED outcomes from the previous meeting on 9 October 2020
- DISCUSSED how outputs of working group will be managed once finalised •
- NOTED the update on stakeholder briefings recently undertaken: •
 - GP webinar
 - **GP** newsletters 0
 - Web content uploaded and more content in development 0
 - Letter from Dr Brendan Murphy sent to the 15 peak bodies 0
 - Professor Kidd social media video published and more content in development 0
 - UQ agreement announcement published on health.gov.au and on social media 0
 - TGA statement about AstraZeneca provisional determination published

Action	Responsible officer/s	Progress
2.1 Seek written consent to publish member	ATAGI COVID-19	Completed
names on website	Working Group	
	Secretariat	
2.2 Half day information sharing for Subgroups:	ATAGI COVID-19	In progress
1-5pm AEDT, Tuesday 10 November 2020	Working Group	
	Secretariat	
2.3 Outline timeframes for when key deliverables	COVID-19 Taskforce	In progress
from Subgroups can be shared with stakeholders		
2.4 Centralise international documents on	ATAGI COVID-19	In progress
SharePoint	Working Group	
	Secretariat and NCIRS	

3. Subgroup membership

Members:

- DISCUSSED the requests for additional members on the Subgroups •
 - Health Economist to be included on Subgroup 1 agreed to approach Professor 0 Kirsten Howard, Chair of Economics Sub Committee (ESC) Ø
 - o Additional Jurisdictional Immunisation Co-ordinators (JIC) member to be included on Subgroup 2 – agreed to approach Scott Brown QLD IC Representative
 - Paul Effler was recently appointed to Subgroup's and Katie Atwell has joined a smaller group of Subgroup 3
- NOTED that this will complete the membership of the Working Group

Action	Responsible officer s	Progress	
3.1 Invite the additional	Chris Blyth and ATAGI COVID-	Completed	
members to Subgroup 1 and	19 Working Group Secretariat		
Subgroup 2			

4. Implementation considerations for COVID-19 vaccine °X

S

- DISCUSSED the Commonwealth leading the initial delivery of the COVID-19 vaccine outside • the National Immunisation Program, with involvement of JICS
- DISCUSSED the importance of modelling to inform the rollout of COVID-19 vaccine to be • led by the modelling team within the Health Economics Research Division
- DISCUSSED No fault compensation and providing indemnity to the manufacturer •

Action	Responsible officer/s	Progress
4.1 Arrange meeting with Health Modelling Team ^{s47F} and ^{s47F}	COVID-19 Taskforce	Completed – Modelling team to present at Subgroup 1 meeting on 27
		October
4.2 Develop a pathway to manage adverse events – link in with TGA pathways and pharmacovigilance plan	Sub-group 3	Will work through logistics and report back to Executive Group

5. Meeting with AstraZeneca 20 October 2020

Members:

NOTED the meeting with AstraZeneca will be on 20 October 2020, 4-6pm AEDT •

Action		Responsible officer/s	Progress
5.1 Respond to email sent by ^{s47F}	on	All AstraZeneca meeting	Completed
15/10/2020 regarding probity arrangement	S	attendees	

6. Meeting with Seqirus 22 October 2020

Members:

NOTED the meeting with Seqirus will be on 22 October 2020, 6-8pm AEDT ٠

Action	Responsible officer/s	Progress
6.1 Provide members with a list of confirmed	COVID-19 Taskforce/	Completed
attendees	Secretariat	

7. Consent-COVID19 Vaccination

Members:

NOTED a standardised consent form and framework will be required as well as an • accompanying information sheet/statement about the vaccine

Action	Responsible officer/s	Progress
7.1 Develop standardised consent form/	NCIRS and Sub-group 2	In progress
framework in line with normal practices		
7.2 Create master list/straw man of the 💙 🖉	NGRS	Completed – on Exec
resources that will be required		agenda 23/10
Australian Immunisation Register (AIR)	O'	
Nil Discussion		
900 °90. °21.		
ommunications		
See Other Business		
He He		
Other Business		


10. Other Business

Members:

NOTED the Collaboration on Social Science and Immunisation (COSSI) paper on COVID-19 • Vaccination and agreed to integrate with the Commonwealth's COVID-19 Communication Strategy

11. Meeting Closed: 1pm

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Executive Team Meeting #7 by Videoconference 23 October 2020, 12-1pm Outcomes



- ENDORSED outcomes from the previous meeting on 16 October 2020
- NOTED an update from the Taskforce including that Jurisdictional Immunisation • Coordinators (JICs) were advised yesterday about the Department's current thinking in relation to the COVID-19 vaccine program
- NOTED upcoming discussions by Government which will inform next steps and that revised ٠ preliminary advice on priority populations developed by Subgroup 1 will be part of these considerations
- NOTED the Commonwealth will not embark on program implementation without discussions • with jurisdictions and messaging will need to be explicit about partnership arrangements

3. Harmonisation of work with JICs

Members:

 NOTED sharing of key deliverables from the ATAGI subgroups will be considered following decisions by Government

Action	Responsible officer/s	Progress
Taskforce to consider ATAGI Working Group's list of documents/deliverables and liaise with ^{s47F}	Lisa Schofield	To progress

4. Subgroup updates

Members:

- NOTED updates from Subgroup leads
- NOTED Subgroup 1 will commence discussions on data modelling next week in consultation with the Department
- DISCUSSED whether a chapter would be required in The Australian Immunisation Handbook given its role as the clinical guideline for vaccine delivery in Australia, or an ATAGI Statement
- AGREED in principle that information would be required in the Handbook however this is likely to be an expedited process with iterative updates required

Action	Responsible officer/s	Progress
Clarify timing and clearance	Hope Peisley	Inprogress
requirements for an expedited		Y-3
Handbook process		
Add Handbook chapter to	NCIRS	In progress
workplan	Ve all all	
Prepare list of outward facing	NCIRSO ^{S47F}	In progress
documents/advice required for	No to the	
consideration at next Exec		
meeting	O' O'	

5. Subgroup 1 papers for endorsement ??

Members:

- ENDORSED two papers developed by Subgroup 1:
 - ATAGI-prelim-advice-COVID-vaccine-priority-grps_Edition2_v4a_(210CT2020) CHAIR ENDORSED
 - ATAGI-prelim-advice-AZD1222-possible-priority-pops_v2.1a-21Oct2020

Action	Responsible officer/s	Progress
Forward both Subgroup 1 endorsed documents	Secretariat	Completed 26/10
to Taskforce		

6. Draft overview of program phases and communication resources

- DISCUSSED draft slides prepared by NCIRS including program phases and program communication resources required
- NOTED that decisions are yet to be made by Government in relation to dates and phases

Action	Responsible officer/s	Progress
Provide feedback to NCIRS on draft program	Exec Team members	In progress (^{s47F}
phases and program communication resources		has provided
		feedback)

7. Meetings held with AstraZeneca and Seqirus

Members:

• NOTED meetings held with AstraZeneca on 20 October and Segirus on 22 October

8. Other Business

Members:

- AGREED to include a representative from TGA on Subgroup 2
- AGREED to invite a representative from TGA to update this Executive Team on a fortnightly basis

Action	Responsible officer/s	Progress
Invite TGA rep to attend Subgroup 2 meetings	Secretariat	Completed
Invite TGA rep to update Exec Team fortnightly	Secretariat	Completed (first update provided by email 28/10)

11. Meeting Closed: approx. 1pm

This document has been released under care and hose care a

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Executive Team Meeting #8 by Videoconference 30 October 2020, 11.30-12.30pm

Outcomes

In attendance: **Executive Members** Chris Blyth (Co-Chair) s11C Nigel Crawford Hope Peisley Katie Flanagan **Robyn Gibbs** Lisa Schofield Nick Henderson

NCIRS support staff

s11C

Department of Health representatives

Sarah Tyquin s47E(c), s47F

Secretariat s22

1. Meeting Opened

- Members:
 - •

2. Subgroup updates

2.1 Vaccine Utilisation and Prioritisation

- opened ers: NOTED Acknowledgement to Country NOTED attendees and apologies (Allen Ch-recLARED no conflicts of interest utates Utilisation and Priori* NOTED Subgroup 1 received a presentation from the Department's data modelling branch • covering two models (economic/workforce and distribution/rollout) and were concerned about the absence of health outcome data and lack of alignment with Subgroup 1 activities
- NOTED advice that the Department has flexibility and capacity to model health as well as economic outcomes and will resource this work
- AGREED data modelling is now the priority for Subgroup 1 and that early conversations • between key members and the Department's data modellers are needed
- NOTED Subgroup 1 intends to scope the University of Queensland vaccine and requested • second meetings with CSL and AstraZeneca be arranged for late 2020

	· · · · · · · · · · · · · · · · · · ·	Progress
2.1.1 Key members from Subgroup 1 and	s47F	In progress
NCIRS to meet with data modellers		
2.1.2 Arrange meetings with CSL and	Secretariat	To progress
AstraZeneca in Nov/Dec 2020		

2.2 Vaccine Distribution and Program Implementation

Members:

- AGREED to provide comments on two discussion papers to ^{s47F} by 2 November to allow endorsement by the Executive Team
 - Multidose vials ('Discussion_paper_MDVs_draft_2020.10.27-clean-for-exec')
 - AIR issues ('Discussion_paper_AIR-issues_V4_clean_20201028')
- NOTED concerns raised by Jurisdictional Immunisation Coordinators (JICs) in relation to information sharing by the Commonwealth on the COVID-19 vaccination program and that the Department anticipates further information will be provided to JICs shortly

2.3 Vaccine Safety, Evaluation, Monitoring and Confidence

Members:

- NOTED the Director of Regulatory Education at TGA had attended a small meeting of Subgroup 3 to discuss communications from the regulator's perspective
- NOTED the US FDA met on 22 October and problicly disseminated information and data on COVID-19
- NOTED Subgroup 3 aims to prepare preliminary advice in relation to three areas confidence/communications (paper currently being finalised), safety and evaluation

3. Half day information sharing session 10 November 2020

- DISCUSSED whether information considered at the half day session could be made public
- DISCUSSED content for the agenda which could include cross cutting issues (priority populations, data modelling, communications, stakeholders, multidose vials, Australian Immunisation Register), key recommendations and gaps to be resolved

Action	Responsible officer/s		Progress
3.1 Discuss with Health Comms whether a forward	Hope Peisley/Secretar	iat	In progress
facing statement, communique or annotated			
agenda can be released for the session			
3.2 Discuss with Taskforce whether JICs can attend	Hope Peisley/Secretar	iat	Completed
the session			
3.3 Meet to develop agenda and content	s47F		In progress
		,	
	NCIRS		
3.4 Prepare a one page summary for consideration	s47F /Lisa Schofi	eld	In progress
by Lisa Schofield to publish on ATAGI webpage			

4. Taskforce update

- Lisa Schofield provided an update on recent discussions with Government around principals for program implementation and advised that
 - o The Secretary is expected to write to stakeholders and Health CEOs again soon
 - While the Commonwealth is taking a lead role and a centralised implementation approach, the program will be designed and operationalised in partnership with jurisdictions and with strong engagement with peak organisations

Members:

 NOTED the Taskforce's update including advice relating to a centralised approach, stakeholder consultations and data modelling (item 2.1)

5. Outcomes and Actions from previous meeting

Members:

- ENDORSED outcomes from the previous meeting on 23 October 2020
- NOTED an email was being drafted to NHMRC seeking advice about timing and clearance requirements for an expedited Handbook process
- NOTED the Taskforce was finalising a list of ATAGI deliverables that would be circulated following the meeting
- NOTED NCIRS had developed an updated list of outward facing advice/documents that would be circulated following the meeting

Action	Responsible officer/s	Progress
5.1 Circulate list of ATAGI deliverables	Taskforce	In progress
5.2 Circulate list of outward facing advice	Secretariat	Completed
documents developed by NCIRS		
5.3 Obtain advice from NHMRC rear	Hope Peisley	In progress
expedited Handbook process	0	

6. Australian Immunisation Register

- NOTED difficulties with some health care workers accessing PRODO, including hospital nursing staff, and that Services Australia will attend a Subgroup 2 meeting to discuss barriers and resolution
- 7. Meeting Closed: approx. 12.30pm

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group **Executive Team Meeting #9 by Videoconference** 6 November 2020, 12-1pm

Outcomes

In attendance: **Executive Members** Chris Blyth (Co-Chair) Allen Cheng (Co-Chair) s11C Nigel Crawford **Robyn Gibbs**

NCIRS support staff

Department of Health representatives s47E(c), s47F

Secretariat s22

1. Meeting Opened

Members:

- partment of Health representatives E(c), s47F Cretariat Opened ers: NOTED attendees and apologies (Katie Flanagan, Hope Peisley, Lisa Schofield, Nick Henderson) • Nick Henderson)
- DECLARED no conflict of interest

2. Outcomes and Actions from previous meeting

Members:

- ENDORSED outcomes from the previous meeting on 30 October 2020 •
- NOTED the Taskforce is considering Working Group deliverables and will provide further • advice
- NOTED the Department has contacted NHMRC in relation to the process for a COVID-19 Handbook chapter and a meeting is being arranged

Action	Responsible officer/s	Progress
Provide advice to Working Group re priority	Taskforce	In progress
issues to be addressed		

3. Taskforce update

Members:

NOTED the Taskforce had been called to another meeting and were not available to provide today's update

- NOTED advice from the Secretariat on the Government's announcement of 5 November 2020 about two new COVID-19 vaccine agreements (Novovax and Pfizer), including information about priority groups, consultations, key vaccination sites and limited tender process
- NOTED the Taskforce advised Jurisdictional Immunisation Coordinators (JICs) about these developments yesterday, participated in a question and answer session and undertook to provide JICs with further information including letter from the Secretary to peak bodies
- NOTED there were two limited tenders underway: one for logistics and another for a data system which will utilise existing systems
- DISCUSSED member concerns about a lack of clarity around Commonwealth, state and territory roles and responsibilities, for example workforce training
- DISCUSSED member concerns about information flow to the ATAGI Working Group and jurisdictions
- NOTED the Secretariat's advice that further communications were underway following the recent announcement, including a meeting with Health CEOs, and that jurisdictional implementation plans were being developed in consultation with each state and territory
- NOTED that the Secretariat would commence planning for an information session with jurisdictions (similar to the upcoming session with ATAGI subgroups) with a tentative date of 19 November

Action	Responsible officer/s	Progress
Raise member concerns with the Department's	Co-chair	In progress
Executive		
Provide copy of Secretary's letter to Working 🖉	Secretariat	Completed
Group	Xe	
Organise information session with JICs	Secretariat	In progress

4. Half day information sharing session 10 November 2020

Members:

- NOTED over 40 acceptances for this session, including around 25 members plus NCIRS and Departmental staff
- NOTED insufficient time to prepare forward facing communications and supported the publication of a communique following the event

Action 🔗	Responsible officer/s	Progress
Draft public communique following information	Secretariat	To progress
session		

5. Subgroup updates

5.1 Vaccine Utilisation and Prioritisation

- NOTED Subgroup 1 members had participated in a meeting with the Department's data modelling branch to discuss two models logistics/distribution and economic
- NOTED a gap in the models including sequencing of priority populations which may be addressed by commissioning further data modelling work
- NOTED that NCIRS requires detailed technical data to undertake its work effectively
- DISCUSSED the need for the Working Group to have early access to vaccine data submitted to TGA and to receive advice from TGA about processes and timelines

- NOTED the next meeting of TGA's Advisory Committee on Vaccines is 2 December
- AGREED that meetings should be arranged with Pfizer and Novovax for vaccine presentations, similar to AstraZeneca and Seqirus

Action	Responsible officer/s	Progress
List questions that need to be answered	Subgroup 1 representatives	In progress
through further data modelling work		
Invite TGA rep to next meeting	Secretariat	In progress
Arrange meetings with Pfizer and Novovax	Secretariat	In progress

5.2 Vaccine Distribution and Program Implementation

Members:

- DISCUSSED consent issues and the need to better understand legal requirements
- AGREED a table would be developed by NCIRS scoping workplace settings and vaccination status including aged care, public and private sectors
- ENDORSED the Consent paper (Discussion_paper_informed-consent_draft_20201104-clean)
- ENDORSED two checklists subject to any further comments from members:
 - Site requirements (Checklist_site_draft_20201104 clean)
 - Equipment (Checklist_equipment_draft_20201104-elean)
- AGREED to the principal of information sharing and to provide documents to JICs, subject to endorsement by the Taskforce

Action	Responsible officer/s	Progress
Develop a table scoping consent issues in workplace settings	NCIRS	In progress
Provide endorsed Working Group	Taskforce/Secretariat	To progress

5.3 Vaccine Safety, Evaluation, Monitoring and Confidence

Members:

 NOTED the update from Subgroup 3, including preparation of advice on vaccine confidence and communications

6. Australian Immunisation Register

Members:

• NOTED public consultation on mandatory reporting to the AIR closes 15 November 2020

7. Meeting Closed: approx. 1pm

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Executive Team Meeting #10 by Videoconference 13 November 2020, 12-1pm Outcomes

s11C Nigel Crawford **Robyn Gibbs** Katie Flanagan Lisa Schofield internation the and hold care Nick Henderson Hope Peisley

NCIRS support staff

In attendance: **Executive Members** Chris Blyth (Co-Chair) Allen Cheng (Co-Chair)

s11C

Department of Health representatives s47E(c), s47F

Secretariat s22

1. Meeting Opened

- Members:
 - NOTED attendees and apologies
 - DECLARED no conflicts of interest

2. Outcomes and Actions from previous meeting

Members:

ENDORSED outcomes from the previous meeting on 6 November 2020 •

3. TGA update

Members:

- NOTED an update from TGA including:
 - two provisional determinations (AstraZeneca and Pfizer) which do not pre-suppose an outcome
 - limited data available at this stage, with data to be accepted on a rolling basis 0
 - 0 close contact with international regulators including the US FDA
 - provisional approval allows for lawful supply in Australia
- AGREED that TGA would provide fortnightly updates to the Executive Team if needed

4. Taskforce update

Members:

NOTED an update from the Taskforce including:

- National Cabinet's consideration of a COVID-19 Vaccination Policy and the ATAGI advice on priority populations, both of which are expected to be published on the website and circulated to jurisdictions and other stakeholders
- Commencement of bilateral meetings with jurisdictions next week on implementation planning
- Establishment of a COVID-19 Vaccine Strategy Taskforce Division within the Department of Health from next week
- DISCUSSED the draft Roles, Responsibilities and Reporting document prepared by ^{\$47F}

Action	Responsible officer/s	Progress
Circulate two documents (Vaccine Policy and	Taskforce/Secretariat	Completed 13/11
ATAGI advice on priority populations) subject to		
Government approval		
Comment on draft Roles, Responsibilities and	Taskforce	In progress
Reporting lines		

4. Education and Training

Members:

 DISCUSSED workforce training and asked NCIRS to conduct a gap analysis of the existing training landscape for immunisation providers and specific requirements for COVID-19 vaccines

Vacenies		
Action	Responsible officer/s	Progress
Map core training components required for	NCIRS (^{s47F}) and	In progress
COVID-19 vaccines, existing vaccine training	Subgroup 2 with	
programs and how they can be adapted to upski	l assistance from	
providers, any gaps and consider international	Subgroup 3 on	
training programs	international programs	

5. Subgroup updates

5.1 Vaccine Utilisation and Prioritisation

Members:

 NOTED Subgroup 1 is preparing recommendations on data modelling requirements for consideration at the next Executive Team meeting

5.2 Vaccine Distribution and Program Implementation

- NOTED differences between the consumables procurement list provided by the Taskforce and the Equipment Checklist developed by Subgroup 2
- AGREED to endorse the Equipment Checklist, subject to any further comments from members
- NOTED the issue of multi-dose vials was raised by the Co-chair at the recent Infection Control Expert Group (ICEG) meeting and approval was sought from the ICEG secretariat to bring the ATAGI documents on multi-dose vials to them for consideration
- AGREED Subgroup 2 would bring the Clinical guidance document on multi-dose vials to the next Executive Team meeting for consideration prior to further consultation with ICEG

Action	Responsible officer/s	Progress
Send endorsed Equipment Checklist to Taskforc	e, NCIRS/Secretariat	In progress
subject to any further comments		

Bring ATAGI documents on multi-dose vials to ICEG for consideration when ready	s47F	To progress
Develop an appendix to the Clinical guidance	NCIRS (^{s47F})/	In progress
document with preliminary information on	Secretariat	
vaccine candidates, and bring to next meeting		

5.3 Vaccine Safety, Evaluation, Monitoring and Confidence

Members:

- NOTED NPS MedicineWise had attended a Subgroup 3 meeting to discuss communication • strategies (specifically on Codeine up-scheduling)
- NOTED work underway on an evaluation framework and scenario planning

6. Half day information session 10 November – Key issues identified

Members:

- NOTED additional issues identified at the information session: •
 - Workforce training to be addressed as part of planning processes with states and territories and under consideration by Subgroup 2 (see item 4)
 - Indemnity members noted the Government has provided indemnity to COVID-19 0 vaccine manufacturers and this needs to be addressed in the communications Meetings with vaccine sponsors – preparations underway
 Incident management strategy to be discussed at next Executive Team meeting
 Closed: approx. 1.10pm strategy as part of vaccine confidence. Members raised the possibility of the COVID-

7. Meeting Closed: approx. 1.10pm

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Executive Team Meeting #11 by Videoconference 12 November 2020, 12-1pm

Outcomes

In attendance: **Executive Members** Chris Blyth (Co-Chair) Allen Cheng (Co-Chair) s11C Nigel Crawford **Robyn Gibbs** Katie Flanagan Lisa Schofield Nick Henderson SED outcomes from ' 'iscussions wit' 'I'l work 'I'l work Hope Peisley **NCIRS** support staff s11C **Department of Health representatives** s47Ė(c), s47F Secretariat s22 1. Meeting Opened Members: 2. Outcomes and Actions from previous meeting Members:

- ENDORSED outcomes from the previous meeting on 13 November 2020 •
- NOTED discussions with NHMRC regarding the Handbook chapter for COVID-19 and that • NHMRC will work with the Department to expedite this process
- DISCUSSED the revised Roles, Responsibilities and Reporting lines document developed for • internal purposes, noting that additions/changes are likely to be made following bilateral meetings with jurisdictions
- NOTED the Taskforce is currently engaging directly with jurisdictions and will consider the • ATAGI documents on a case by case basis following these meetings

Action	Responsible officer/s	Progress
Confirm legislative requirements around	Hope Peisley	Completed
consultation timeframes with NHMRC		(legislated 30 days)
Revise Roles, Responsibilities and Reporting lines	Taskforce	In progress
document as information becomes available		

Consider next steps for documents endorsed by	Taskforce	In progress
Working Group		

3. Taskforce update

- Members:
- NOTED an update from the Taskforce on bilateral discussions with jurisdictions including:
 - o Meetings already held with NSW, Tas and Vic and meeting today with NT
 - o Meetings scheduled for remaining jurisdictions early next week
 - Format of meetings covering discussions on program documents (vaccination policy) and questions on systems in place within each jurisdiction
 - o Strong interest from jurisdictions in the Site Checklist developed by ATAGI
 - Next steps involving the Taskforce drafting state/territory implementation plans for comment and consideration by Government
 - The possibility for different types of jurisdictional models, with the Commonwealth role remaining consistent
- DISCUSSED approaches to vaccination in Indigenous communities including states/territories having responsibility and the need to be pragmatic eg by vaccinating all Indigenous adults in a community rather than specific risk groups
- NOTED the Taskforce will become a Division in its own right with three branches and additional staff to manage the vaccine rollout

4. Incident Management Strategy

Members:

- NOTED an update from ^{s47F} including discussions with Corona Comms about a list of potential incidents to be fleshed out with mock scenarios as part of an incident management strategy, including clinical interplay and communications
- NOTED advice from the Department that TGA is undertaking incident scenario work
- DISCUSSED the possibility of establishing a small and/or independent group to consider an incident management strategy
- AGREED to invite TGA to the next meeting to discuss this item

Action	Responsible offic	er/s Progress
Bring incident list to next meeting for discussion	s47F /	Circulated by s47F
	Secretariat	23/11
Invite TGA to next meeting to discuss incident	Secretariat	Completed
management 🔗		

5. Education and Training

- NOTED preliminary work done by Subgroup 2 to analyse gaps in workforce training
- DISCUSSED workforce training including:
 - Advantages of modular training that allows one or more person to be involved in the administration of a vaccine and can be built upon as a program evolves
 - Numerous existing training pieces, resulting in the need to focus on designing new training in two areas – using multi-dose vials and specific vaccines
 - Focus on GPs, nurse immunisers, Aboriginal Medical Services and Aboriginal Community Controlled Health Organisations
- NOTED the National Immunisation Education Framework outlines training requirements

• AGREED to consider next steps in relation to education and training once the gap analysis has been finalised by Subgroup 2

6. Subgroup updates

6.1 Vaccine Utilisation and Prioritisation

Members:

- DISCUSSED Subgroup 1 advice to the Department recommending additional work be undertaken including epidemic dynamic models and health utility models
- NOTED resources may be available in the Department to assist and that Lisa Schofield will circulate the advice to relevant area/s for further consideration
- ENDORSED Subgroup 1 recommendations subject to any further comments from members
- NOTED NCIRS documents comparing key vaccines on immunogenicity and clinical trials will be provided to members when ready, to assist with understanding vaccine characteristics

Action	Responsible officer/s	Progress
Provide data modelling advice to Lisa Schofield for	Secretariat	Completed
further discussions and consideration within Dept	, es	
Provide comments on data modelling paper	Members	Completed

5.2 Vaccine Distribution and Program Implementation

Members:

- NOTED two documents developed by Subgroup 2:
 - Review of lessons learned from the experience implementing the 2009 H1N1 pandemic influenza vaccine program
 - Guideline for the administration of SARS-CoV-2 vaccine from multi-dose vials
- AGREED a process needs to be developed for approval of key ATAGI Working Group documents, including outward facing documents such as the MDV Guideline
- AGREED to submit the MDV Guideline paper, subject to any further comments, for discussion at ICEG

Action	Responsible officer/s	Progress
Provide comments on H1N1 paper	Members	Completed
Provide comments on MDV Guideline	Members	Completed
Provide H1N1 Lessons Learned document to	Secretariat	In progress
Subgroups 1 and 3 🧳		
Prepare summary of ATAGI endorsed papers and next	Secretariat	In progress
steps to assist in tracking documents and share with		
the Executive Group		
Develop process for approval of key ATAGI WG	Taskforce	To progress
documents, including outward facing		
Send MDV Guideline paper to ICEG Secretariat for	Secretariat/ ^{s47F}	In progress
comment		

5.3 Vaccine Safety, Evaluation, Monitoring and Confidence

Members:

 NOTED that Subgroup 3 is finalising advice on confidence/communications and safety for consideration by the Executive • AGREED that work by Subgroup 3 to develop an evaluation framework covering real time monitoring, medium term and longer term transition to the National Immunisation Program is important work that needs to be undertaken

6. Other business

Members:

- NOTED Chris Blyth is preparing public information pieces on COVID-19 vaccine •
- NOTED upcoming events including: •
 - o JIC information sharing session on 26 November
 - Second subgroup information sharing session on 15 December
 - Meetings with vaccine sponsors dates to be confirmed
- 7. Meeting Closed: approx. 1.10pm

This document has been released under Care Act 1982 oed Care the been at the and Aged Care the art and Aged Care the art and Aged Care the art of the art and Aged Care the art of the art of the art and Aged Care the art of the art

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Executive Team Meeting #12 by Videoconference 27 November 2020, 12-1pm

Outcomes

In attendance:

Executive Members Allen Cheng (Co-Chair) Chris Blyth (Co-Chair) - part meeting s11C Nigel Crawford **Robyn Gibbs** Katie Flanagan **Hope Peisley**

NCIRS support staff s11C

Department of Health representatives s47E(c), s47F

Elspeth Kay – part meeting s47E(c), s47F

Secretariat

s22

1. Meeting Opened

Members:

- partment of Health representatives

 E(c), s47F

 peth Kay part meeting

 =(c), s47F

 part meeting

 =(c), s47F

 part meeting

 =(c), s47F

 part meeting

 cretariat

 Opened

 ers:

 NOTED attendees and apologies (Chris B)yth, Lisa Schofield, Nick Henderson, s11C

 DECLARED no conflicts of interest
- Hment DECLARED no conflicts of interest

2. TGA update

provided an update on TGA pharmacovigilance planning including Elspeth Kay and s47E(c) development of scenarios, linkages across the department and coordination with clinical, technical and government areas across Australia

- DISCUSSED •
 - establishing an incident management team with representation from TGA, 0 jurisdictions, Taskforce and ATAGI to coordinate responses to incidents
 - a safety response/communication plan previously developed/published 0
- AGREED to provide TGA with the following Subgroup 3 documents for circulation internally, noting they are draft and have not yet been endorsed by the Working Group
 - Adverse Events of Special Interest
 - Vaccine Enhanced Disease

Action	Responsible officer/s	Progress
Identify safety response/communication plan and	Secretariat	To progress
circulate to Subgroup 3		
Map out proposed incident management team and	Subgroup 3	To progress
key participants		

Provide draft Subgroup 3 documents to TGA for	Secretariat/ ^{s47F}	Complete
internal use		

3. Outcomes and Actions from previous meeting

- Members:
 - ENDORSED outcomes from the previous meeting on 20 November 2020
- NOTED actions including:
 - NHMRC legislative requirement for minimum 30 days public consultation (and likelihood of need for outward facing ATAGI statement/s to support the rollout)
 - Need for a clear process for reviewing and endorsing ATAGI statements with the Taskforce to meet shortly to consider:
 - Approval processes
 - Additional advice needed from ATAGI
 - Roles, responsibilities and reporting lines

Action	Responsible officer/s	Progress
Meet to consider approvals, additional advice and	Taskforce	In progress
roles/responsibilities and advise ATAGI re next steps	200. 10	

3. Taskforce update

The Taskforce provided an update including:

- Completion of bilateral meetings as outlined at the shared information session with Jurisdictional Immunisation Coordinators on 26 November
- Commonwealth implementation plan to follow the structure of the Australian COVID-19 Vaccination Policy with headings such as workforce, surveillance etc
- Consideration of Subgroup 1 data modelling advice within the department, including meetings with key areas and stakeholders
- Consideration of workforce training on multi-dose vials within the department, including meetings with key stakeholders
- Two new ATAGI Working Group members with general practice expertise: Dr Richard Kidd (Subgroup 1) and DCChris Moy (Subgroup 2)
- Vaccine journey (one page PDF) available on SharePoint

4. Subgroup updates

4.1 Vaccine Utilisation and Prioritisation

- NOTED that Subgroup 1 is scoping each vaccine in detail and will do a deep dive on the AstraZeneca vaccine at the next meeting
- DISCUSSED prioritisation of certain groups, with Subgroup 1 to consider:
 - how critical workers are classified, noting that jurisdictions are seeking national consistency
 - gathering more information on critical groups including size, risk factors and level of complexity in reaching them
 - \circ ring fencing
 - requests from special risk groups for prioritisation (eg laboratory staff working with COVID-19), noting ATAGI's prioritisation matrix

Action		Responsible officer/s	Progress
Further consider priorit	isation of critical worker and	Subgroup 1	In progress
other special risk group	s, along with ring fencing		

6.2 Vaccine Distribution and Program Implementation

Members:

- ENDORSED two documents developed by Subgroup 2: •
 - Overview of mandatory vaccination policies
 - Gap analysis workforce training
- NOTED •
 - o these documents were prepared as advice to the Taskforce
 - the Taskforce has been given a package of documents endorsed by the Working 0 Group, some of which may be provided to jurisdictions to support their implementation planning

Action	Responsible officer/s	Progress
Provide two documents to Taskforce – mandatory	Secretariat	In progress
vaccination policies and workforce training gap analysis		

6.3 Vaccine Safety, Evaluation, Monitoring and Confidence

Members:

- ENDORSED the following communications advice prepared by Subgroup 3: •
 - ATAGI COVID19 WG3 Comms strategy Preliminary advice
 - COSSI Working Paper COVID19 vaccination
 - Australian Immunisation stakeholder list (living document)
- AGREED that future Working Group agendas will include documents for endorsement up • front (after outcomes from previous meeting) to allow more time for discussion, with Subgroup updates to be shown as a separate item NOTED Subgroup 3 is undertaking preliminary work on a program evaluation framework
- •

iorm

7. Other business

Members:

AGREED to refer corresponde Transplantation Society of Australia and New • Zealand to Subgroup 1

Action	Responsible officer/s Progress
Add TSANZ letter to Subgroup 1 agenda	Secretariat In progress

8. Meeting Closed: app

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Executive Team Meeting #13 by Videoconference 4 December 2020, 12-1pm

Outcomes

In attendance: **Executive Members** Allen Cheng (Co-Chair) Chris Blyth (Co-Chair) s11C Nigel Crawford **Robyn Gibbs** Katie Flanagan Lisa Schofield pologies (nil) finterest Hope Peisley **NCIRS** support staff s11C **Department of Health representatives** s47Ė(c), s47F part meeting s47E(c), s47F Secretariat s22 1. Meeting Opened Members: NOTED attendees and apologies (nil) DECLARED no conflicts of interest 2. Outcomes and Actions from previous meeting Members: ENDORSED outcomes from the previous meeting on 27 November 2020 • NOTED actions to be discussed under Item 5 (Taskforce: Next steps) •

3. TGA update

s47E(c), s47F provided an update from TGA including:

- three provisional determinations granted and three applications
- close work with sponsors and international regulators/organisations
- challenges including internationally harmonised label, communications, training for immunisers and multiple manufacturing sites

Members DISCUSSED

- the importance of ATAGI and NCIRS obtaining access to vaccine data to inform prioritisation and program roll out
- work underway within the Department to facilitate access to vaccine data via agreement from sponsors

Action	Responsible officer/s	Progress
Draft letters to vaccine sponsors requesting access to	Secretariat and TGA	In progress
vaccine data		

4. Documents for endorsement

Members:

- NOTED the Vaccine Safety Preliminary Advice prepared by Subgroup 3 and that its audience is the Taskforce followed by TGA
- AGREED to provide any further feedback by Monday 7 December, then provide this advice to the Taskforce

Action	Responsible officer/s	Progress
Incorporate further feedback from members and	NCIRS and Secretariat	In progress
forward safety advice to Taskforce		

5. Taskforce update

The Taskforce provided updates and facilitated discussions on:

Commonwealth, state and territory planning

- Collaboration with states and territories regarding implementation plans, with draft plans to be circulated to jurisdictions shortly and finalised by January 2021 for a March rollout
- Development of stand-alone implementation plans for aged care and disability groups and Aboriginal and Torres Strait Islander peoples
- Use of ATAGI documents
 - as attachments to implementation plans (eg checklists of minimum requirements to administer COVID-19 vaccine and for immunisation service provider sites)
 - o as input to implementation plans (eg advice on workforce competencies & training)
- Commonwealth support in relation to workforce; understanding existing workforces in jurisdictions and addressing gaps to ensure the right people in the right places
- Procurement underway for ogistics and data, noting that processes have not been finalised and further advice will be provided shortly

Flu

- Intersection with the annual flu program including staggering the dosing schedule for flu and COVID-19, noting priority populations are the same for both
- Development of principles on how to manage COVID-19 and Fluvax rollout concurrently, including theoretical and scientific rationale for co-administration (safety and feasibility)
- ATAGI full meeting on 11 December to include an item on the flu statement and handbook

ATAGI outputs

- Taskforce meeting to discuss next steps for ATAGI advice, that will be categorised as either
 - Documents for publishing (for providers and others), or
 - Advice to Government
- Summary of documents and categories to be provided to members for discussion next week
- Data modelling advice from Subgroup 1 under consideration within relevant areas of the Department with a further update to be provided

Next steps – advice required from Working Group

Subgroup 1

- Revisit prioritisation advice to provide greater level of granularity including
 - priority population groups eg high transmission v critical industry, and underlying medical conditions

- levels of priority within the priority population groups, noting limited supply of 0 vaccine (eg which health care workers, what comorbidities and what age ranges)
- consider strategies in different epidemiological scenarios (eg no disease and community • transmission) and supply/demand challenges

Subgroup 2

- No further advice required at this stage, noting work now underway within jurisdictions regarding implementation planning
- Taskforce meeting with Health Education Services Australia next week with further consideration of how to roll out nationally consistent training

Subgroup 3

No further action required until discussion takes place in relation to evaluation planning to clarify responsibilities

ATAGI Working Group Information Session 15 December

- Agenda to focus on the workplan and the milestones for delivery what needs to be done, when and by whom to meet deadlines
- Consider evaluation at the session along with other items where there may be duplication or lack of clarity (eg training and safety) Priority populations and flu principles (Subgroup 1) No new work for Subgroup 2 at this stage

Summary of priorities

Action	Responsible officer/s	Progress
Revisit priority populations advice	Subgroup 1	In progress
Develop principles by January on managing COVID-19	Subgroup 1	In progress
and Fluvax rollout		
Provide members with summary of ATAG documents	Secretariat	In progress
and categories for next steps (internal/external)		
Provide members with update on Departmental	Lisa Schofield	Completed –
meeting 4/12 re data modelling		email 4/12
Discuss evaluation planning to clarify responsibilities	Taskforce	In progress
Add agenda item to information session on 15/12 to	Secretariat	In progress
discuss evaluation and other areas of possible		
duplication (training, safety)		

6. Other business – meeting schedule

Members AGREED:

- the information session on 15 December will be the last meeting of the Working Group and Subgroups for 2020 and the Executive Group will reconvene on 8 January 2020
- to cancel the Executive meeting on 11 December due to a clash with the full ATAGI meeting feedback on ATAGI deliverables will be provided at that meeting
- Future meetings will be scheduled around deliverables in the workplan •

Action	Responsible officer/s	Progress
Cancel remaining Exec meetings for 2020	Secretariat	Completed
Advise Secretariat of leave arrangements over	All	In progress
Christmas/New Year		

7. Meeting Closed: approx. 1.10pm

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Executive Team Meeting #14 by Videoconference 18 December 2020, 10-11am

Outcomes

In attendance: **Executive Members** Allen Cheng (Co-Chair) Chris Blyth (Co-Chair) s11C Robyn Gibbs Katie Flanagan

Lisa Schofield **Hope Peisley**

NCIRS support staff s11C

Department of Health representatives s47E(c), s47F

Secretariat s22

1. Meeting Opened

- Members:
- partment of Health representatives E(c), s47F Cretariat Opened ers: NOTED attendees and apologies (Nigel Crawford, Nick Henderson) DECLARED bo conflicts of interest
 - DECLARED no conflicts of interest

2. Outcomes and Actions from previous meeting

Members:

- ENDORSED outcomes from the previous meeting on 4 December 2020
- NOTED actions arising: •
 - Following permission from AstraZeneca, TGA has arranged for specified ATAGI 0 members and NCIRS staff to access data through GovTEAMS
 - Pfizer has not provided permission to access data 0

3. Feedback from Information Sharing Session on 15 December

Members DISCUSSED feedback including:

- Challenges of managing a large number of members, meetings and issues •
- More detail needed on pharmacovigilance roles and responsibilities
- Length of session (3 hours) requires a break

Members AGREED to hold another information sharing session in the week of 1 February 2021

Action	Responsible officer/s	Progress
Circulate latest information from TGA on its	Lisa Schofield	Completed
pharmacovigilance plan for COVID-19 vaccines		
Send invitations for next session (2 February)	Secretariat	To progress

4. Key deliverables December / early 2021

Members DISCUSSED priorities for Subgroup 1:

- More granular prioritisation advice (top priority and due by Christmas)
 - Two scenarios needed to cover current epidemiology (low transmission) and any changes/outbreaks
 - Challenging given lack of data modelling
 - o Numbers need refining for front line health care workers
 - o Taskforce has requested quarantine worker numbers from jurisdictions
 - o Prioritisation of groups is sufficient if numbers aren't precise
- Managing COVID-19 and flu rollout (second priority and due in January)
- Clinical guidance for health care providers (third priority and due in January)

Members DISCUSSED a Handbook chapter or equivalent:

- NCIRS is drafting a suite of documents for providers including training materials for each vaccine (more specific than the information produced by companies) and communication materials
- The Government has not made a decision in relation to consent (written or verbal) and further information will be provided by the Taskforce when available

Members NOTED the list of key deliverables and timeframes circulated by NCIRS prior to the meeting (annotated version at **Attachment A**)

Members AGREED:

- Advice on key components of an evaluation plan is due by mid-January
- The role of Subgroup 3 is to develop advice to Government, rather than undertake the evaluation itself
- Given competing provides across the entire workplan, establishment of any additional groups should first be considered by the Executive Group in terms of purpose, outputs and resourcing

Action	Responsible officer/s	Progress
Prepare the first tranche of provider materials for	NCIRS	In progress
Pfizer and AZ vaccines		
Advise re any Government decision about consent	Taskforce	In progress

5. Taskforce update

The Taskforce provided an update on:

- commencement of the second round of bilateral discussions with jurisdictions with the next draft implementation plans to be circulated in early January
- logistics partner expected to be announced shortly

Meeting Closed: approx. 11am

Attachment A - Advice/documents for COVID-19 program rollout

Attachment A

Advice/documents for COVID-19 program rollout

Document	Scope/ Content in brief	Person responsible	SG responsible	Timeline for completion of preliminary draft ready for WG/Exec Team consideration
Priority populations for initial stages of vaccination	Granular priority groups – break down groups by number of available vaccines	s47F	SG1	Preliminary draft before Xmas (<mark>Agreed)</mark>
Co-administration with flu vaccines	Clinical advice on administration of COVID and flu vaccines (does not address implementation issues)	s47 F	SG1	Preliminary draft before Xmas (Now January)
Clinical statement on COVID-19 vaccines	Clinical guidance for providers on use of Pfizer and AZ vaccines	547 F	\$61 0 CAN	Preliminary draft before Xmas (Now January)
Consent form	1 page brief consent document (content based on consent advice developed by SG2)	sare relection	SG2	Preliminary draft in early Jan (Subject to Govt decision on consent)
Discussion points for consent for providers	Brief 1-2 page max with points for discussion for providers, referencing other providers FAQs	1847FOT	SG2	Preliminary draft in early Jan (Subject to Govt decision on consent)
Provider information sheet	and flu vaccines (does not address implementation issues) Clinical guidance for providers on use of Pfizer and AZ vaccines 1 page brief consent document (content based on consent advice developed by SG2) Brief 1-2 page max with points for discussion for providers, referencing other providers FAQs Scope not entirely clear yet – provider FAQs that may come up during consent but also other aspects of vaccination program?	s47F	SG1/2? (if part of consent package, then SG2)	Preliminary draft in mid Jan
Consumer info sheet	Points for inclusion in a consumer info sheet (vaccine specific info is separate from vaccine program info e.g. f/u on AEs)	We will list points for inclusion, but this is likely to developed by DoH/someone else	SG2	Preliminary draft in early Jan

Australian Technical Advisory Group on Immunisation (ATAGI) COVID Working Group Executive Team Meeting #15 by Videoconference 8 January 2021, 12-1pm Outcomes

In attendance: **Executive Members** Chris Blyth (Co-Chair) s11C **Robyn Gibbs** Katie Flanagan Nigel Crawford Lisa Schofield **Hope Peisley**

NCIRS support staff

s11C

Department of Health representatives s47Ė(c), s47F

Secretariat

s22

1. Meeting Opened

Members:

2. Outcomes from previous meeting

Members:

•

3. Taskforce Update

- - COVID-19 Vaccination Program to commence earlier (February 2021)
 - Different locations for Pfizer and AstraZeneca vaccinations across Australia
 - Further information at \circ https://www.health.gov.au/resources/publications/australias-epidemiologyand-covid-19-vaccine-roadmap
- NOTED other developments including:
 - Draft implementation plans for aged and disability sectors, culturally and 0 linguistically diverse groups, Aboriginal and Torres Strait Islander and vulnerable populations
 - Two tenders closing shortly with providers to be engaged for:

- Workforce surge capacity
- Vaccine training packages for Pfizer and AstraZeneca vaccines
- Weekly engagement through jurisdictions 0

Members DISCUSSED:

- Communications along with logistical issues, training and site setup
- Efficacy considerations two concepts: product registration and programmatic discussion (benefit to the population)
- Importance of vaccine clinical details as well as data modelling to inform decision making, including spacing of vaccine doses

4. TGA Update

Members NOTED:

- Pre market activities underway at TGA from both clinical and quality perspectives
- Advisory Committee on Vaccines meeting to be held next week and expected to provide advice in relation to any licensing restrictions
- Post market activities including Pharmacovigilance Plan and data sharing with international regulators regarding safety signals

5. Key Deliverables in January 2021

Members NOTED deliverables required by the Taskforce

- rerables in January 2021 Provide the Taskforce of the Construction incorporating comments from Subgroup a during the development phase (full S. accreditation unlikely due to timeframes)
- Prioritisation (more granular advice to be considered by Government in January)
 - Communications to occur later in January around prioritising front line workers C'IL R to protect others
 - General agreement that aged care staff and residents are priorities
- COVID-19 and flu advice to be provided to Executive for endorsement at next meeting for messaging to the public in February
- **Consent** ATAGladvice required (what does obtaining consent mean and how will it work - what are the implications for different population groups?)
 - Principles based advice to allow Government to make a decision on next steps 0
 - (ie. Do existing Handbook requirements apply to COVID-19?)
 - Focus on the how (leave written/verbal consent discussion for later)
- Evaluation framework tracking business improvement and longer term issues
 - Two levels of advice proposed by Subgroup 3 high level advice to be provided next week with more detailed advice to follow subject to direction from ATAGI Working Group Executive

Members NOTED an update from Subgroup 3 on the proposal for an incident management team, which has partly been addressed by scenario planning, along with work around Adverse Events of Special Interest and communications from a social science perspective

Action	Responsible officer/s	Progress
Provide draft consent documents (currently on Sharepoint)	Secretariat	In progress
to SG2 and Executive for discussion at next meetings		
Provide further advice to ATAGI Exec on consent issue and	Lisa Schofield	In progress
deliverables required, including whether standard/		
consistent information should be provided across Australia		

5. Other Business

Members NOTED:

- Provider materials are being developed by the Department's Communications team
- Subgroup 1 is finalising a clinical advice statement (for Exec endorsement next week) that forms a framework for the Handbook

Action	Responsible officer/s	Progress
Review public facing documents being prepared by Comms	Hope Peisley	In progress
and provide advice to ATAGI Exec re any gaps		

Meeting Closed: approx. 1pm



Australian Technical Advisory Group on Immunisation (ATAGI) COVID-19 Working Group Information Sharing Session 15 December 2020, 1-4pm Outcomes

In attendance:		
Executive members	Subgroup 3 members	Department of Health
Chris Blyth (Co-Chair)	Nigel Crawford (Lead)	s47E(c), s47F
Allen Cheng (Co-Chair)	Tony Korman	
Robyn Gibbs	Margie Danchin	
Nigel Crawford	Deb Petrys	
s11C	Diane Walsh	
Lisa Schofield	Alan Leeb	
Hope Peisley	s47E(c), s47F	
Subgroup 1 members	John Kaldor	
Bette Liu	Paul Effler	
Tom Snelling	Cheryl Jones	
Jodie McVernon	Katie Attwell	
Penny Burns	NCIRS technical support	S S S S S S S S S S S S S S S S S S S
Angus Dawson	s11C	Caxe
Kanta Subbarao		6
James Wood (A/g Lead)	Se Ose	0
Kirsten Howard	No Charles P	
James Ward	ro pono	
_Richard Kidd		
s11C	De Str Min	
David Durrheim	25 star 100	Secretariat
Christopher Etherton-Beer	× () × () × ()	\$22
Subgroup 2 members		
Robyn Gibbs (Lead)		
Annaliese van Diemen		
Madeline Hall	0, 0,	TGA
Karen Bellamy	OCK	s47E(c), s47F
Katherine Gibney		
Nick Silberstein		
Lena Sanci	Katie Attwell NCIRS technical support s11C UI	Apologies
Scott Brown		Katie Flanagan (SG1 Lead)
Michelle Giles		

1. Meeting Opened

Members:

- NOTED attendees and apologies (Katie Flanagan)
- New members (^{\$11C}, Richard Kidd, Chris Moy and Katie Attwell)
- DECLARED no conflicts of interest

2. Probity briefing

s47F

provided a probity briefing.

Members NOTED:

• Member and observer probity obligations and requirements in relation to the ATAGI COVID-19 Working Group responsibilities

- Probity principles including integrity, confidentiality and management of conflict of interest
- Roles of probity advisers and their contact details as provided on SharePoint for any questions

3. COVID-19 Vaccine Strategy Taskforce update

Ms Lisa Schofield provided an update on Taskforce activities, provided sincere thanks to all members in recognition of the volume and quality of work already completed, and discussed future priorities.

Members NOTED:

- Commonwealth continues to monitor vaccine candidates globally, has deals with AstraZeneca, Novavax and Pfizer and the TGA has provided provisional registration for Janssen/Johnson & Johnson
- Change to the Commonwealth's vaccine portfolio, noting decision to cease development of the CSL/ University of Queensland vaccine, to ensure vaccine confidence, and subsequent procurement of additional AstraZeneca and Pfizer doses. ATAGI Working Group will be advised if/when any deals are made with additional vaccine sponsors
- Rollout planning ongoing, aim to commence in early March 2021, based on regulatory approvals and availability of vaccines in Australia
- Commonwealth will continue to engage:
 - with States and Territories to discuss key issues, e.g. vaccination sites, workforce training and priority populations
 - fortnightly Health CEOs and Chief Health Officers (CHOs) to enable national discussion on program rollout and national approach to addressing any issues that may arise
 - with peak bodies and a number of advisory groups across a range of sectors: Aboriginal and Torres Strait Islander groups, aged care, disability, culturally and linguistically diverse (CALD), rural and regional, Public Health Networks(PHNs), General Practitioners (GPs), and nurses
- Commonwealth is aiming to finalise the overall implementation strategy plan and individual jurisdictional implementation plans by late January
 - First drafts of the jurisdictional plans were sent out last week (wk beg 07/12) and feedback has been received from nearly all states, second round of bilateral discussions commencing this week (wk beg 14/12);
 - Some elements of the jurisdiction plans will remain the same (e.g. site and training requirements) and some will be iterative to allow for flexibility in responding to the program rollout (e.g. scaling up sites)
- There are several key pieces of ATAGI work required quickly to support the Commonwealth (to be discussed in Item 6)

4. Commonwealth Communications Activities s47E(c), s47F provided an undete of

provided an update on communications activities.

Members NOTED:

- The overview of the communications approach and the focus on building confidence in safety, efficacy and success of the vaccine
- Continuous research tracking is ongoing, identifying potential concerns from the public and there is potential for the survey results to be shared with the Working Group to identify gaps
- Commonwealth has fortnightly engagement with GPs, regular discussions with various peak bodies such as AMA and RACGP, and has established networks with peak bodies and stakeholders with

Aboriginal and Torres Strait Islander communities to seek input and review of communications plan specific to these communities

- Commonwealth is planning to go out to various entities to discuss vaccine communications adaptions
- The strategies being used to ensure accurate information on key social media platforms and using spokespeople to be "trusted advisers"
- Explainer videos will be provided through the Department's channels/social media channels
- Department's vaccine hub allows public to subscribe for updates
- The current focus is on building confidence, however Commonwealth will explore the issue of protection from infection versus risk of transmission in the research

5. Therapeutic Goods Administration s47E(c), s47F provided an ur

provided an update and re-cap on pre-market activities.

Members NOTED:

- TGA update on the provisional registration approval pathway, including provisional approvals to Janssen/ Johnson and Johnson, AstraZeneca and Pfizer
- The significant challenges outlined by the TGA in managing the receipt and assessment of rolling data provided by the sponsors, requires tight communications with the sponsors to understand estimated timelines for submission of data tranches
- Pfizer is considered the most advanced in terms of quality of information and data and the TGA is expecting additional data tranches in the lead up to Christmas
- The difficulties described by the TGA in predicting decision dates for granting provisional registration approval until last data roll is seen and gaps have been identified
- TGA needs time to consider and develop consistent, appropriate validation methodologies for the assessment of batches before they are released
- TGA advice regarding the changes to labels, for example: labels will not include an AusPAR number, some labels may refer to "emergency use" if manufactured overseas, batch expiry will be limited, and TGA is working with other regulators about using an internationally harmonised label
- There is limited safety data so far (two months), noting that the benefit of the emergency use approvals overseas will be the real world data
- TGA continues to maintain close liaison with international regulatory authorities such as Access
 Consortium
- TGA is expecting rolling data from Pfizer through to the end of the year/early new year and AstraZeneca in March 2021.
- The clinical data will articulate if there is an efficacy data gap for specific subpopulations
- The unique logistics requirements for Australia and New Zealand are in the forefront of consideration by the TGA evaluators
- TGA vaccine hub is available now at https://www.tga.gov.au/covid-19-vaccines

s47E(c), s47F provided an update on post-market activities.

Members NOTED:

- TGA and AIR are now linked, so there is a dominator for adverse event following immunisation (AEFI) data, but in absence of a comparator will rely on disproportionate analysis
- TGA will establish a team of forensic doctors to gather information in the event of any fatal AEFI
- TGA is hosting two groups of medical regulators, one on safety signals and another on vaccine confidence, who are meeting fortnightly
- There is a need to accurately communicate the robustness of TGA regulatory processes

- Other than two reported anaphylactic cases in the United Kingdom, there are no safety signals at this stage
- There are challenges with sharing data beyond the seven usual regulators, with Periodic Safety Updates to be discussed at the next meeting (tonight).

6. Workplan

Ms Schofield revisited and acknowledged some of the key pieces of work that the Working Group have done and how these have been used, including:

Subgroup 1

- Preliminary advice on prioritisation has been a key piece in informing Government, very useful in public messaging and has been published by Government;
- Modelling advice to Government has been helpful in raising issues for consideration

Subgroup 2

- Advice on workforce competencies, checklists for equipment and site requirements was very useful and has been shared with jurisdictions during the bilateral meetings as part of the jurisdictional implementation plans, to assist with national consistency
- MDV and AIR advice to Government discussion papers have helped inform Commonwealth conversations regarding implementation

Subgroup 3

Useful feedback on key stakeholders to engage with and issues to address

Ms Schofield again thanked the Working Group for their work and contributions to date

Members NOTED next key deliverables and timeframes for ATAGI (refer Table 1).

Table 1: Key deliverables and timeframes for ATAGI: December 2020 – Early 2021

Item	Description	WG Responsible	Delivery Date/ Status
1	 Granular view of prioritisation: a few different views of prioritisation are required to allow Taskforce to consider various options/implementation issues and allow for flexibility as needs may change: month by month by categories (number of people and how to split that down month by month) who would get first 1 million Pfizer doses? who would get first 3.5 million AstraZeneca doses? 	SG#1	As soon as possible, prior to Christmas Complete (subject to further revisions if/when required)
2	 Evaluation: two key components a process / administration / lessons learned, to occur as rollout happens (Commonwealth lead); and the bigger picture evaluation, as would occur for a routine vaccination program, e.g. impacts of vaccination program on disease burden 	Commonwealth SG#3	Mid- January In progress
3	What does COVID-19 vaccine rollout alongside flu vaccine mean?	SG#1	End January 2021 In progress

	 Review of documentation from the UK and US programs has very limited detail, e.g. in the UK documents Pfizer has noted a 14 day interval Any thinking and advice to Government would be useful 	Input from other groups as required	
4	 Information for healthcare providers/GPs when talking to patients/ consumers Review of documentation from the UK and US programs has very limited public information/ detail Any advice to Government on the questions the Commonwealth should be focussing on would be useful 	SG#3 Input from other groups as required	Mid – late January 2021 To progress

Subgroup 1 update

s47F

provided an update on behalf of SG#1.

Members DISCUSSED:

- Effects of the vaccine candidates on transmission is still unknown, requiring an alternative strategy by looking at a transmission priority organisation and a risk priority organisation.
- Risks are at ports of entry, uncertainties whether vaccine/s will address this
- As timeframes remain uncertain, it may be better to look at first 500,000 doses?
- Age as most critical risk factor; consider smaller groupings, starting with the oldest, to get to granularity
- What happens after the first 1 million Pfizer doses and 3.5 million AstraZeneca doses?
 - Ms Scofield noted a rough overview has been provided to SG1 to inform their work
 - The month by month prioritisation list of populations will help the Taskforce consider all issues in implementation and allow for flexibility to changing needs.
 - Acknowledged that efficacy between vaccines looks different at the moment, however currently doses are limited and further details of future production are not yet available, so ATAGI advice to Government is required to inform which groups are the immediate priorities for vaccine candidates and the Commonwealth will take that forward
- Possibility for vaccine wastage if dosing intervals are starting to creep
- Communication regarding the transmission rollout model versus no community transmission model
- Importance of protecting healthcare workers at greatest risk
- The need for consideration of quarantining doses for outbreak management and ring fencing
 - Commonwealth noted it would appreciate ongoing advice on this as appropriate, noting limited does in the first phase

Subgroup 2 update

sought feedback on proposed priorities identified for SG#2:

- What was needed to get sites ready; and
- What those immunisation providers might need to start the program.
- Delivery date: mid-February 2021.

Members DISCUSSED and NOTED:

- What sites and immunisation providers need to get ready for the rollout
 - Ms Scofield noted a range of advice from SG#2 on site requirements has already been shared with jurisdictions during bilateral discussions, and Commonwealth and jurisdictions

have discussed that all sites would go through pre-qualification process, e.g. to demonstrate capacity to receive delivery of doses, ability to upload to AIR

- Commonwealth would be interested in advice from SG#2 on what other issues need to be 0 considered, e.g. Pfizer vaccine logistics/implementation issues, for example will possibly be using sites that wouldn't normally be vaccination sites
- Qualification process and what it should look like
- Development of three documents: Patient information, provider information and consent framework template (i.e. a nationally consistent list for providers to ensure they have covered key information for patients)
 - Need to ensure all parties (sponsors, TGA and Commonwealth/ATAGI) are playing their own 0 role, e.g. it is important that sponsors take responsibility for elements they have responsibility for (e.g. product information), noting that sponsors do not inform consent process
 - It was noted the UK and US have similar advice, however this isn't the ATAGI-equivalent 0 organisation developing
 - Noted that in Australia, providers don't tend to use Product Information provided by 0 companies, rather they rely on the advice provided ATAGI/NCIRS/NIP
- Importance of consistent patient and provider information sheets across the poard
- Commonwealth to have further discussions with Jurisdictional Immunisation Coordinators (JIC) to progress national consistent training package/program Government has stated that GPs will be involved in the follow
- Contracts with preferred data/ logistics tenderers not yet finalised
 - Logistics and data partners are separate noting that logistics will have track and trace 0 elements however, data partner will provide separate data from acceptance of doses to adverse events following immunisation
 - Terms of Reference for data and logistics providers to be provided to the Working Group \cap when available ŝ
- National booking system being discussed with JICs
- No decisions made on consent at this stage; may not need a consent model across the board, other than what happens in normal circumstances
- Concerns about pre-consent (e.g. via online booking) that does not give recipients adequate opportunity to ask questions

Action	Responsible officer/s	Progress
SG#2 to provide advice on how to get sites and	Subgroup 2/NCIRS	To progress (due mid-
immunisation providers ready for rollout		February)
Advice on what needs to be considered (e.g. Pfizer vaccine	Subgroup 2/NCIRS	To progress
logistics/implantation issues; GP capacity with vaccination,		
using sites that would not normally be vaccination sites)		
Provide Terms of Reference of data/ logistics contracts to	Lisa Schofield/ Secretariat	Complete: media
Working Group when available		release provided on
		SharePoint
Develop patient information sheet	Subgroup 2/NCRIS	To progress
Develop provider information sheet	Subgroup 2/NCRIS	To progress
Develop consent framework template	Subgroup 2/NCRIS	To progress

<u>Subgroup 3</u> s47F

provided a presentation and update.

Members NOTED:

- Safety is featured in all implementation plans and bilateral discussions, and TGA's pharmacovigilance • plan slide deck to be shared with Working Group
- Department's market research is underway, and Commonwealth noted products can be shared • when available

Action	Responsible officer/s	Progress
Provide TGA's pharmacovigilance plan slide deck to	Lisa Schofield/	Completed
Working Group, when available	Secretariat	

7. Next steps

Members AGREED:

• Secretariat to progress meeting dates for 2021

Responsible officer/s	Progress
Secretariat	To progress
S. PC and	
Lie alth	

ATAGI COVID-19 Working Group Executive Group							
			eting outcomes				
Meeting date	Action item	Action	Responsible officer/s	Progress / Comments	Complete Y/N		
1-Sep-20	2.1	Review ToR and add suggested updates	ATAGI Secretariat	Completed	Y		
1-Sep-20 1-Sep-20	2.2	Endorse Working Group ToR with changes	Co-Chairs	Completed	Y		
I-Sep-20	2.3	Draft mud map of COVID-19 Committees and how they integrate with one another	COVID-19 Taskforce	See outstanding item for 2020 below	N		
4-Sep-20	2.4	Make recommendations of possible Primary Care representatives for the Working Group	Executive members	Completed	Y		
4-Sep-20	3.1	Review NCIRS work plan to identify gaps and ensure key	COVID-19 Taskforce	Completed	Y		
4-Sep-20	5.1	deliverables of each sub group are included Approved work plan to be provided to Sub Group leads for		completed			
+-3ep-20	3.3	comment	ATAGI Secretariat	Completed and on Sharepoint	Y		
4-Sep-20	3.4	Establish new email inbox and a Working Group SharePoint	ATAGI Secretariat	Completed	Y		
4-Sep-20	3.5	page for the ATAGI COVID Working Group Establish a team to provide support to the ATAGI COVID	Immunisation and Communicable				
		Working Group and the JIC COVID Working Group	Disease Branch	Completed	Y		
1-Sep-20	3.6	Provide link to the COVID-19 Vaccines and Treatments for Australia Science and Industry Technical Advisory Group webpage	COVID-19 Taskforce	Completed	Y		
4-Sep-20	3.7	Schedule weekly Executive Working Group meeting	ATAGI Secretariat	Completed	Y		
4-Sep-20	3.8	Schedule initial meetings for each Sub Group	ATAGI Secretariat	Competed	Y		
1-Sep-20	3.9	Provide the COVID-19 Taskforce with a list of data required	NCIRS	Completed	Y		
4-Sep-20	3.1	Arrange CDNA representation on each Subgroup	ATAGI Secretariat	Completed	Ŷ		
11-Sep-20		Update and Finalise ATAGIs Preliminary advice on general	Subgroup 1 – Vaccine utilisation and	Completed - preliminary advice on COVID			
	2.1	principles to guide the prioritisation of target populations in a COVID-19 vaccination program in Australia	prioritisation	vaccine priority groups endorsed by Co- Chairs on 17 September	Y		
11-Sep-20		First draft of ATAGIs COVID19 vaccine prioritisation matrix	Subgroup 1 – Vaccine utilisation and prior	Completed (first version of the			
	2.2			prioritisation matrix provided to Taskforce)	Y		
11-Sep-20	2.4	Monitoring of COVID-19 vaccines	COVID-19 Taskforce	Completed - weekly State of Play report	Y		
11-Sep-20		Prepare implementation plan for rollout of Oxford, UQ and	Subgroup 2 – Vaccine distribution and	Completed (paper on frozen vaccines to			
	2.5	RNA vaccines	program implementation	Exec 9/10) Also see 18/9 item 4.3 below	Y		
11-Sep-20	2.6	Prepare advice on Workforce required for implementation of COVID-19 vaccine – determine how many and what sort of training will be required	Subgroup 2 – Vaccine distribution and program implementation	Completed (workforce paper to Exec 9/10) Also see 18/9 item 4.3 below	Y		
11-Sep-20	2.7	Plan for monitoring and tracking doses of the COVID-19	Subgroup 2 – Vaccine distribution and	NFA - referred to Commonwealth and JICS	Y		
11-Sep-20		vaccine Prepare advice on safety and surveillance, monitoring system	program implementation Subgroup 3 – Vaccine Safety, Evaluation	NFA - referred to Commonwealth and JICS			
	2.8	to be used- how existing systems such as AusVaxSafety and AIR fit	Monitoring and Confidence		Y		
11-Sep-20	2.9	Test the communication strategy and messaging around the CC	Monitoring and Confidence	Discussed at meeting on 2/10	Y		
11-Sep-20	2.10	NCIRS technical leads to be invited to Executive Group meetings	ATAGI Secretariat	Completed	Y		
11-Sep-20	3.1	s47F to meet with NCIRS technical leads prior to sub	NCIRS technical leads and Subgroup 1	Completed	Y		
11-Sep-20	3.2	group1 meeting. ATAGI secretariat to establish process with TGA to share information	Lead ATAGI Secretariat	Completed (weekly meetings)	Y		
11-Sep-20	3.4	Establish new email inbox and a Working Group SharePoint page for the ATAGI COVID Working Group. Provide details to	ATAGI Secretariat	Completed-Email to Members with SharePoint and inbox details 14/9/2020	Y		
11-Sep-20	3.5	Working Group members AIR should be a standing item on the Executive Meeting	ATAGI Secretariat	Completed	Y		
18-Sep-20		Agenda		Completed	ř		
18-Sep-20	4.1	Workshop ring-fencing and incorporate into prioritisation document	Subgroup 1 – Vaccine utilisation and prioritisation	Completed	Y		
18-Sep-20	4.2	Overlay priority populations with the Oxford vaccine	Subgroup 1 – Vaccine utilisation and	Completed - Endorsed by Exec 23/10/20	Y		
18-Sep-20		Overlay priority populations with the Uo vaccine	prioritisation Subgroup 1 – Vaccine utilisation and				
	4.2	Overlay priority populations with the UQ vaccine	prioritisation	No longer applicable	N/A		
18-Sep-20	4.3	Prepare implementation plan for the rollout of each vaccine - Oxford, UQ and RNA vaccines. How would you roll out a targeted program? Provide different scenarios	Subgroup 2 – Vaccine distribution and program implementation	Completed - Taskforce developing implementation plans and SG 2 providing technical advice	Y		
18-Sep-20	4.4	COVID 19 vaccine Taskforce to meet with S47F to further explore scenarios to be tested	COVID-19 Vaccine Taskforce and Subgroup 2 Lead	Completed	Y		
18-Sep-20	4.5	Test Communication Strategy with various advisory groups including COVID-19 ATAGI working Group	COVID-19 Vaccine Taskforce and Subgroup 3 – Vaccine Safety, Evaluation, Monitoring and Confidence	Completed	Y		
18-Sep-20	4.6	Update ATAGI webpage to include information about the	ATAGI Secretariat	Completed, website page forwarded to	Y		
18-Sep-20		ATAGI COVID-19 Working Group Arrange a meeting with AstraZeneca to brief the ATAGI COVID-		comms team			
	5.1	Arrange a meeting with Astrazeneca to brief the ATAGI COVID- 19 Working Group	COVID-19 Vaccine Support Section	Completed - meeting held 20 October	Y		
18-Sep-20	5.2	ATAGI to provide the Department with themes/questions they would like to discuss with AstraZeneca	ATAGI Co-Chairs	Completed - Questions to AZ 23/9	Y		
18-Sep-20	5.3	Provide overview brief of what NITAGS are doing in the COVID-	NCIRS	Completed 9 October 2020 and on	Y		
24-Sep-20	2.1	19 space	Secretariat	Sharepoint			
		Upload draft communication plan on a page on Sharepoint		Completed	Y		
24-Sep-20	2.2	Provide feedback on communication plan, including suggestions to disseminate information to key groups	Members	Completed	Y		
24-Sep-20	2.3	Incorporate feedback and bring revised plan back to Working	Jodie Grieve	Completed (update at half day	Y		
24-Sep-20		Group Update ATAGI website with information about Working Group		information session 10 November Completed - preliminary information			
	2.4	and Subgroups	ATAGI Secretariat	published 9 October	Y		
24-Sep-20	2.5	Seek advice from Subgroup members regarding publication of names on website	ATAGI Secretariat	Completed (on SG meeting agendas)	Y		
		interior in cosite	ATAGI Secretariat				

24-Sep-20	4.1	Plan to bring Subgroup members together for half day information sharing (end of October)	ATAGI Secretariat	Completed - discussed at Exec meeting 9/10 (to be held in November)	Y
24-Sep-20	4.2	Embed process to seek Executive approval of Subgroup documents	ATAGI Secretariat and Subgroup leads	Completed	Y
24-Sep-20	5.1	Arrange Friday meetings commencing 9 October	ATAGI Secretariat	Completed	Y
9-Oct-20 9-Oct-20	2.1	Seek written consent from all subgroup members to publish na	ATAGI Secretariat ATAGI Secretariat	Completed	Y
9-Oct-20	2.2	Organise half day session for all members in November Advise on the process around information prepared by the	Lisa Schofield	Scheduled for 10 November Completed - update provided at Exec	Y
	4.1	ATAGI COVID-19 Working Group and whether further input is needed		meeting 23/10	Y
9-Oct-20 9-Oct-20	4.2	Extend invitation to s47F Advise on next steps in relation to discussion papers on workfor	s47F	Completed Completed - update provided at Exec	Y
	5		Lisa Schofield	meeting 23/10	Y
9-Oct-20	6	Email to be sent to ATAGI members seeking confirmation regar	Taskforce	Completed	Y
9-Oct-20 9-Oct-20	8.1 8.2	Clarify what COVID-19 stakeholder briefings have been done or Discuss stakeholder briefings with Lisa Schofield	s47F	Completed Completed	Y Y
9-Oct-20	9	Organise meeting with ACV and ATAGI Chairs subject to advice from Lisa Schofield	ATAGI Secretariat	Completed - TGA rep (responsible for ACV) attending Exec 13/11 (Allen Cheng also in	Ŷ
16-Oct-20	2.1	Seek written consent to publish member names on website	ATAGI COVID-19 Working Group	attendance) Completed	Y
16-Oct-20	2.2	Half day information sharing for Subgroups: 1-5pm AEDT,	Secretariat ATAGI COVID-19 Working Group	Completed	Y
16-Oct-20	2.3	Tuesday 10 November 2020 Outline timeframes for when key deliverables from Subgroups	Secretariat COVID-19 Taskforce	Completed - update provided at Exec	Y
16-Oct-20	2.4	can be shared with stakeholders Centralise international documents on SharePoint	ATAGI COVID-19 Working Group	meeting 23/10 Completed - centralised resource area	Y
16-Oct-20	3.1	Invite the additional members to Subgroup 1 and Subgroup 2	Secretariat and NCIRS s47F and ATAGI COVID-19 Working	established on sharepoint Completed	Y
16-Oct-20	4.1	Arrange meeting with Health Modelling Team	Group Secretariat COVID-19 Taskforce	Completed - SG1 meeting 27/10	Y
16-Oct-20	4.2	Develop a pathway to manage adverse events – link in with TGA pathways and pharmacovigilance plan	Sub-group 3	Completed - TGA presentation at SG3 16/10 and ongoing discussions	Ŷ
16-Oct-20	5.1	Respond to email sent by S47F on 15/10/2020 regarding probity arrangements	All AstraZeneca meeting attendees	Completed	Y
16-Oct-20	6.1	Provide members with a list of confirmed attendees	COVID-19 Taskforce/ Secretariat	Completed	Y
16-Oct-20 16-Oct-20	7.1	Develop standardised consent form/ framework in line with normal practices Create master list/straw man of the resources that will be	NCIRS and Sub-group 2	Completed - endorsed by SG2 4/11 and to Exec	Y
23-Oct-20	7.2	required Taskforce to consider ATAGI Working Group's list of	NCIRS	Completed – on Exec agenda 23/10	Y
23-Oct-20	3	documents/deliverables and liaise with s47F Clarify timing and clearance requirements for an expedited	Lisa Schofield	Completed - discussed Exec meeting 30/10	Y
	4.1	Handbook process	Hope Peisley	Completed - discussed Exec meeting 30/10	Y
23-Oct-20 23-Oct-20	4.2	Add Handbook chapter to workplan Prepare list of outward facing documents/advice required for	NCIRS	In progress	Y
23-Oct-20	4.3	consideration at next Exec meeting	NCIRS SATE	Completed - discussed Exec meeting 30/10	Y
23-Oct-20	5	Forward both Subgroup 1 endorsed documents to Taskforce Provide feedback to NCIRS on draft program phases and	Secretariat	Completed 26/10	Y
23-Oct-20	6 8.1	program communication resources	Exec Team members Secretariat	Completed Completed	Y Y
23-Oct-20	8.2	Invite TGA rep to update Exec Team fortnightly	Secretariat	Completed (first update provided by email 28/10)	Y
30-Oct-20	2.1.1	Key members from Subgroup 1 and NCIRS to meet with data modellers	s47F	Completed - emails sent and dates being determined	Y
30-Oct-20	2.1.2	Arrange meetings with CSL and Astrazeneca in Nov/Dec 2020	Secretariat	Completed	Y
30-Oct-20	3.1	Discuss with Health Comms whether a forward fating statement, communique or annotated agenua can be released for the session	Hope Peisley/Secretariat	Completed - under discussion for Exec agenda 6/11	Y
30-Oct-20	3.2	Discuss with Taskforce Whether JJCS can attend the session	Hope Peisley/Secretariat	Completed (separate session to be held)	Y
30-Oct-20	3.3	Meet to develop agenda and content	s47F	Completed 4/11	Y
30-Oct-20	3.4	Prepare a one page summary for consideration by Lisa Schofield to publish on ATAGI webpage	S47F /Lisa Schofield	Completed - S4 and S4 published article in The Conversation 2/12/20	Y
30-Oct-20	5.1	Circulate list of ATAGI deliverables	Taskforce	Discussed at meeting on 6/11 - see item 2.1 below	Y
30-Oct-20	5.2	Circulate list of outward facing advice/ documents developed by NCIRS	Secretariat	Completed	Y
30-Oct-20	5.3	Obtain advice from NHMRC re an expedited Handbook process	Hope Peisley	Completed	Y
6-Nov-20	2.1	Provide advice to Working Group re priority issues to be addressed	Taskforce	Completed - initial advice provided by email 2/12/20	Y
6-Nov-20	3.1	Raise member concerns with the Department's Executive	Co-chair	Completed	Y
6-Nov-20 6-Nov-20	3.2 3.3	Provide copy of Secretary's letter to Working Group Organise information session with JICs	Secretariat Secretariat	Completed Completed	Y Y
6-Nov-20	4		Secretariat	Completed - communique drafted (not	Y
6-Nov-20	5.1.1	Draft public communique following information session List questions that need to be answered through further data	Secretariat Subgroup 1 representatives	published yet) Completed	Y
6-Nov-20	5.1.2	modelling work Invite TGA rep to next meeting	Secretariat	Completed	Y
6-Nov-20	5.1.2	Arrange meetings with Pfizer and Novovax	Secretariat	Completed	Y
6-Nov-20	5.2.1	Develop a table scoping consent issues in workplace settings	NCIRS	Completed	Ŷ
6-Nov-20	5.2.2	Provide endorsed Working Group documents to JIC	Taskforce/Secretariat	Discussed by Taskforce 4 December 2020 (some docs attached to jur implmn plans)	Y
		Circulate two documents (Vaccine Policy and ATAGI advice on priority populations) subject to Government approval	Taskforce/Secretariat	Completed 13/11	Y
13-Nov-20	4.1				

v b iri L S 2 c 3 p 7 C 3 p 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c	Vap core training components required for COVID-19 vaccines, existing vaccine training programs and how they can be adapted to upskill providers, any gaps and consider nternational training programs Gend endorsed Equipment Checklist to Taskforce, subject to my further comments Bring ATAGI documents on multi-dose vials to ICEG for consideration when ready Develop an appendix to the Clinical guidance document with preliminary information on vaccine candidates, and bring to next meeting Confirm legislative requirements around consultation imeframes with NHMRC Revise Roles, Responsibilities and Reporting lines document as nformation becomes available consider next steps for documents endorsed by Working	NCIRS S47F) and Subgroup 2 with assistance from Subgroup 3 on international programs NCIRS/Secretariat S47F NCIRS S47F)/ Secretariat Hope Peisley	Completed Completed Completed (see 20/11 item 6.2.6) Completed	Y Y Y Y	
b ir a 2 b 2 c c c c c c c c c c c c c c c c c	be adapted to upskill providers, any gaps and consider nternational training programs Siend endorsed Equipment Checklist to Taskforce, subject to my further comments Bring ATAGI documents on multi-dose vials to ICEG for consideration when ready Develop an appendix to the Clinical guidance document with reliminary information on vaccine candidates, and bring to next meeting Confirm legislative requirements around consultation imeframes with NHMRC Revise Roles, Responsibilities and Reporting lines document as nformation becomes available	international programs NCIRS/Secretariat S47F NCIRS S47F)/ Secretariat	Completed Completed (see 20/11 item 6.2.6)	Y Y	
ir S S C C C C C C C C C C C C C C C C C	nternational training programs iend endorsed Equipment Checklist to Taskforce, subject to any further comments sring ATAGI documents on multi-dose vials to ICEG for consideration when ready Develop an appendix to the Clinical guidance document with oreliminary information on vaccine candidates, and bring to next meeting Confirm legislative requirements around consultation imeframes with NHMRC Revise Roles, Responsibilities and Reporting lines document as nformation becomes available	NCIRS/Secretariat S47F NCIRS S47F)/ Secretariat	Completed (see 20/11 item 6.2.6)	Y	
L a 2 c 3 p 1 3 p 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	any further comments aring ATAGI documents on multi-dose vials to ICEG for consideration when ready Develop an appendix to the Clinical guidance document with oreliminary information on vaccine candidates, and bring to next meeting Confirm legislative requirements around consultation imeframes with NHMRC Revise Roles, Responsibilities and Reporting lines document as nformation becomes available	S47F NCIRS S47F)/ Secretariat	Completed (see 20/11 item 6.2.6)	Y	
2 B c C D D D D D D C C C C C C C C C C C C	Bring ATAGI documents on multi-dose vials to ICEG for consideration when ready Develop an appendix to the Clinical guidance document with reliminary information on vaccine candidates, and bring to next meeting Donfirm legislative requirements around consultation imeframes with NHMRC Revise Roles, Responsibilities and Reporting lines document as nformation becomes available	NCIRS S47F)/ Secretariat			
C C C C C C C C C C C C C C C C C C C	Develop an appendix to the Clinical guidance document with oreliminary information on vaccine candidates, and bring to next meeting Confirm legislative requirements around consultation imeframes with NHMRC Revise Roles, Responsibilities and Reporting lines document as nformation becomes available	NCIRS S47F)/ Secretariat			
3 p n C ti R ir C G G	oreliminary information on vaccine candidates, and bring to rext meeting Confirm legislative requirements around consultation imeframes with NHMRC Revise Roles, Responsibilities and Reporting lines document as nformation becomes available		Completed	Y	
C ti R ir C G	Confirm legislative requirements around consultation imeframes with NHMRC Revise Roles, Responsibilities and Reporting lines document as nformation becomes available	Hope Peisley			
ti R ir C G	imeframes with NHMRC Revise Roles, Responsibilities and Reporting lines document as nformation becomes available	Hope Peisley			
R ir C G	Revise Roles, Responsibilities and Reporting lines document as nformation becomes available		Completed (legislated 30 days)	Y	
C		Taskforce	Completed (Taskforce provided comment	Y	
G			to Exec on initial draft)		
	Group	Taskforce	Completed 4 December 2020	Y	
В	Bring incident list to next meeting for discussion	s47F / Secretariat	Circulated by s47F 23/11	Y	
li li	nvite TGA to next meeting to discuss incident management	Secretariat	Completed	Y	
P	Provide data modelling advice to Lisa Schofield for further	Secretariat	Completed	Y	
		Members	Completed	Y	
р 3	Provide H1N1 Lessons Learned document to Subgroups 1 and	Secretariat	Completed - see SG2 action items 18/11	Y	
P	Prepare summary of ATAGI endorsed papers and next steps to		(SGI advised at meeting 1/12)		
		Secretariat	Completed	Y	
n					
2		Taskforce	Completed 4 December 2020	Y	
		Construction of APPE	Completed 1/12/20	Y	
		Secretariat/S47F			
		Secretariat	Completed 2/12/20	Y	
		Subgroup 3	Cox has mapped out its internal govt response processes for confirmed significant safety situals, including Inkages, and building on established pathways. SG9 has done scenario planning and will continue to discuss.	Y	
	Provide draft Subgroup 2 desuments to TCA for internal use	Secretariate 475		v	
		Secretariat/S4	Completed		
		Taskforce	Completed	Y	
F	Further consider prioritisation of critical worker and other	Subgradual		Y	
			Completed - discussed SG1 1/12		
			Completed	Y	
				N N	
		Secretariat	Completed - discussed SG1 1/12		
d	data 💦 🕹	Secretariat and TGA	Completed	Y	
		NCIRS and Secretariat	Completed	Y	
R	Revisit priority populations advice	Subgroup 1	Completed (SG1 meeting 22/12)		
C	Develop principles by January on managing COVID-19 and			Y	
-		Subgroup 1	Completed (see SG1 8/12, item 5)	Y Y	
F	Fluvax rollout			Y	
F P C	Fluvax rollout Provide members with summary of ATAGroocuments and categories for next steps (internal/external)	Subgroup 1 Secretariat	Completed (see SG1 8/12, item 5) Completed		
F P C P	Iluvax rollout Provide members with summan of ATAG documents and ategories for next steps (internal/external) Provide members with update on DG atmental meeting 4/12	Secretariat		Y	
F P C P ri	Fluvax rollout Provide members with summary of ATAGroocuments and categories for next steps (internal/external)		Completed	Y Y	
F P C P rr D A	Iluva: rollout Provide members with summan of ATAG documents and ategories for next steps (internal/external) Provide members with update on Departmental meeting 4/12 re data modelling Discuss evaluation planning to clarify responsibilities Add agenda item to information session on 15/12 to discuss	Secretariat Lisa Schofield Taskforce	Completed Completed – email 4/12 Completed	Y Y Y	
F P c P ru D A e	Iluva: rollout Provide members with summan of ATAG documents and ategories for next steps (internal/external) Provide members with update on Departmental meeting 4/12 re data modelling Discuss evaluation planning to clarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training,	Secretariat Lisa Schofield	Completed Completed – email 4/12	Y Y Y Y	
F P C P rr D A e S C C	Iluva: rollout Provide members with summan) of ATAG documents and attegories for next steps (internal/external) Provide members with update on DEpartmental meeting 4/12 e data modelling Discuss evaluation planning to clarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, iafety) Cancel remaining Exec meetings for 2020	Secretariat Lisa Schofield Taskforce	Completed Completed – email 4/12 Completed	Y Y Y	
F P C P r C C C A e S S C C	Iluva: rollout Provide members with summan of ATAG documents and actegories for next steps (Internal/external) Provide members with update on Departmental meeting 4/12 e data modelling Discuss evaluation planning toclarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, safety) Advise Secretariat of leave arrangements over Christmas/New	Secretariat Lisa Schofield Taskforce Secretariat	Completed Completed – email 4/12 Completed Completed	Y Y Y Y Y Y	
F P C P P rr D C C C C C C C Y	Iluva: rollout Provide members with summan) of ATAG documents and attegories for next steps (internal/external) Provide members with update on DEpartmental meeting 4/12 e data modelling Discuss evaluation planning to clarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, iafety) Cancel remaining Exec meetings for 2020	Secretariat Lisa Schofield Taskforce Secretariat Secretariat All	Completed Completed – email 4/12 Completed Completed Completed Completed	Y Y Y Y	
F P C C P P r r C D C C C C C C	Iluvar vollout Provide members with summary of ATAG documents and ategories for next steps (internal/external) Provide members with update on Departmental meeting 4/12 te data modelling Discuss evaluation planning toclarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, rafety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New fear	Secretariat Lisa Schofield Taskforce Secretariat Secretariat	Completed Completed – email 4/12 Completed Completed Completed	Y Y Y Y Y Y	
F P C C P T T A A e S S C C A Y Y C C P	Iluvar rollout Provide members with summan) of ATAG documents and ategories for next steps (Internal/external) Provide members with update on DEPartmental meeting 4/12 re data modelling Siscuss evaluation planning toclarify responsibilities Add agenda item to information session (2000) Siscuss evaluation and other areas of possible duplication (training, afety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New (ear Dirculate latest information from TGA on its	Secretariat Lisa Schofield Taskforce Secretariat Secretariat All	Completed Completed – email 4/12 Completed Completed Completed Completed	Y Y Y Y Y Y Y	
F P C P Tri C A A e S S C C C P C C P S S S	Iluvar vollout Provide members with summary of ATAGrdocuments and attegories for next steps (internal/external) Provide members with rundate on DePartmental meeting 4/12 e data modelling Discuss evaluation planning toclarify responsibilities Add agenda item to information session (2007) 15/12 to discuss evaluation and other areas of possible duplication (training, tafety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New (ear Circulate latest information from TGA on its bharmacovigilance plan for COVID-19 vaccines	Secretariat Lisa Schofield Taskforce Secretariat Secretariat All Lisa Schofield	Completed Completed – email 4/12 Completed Completed Completed Completed Completed	Y Y Y Y Y Y	
F P C P P T C C C C C C C C C C C C C C C	Iluvar vollout Provide members with summany of ATAG documents and ategories for next steps (internal/external) Provide members with update on DEPartmental meeting 4/12 te data modelling Discuss evaluation planning toclarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, tarlety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New (ear Circulate latest information from TGA on its soharmacovigilance plan for COVID-19 vaccines Send invitations for next combined info session (2 February)	Secretariat Lisa Schofield Taskforce Secretariat Secretariat All Lisa Schofield	Completed Completed – email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed	Y Y Y Y Y Y Y	
F P C P P T C C C C C C C C C C C C C C C	Iluva: rollout Provide members with summan) of ATAG documents and attegories for next steps (internal/external) Provide members with update on DEPartmental meeting 4/12 e data modelling Discuss evaluation planning to clarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, tafety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New (ear Circulate latest information from TGA on its pharmacovigilance plan for COVID-19 vaccines Seend invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and	Secretariat Lisa Schofield Taskforce Secretariat Secretariat All Lisa Schofield Secretariat	Completed Completed – email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed Completed week of 11/1/21 Completed - discussed Exec meeting	Y Y Y Y Y Y Y Y	
F P C P P T C C C C C C C C C C C C C C C	Iluva: rollout Provide members with summan) of ATAG documents and attegories for next steps (internal/external) Provide members with update on DEPartmental meeting 4/12 e data modelling Discuss evaluation planning to clarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, tafety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New (ear Circulate latest information from TGA on its pharmacovigilance plan for COVID-19 vaccines Seend invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and	Secretariat Lisa Schofield Taskforce Secretariat Secretariat All Lisa Schofield Secretariat	Completed Completed – email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed	Y Y Y Y Y Y Y Y	
F P C P P T C C C C C C C C C C C C C C C	Iluva: rollout Provide members with summan) of ATAG documents and attegories for next steps (internal/external) Provide members with update on DEPartmental meeting 4/12 e data modelling Discuss evaluation planning to clarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, tafety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New (ear Circulate latest information from TGA on its pharmacovigilance plan for COVID-19 vaccines Seend invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and	Secretariat Lisa Schofield Taskforce Secretariat Secretariat All Lisa Schofield Secretariat	Completed Completed – email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed Completed week of 11/1/21 Completed - discussed Exec meeting 8/1/21 - ATAGI advice sought re what	Y Y Y Y Y Y Y Y	
F P C D D A e e S S C C C C C C C C C C C C C C C C	Iluvar vollout Provide members with summan) of ATAGr documents and attegories for next steps (internal/external) Provide members with update on DEpartmental meeting 4/12 e data modelling Discuss evaluation planning toclarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, iafety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New Cear Circulate latest information from TGA on its pharmacovigilance plan for COVID-19 vaccines Send invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and AZ vaccines	Secretariat Lisa Schofield Taskforce Secretariat All Lisa Schofield Secretariat NCIRS	Completed Completed – email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed Completed week of 11/1/21 Completed - discussed Exec meeting 8/1/21 - ATAGI advice sought re what consent means and how it will work with	Y Y Y Y Y Y Y Y	
F P C D D A e e S S C C C C C C C C C C C C C C C C	Iluvar vollout Provide members with summan) of ATAGr documents and attegories for next steps (internal/external) Provide members with update on DEpartmental meeting 4/12 e data modelling Discuss evaluation planning toclarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, iafety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New Cear Circulate latest information from TGA on its pharmacovigilance plan for COVID-19 vaccines Send invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and AZ vaccines	Secretariat Lisa Schofield Taskforce Secretariat All Lisa Schofield Secretariat NCIRS	Completed Completed – email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed Completed Completed veek of 11/1/21 Completed - discussed Exec meeting 8/1/21 - ATAGI advice sought re what consent means and how it will work with different populations	Y Y Y Y Y Y Y Y	
F P C P P P P A C C C P P C C P P C C C P C C C C	Iluvar rollout Provide members with summan) of ATAG documents and attegories for next steps (Internal/external) Provide members with undate on DEPartmental meeting 4/12 (e data modelling) Siscuss evaluation planning toclarify responsibilities Add agenda item to information session (2) 15/12 to discuss evaluation and other areas of possible duplication (training, afety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New (ear Circulate latest information from TGA on its sharmacovigilance plan for COVID-19 vaccines send invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and AZ vaccines Advise re any Government decision about consent Draft mud map of COVID-19 Committees and how they	Secretariat Lisa Schofield Taskforce Secretariat All Lisa Schofield Secretariat NCIRS	Completed Completed – email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed Completed week of 11/1/21 Completed - discussed Exec meeting 8/1/21 - ATAGI advice sought re what consent means and how it will work with	Y Y Y Y Y Y Y Y	
F P C P P P P A C C C P P C C P P C C C P C C C C	Iluvar vollout Provide members with summan) of ATAGrodocuments and ategories for next steps (internal/external) Provide members with update on Departmental meeting 4/12 e data modelling Discuss evaluation planning toclarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, iafety) Circulate latest information from TGA on its obarmacovigilance plan for COVID-19 vaccines Send invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and Az vaccines	Secretariat Lisa Schofield Taskforce Secretariat All Lisa Schofield Secretariat NCIRS	Completed Completed – email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed Completed week of 11/1/21 Completed - discussed Exec meeting 8/1/21 - ATAGI advice sought re what consent means and how it will work with different populations	Y Y Y Y Y Y Y Y	
F P C P P P P A C C C P P C C P P C C C P C C C C	Iluvar rollout Provide members with summan) of ATAG documents and attegories for next steps (Internal/external) Provide members with undate on DEPartmental meeting 4/12 (e data modelling) Siscuss evaluation planning toclarify responsibilities Add agenda item to information session (2) 15/12 to discuss evaluation and other areas of possible duplication (training, afety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New (ear Circulate latest information from TGA on its sharmacovigilance plan for COVID-19 vaccines send invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and AZ vaccines Advise re any Government decision about consent Draft mud map of COVID-19 Committees and how they	Secretariat Lisa Schofield Taskforce Secretariat All Lisa Schofield Secretariat NCIRS Taskforce	Completed - email 4/12 Completed - email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed Completed exec meeting 8/1/21 - ATAGI advice sought re what consent means and how it will work with different populations	Y Y Y Y Y Y Y Y Y	
F P C C P C A A e e S C C C C C C C C C C C C C C C C C	Iluvar rollout Provide members with summan) of ATAGrodocuments and attegories for next steps (Internal/external) Provide members with update on Departmental meeting 4/12 e data modelling Discuss evaluation planning toclarify responsibilities Add agenda then to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, safety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New (ear Circulate latest information from TGA on its sharmacovigilance plan for COVID-19 vaccines Send invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and Az vaccines Advise re any Government decision about consent Draft mud map of COVID-19 Committees and how they ntegrate with one another	Secretariat Lisa Schofield Taskforce Secretariat All Lisa Schofield Secretariat NCIRS Taskforce	Completed - email 4/12 Completed - email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed Completed exec meeting 8/1/21 - ATAGI advice sought re what consent means and how it will work with different populations	Y Y Y Y Y Y Y Y Y	
F P C D D A A e e S C C C C C C C C C C C C C C C C C	Iluvar rollout Provide members with summan) of ATAGr documents and attegories for next steps (Internal/external) Provide members with undate on Departmental meeting 4/12 te data modelling Discuss evaluation planning to clarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, tarlety) ancel remaining Exec meetings for 2020 Advise Secretariat of leave transferments over Christmas/New (ear Circulate latest information from TGA on its pharmacovigilance plan for COVID-19 vaccines Send invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and Advise re any Government decision about consent Draft mud map of COVID-19 Committees and how they ntegrate with one another Provide draft consent documents (currently on Sharepoint) to	Secretariat Lisa Schofield Taskforce Secretariat All Lisa Schofield Secretariat NCIRS Taskforce Taskforce	Completed - email 4/12 Completed - email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed Completed week of 11/1/21 Completed - discussed Exec meeting 8/1/21 - ATAGI advice sought re what consent means and how it will work with different populations	Y Y Y Y Y Y Y Y Y	
F P C D D A A e e S C C C C C C C C C C C C C C C C C	Iluvar rollout Provide members with summan) of ATAGrodocuments and attegories for next steps (Internal/external) Provide members with update on Departmental meeting 4/12 e data modelling Discuss evaluation planning toclarify responsibilities Add agenda then to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, safety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New (ear Circulate latest information from TGA on its sharmacovigilance plan for COVID-19 vaccines Send invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and Az vaccines Advise re any Government decision about consent Draft mud map of COVID-19 Committees and how they ntegrate with one another	Secretariat Lisa Schofield Taskforce Secretariat All Lisa Schofield Secretariat NCIRS Taskforce	Completed - email 4/12 Completed - email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed Completed exec meeting 8/1/21 - ATAGI advice sought re what consent means and how it will work with different populations	Y Y Y Y Y Y Y Y Y	
F P C D D A A e s S C C C C A A Y Y C C C C A A S C C C C C C C C C C C C C	Iluvar rollout Provide members with summan) of ATAG documents and attegories for next steps (Internal/external) Provide members with undate on Departmental meeting 4/12 (e data modelling) Siscuss evaluation planning to clarify responsibilities Add agenda item to information session (p) 15/12 to discuss evaluation and other areas of possible duplication (training, lardety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave transferments over Christmas/New (ear Circulate latest information from TGA on its pharmacovigilance plan for COVID-19 vaccines Send invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and Advise re any Government decision about consent Advise re any Government decision about consent Draft mud map of COVID-19 Committees and how they ntegrate with one another Provide draft consent documents (currently on Sharepoint) to G2 and Executive for discussion at next meetings Provide further advice to ATAGI Exec on consent issue and	Secretariat Lisa Schofield Taskforce Secretariat All Lisa Schofield Secretariat NCIRS Taskforce Taskforce	Completed - email 4/12 Completed - email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed Completed week of 11/1/21 Completed - discussed Exec meeting 8/1/21 - ATAGI advice sought re what consent means and how it will work with different populations	Y Y Y Y Y Y Y Y Y	
F P C C P C C C C C C C C C C C C C C C	Iluvar rollout Provide members with summan) of ATAGr documents and attegories for next steps (internal/external) Provide members with update on Departmental meeting 4/12 e data modelling Discuss evaluation planning to clarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, tafety) ancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New (ear Circulate latest information from TGA on its pharmacovigilance plan for COVID-19 vaccines Seend invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and AZ vaccines Advise re any Government decision about consent Draft mud map of COVID-19 Committees and how they ntegrate with one another Provide draft consent documents (currently on Sharepoint) to SG2 and Executive for discussion at next meetings Provide further advice to ATAGI Exec on consent issue and deliverables required, including whether standard/consistent	Secretariat Lisa Schofield Taskforce Secretariat All Lisa Schofield Secretariat NCIRS Taskforce Secretariat Secretariat	Completed – email 4/12 Completed – email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed week of 11/1/21 Completed - discussed Exec meeting 8/1/21 - ATAGI advice sought re what consent means and how it will work with different populations Taskforce is progressing priority implementation activities and this item has been overtaken by events (Jan 2021) In progress	Y Y Y Y Y Y Y Y Y	
F P C C P C C C C C C C C C C C C C C C	Iluvar rollout Provide members with summan) of ATAG documents and attegories for next steps (Internal/external) Provide members with undate on Departmental meeting 4/12 (e data modelling) Siscuss evaluation planning to clarify responsibilities Add agenda item to information session (p) 15/12 to discuss evaluation and other areas of possible duplication (training, lardety) Cancel remaining Exec meetings for 2020 Advise Secretariat of leave transferments over Christmas/New (ear Circulate latest information from TGA on its pharmacovigilance plan for COVID-19 vaccines Send invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and Advise re any Government decision about consent Advise re any Government decision about consent Draft mud map of COVID-19 Committees and how they ntegrate with one another Provide draft consent documents (currently on Sharepoint) to G2 and Executive for discussion at next meetings Provide further advice to ATAGI Exec on consent issue and	Secretariat Lisa Schofield Taskforce Secretariat All Lisa Schofield Secretariat NCIRS Taskforce Taskforce	Completed - email 4/12 Completed - email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed Completed week of 11/1/21 Completed - discussed Exec meeting 8/1/21 - ATAGI advice sought re what consent means and how it will work with different populations	Y Y Y Y Y Y Y Y Y	
F P C P P C C C C C C C C C C C C C C C	Iluvar rollout Provide members with summan) of ATAGroutments and attegories for next steps (internal/external) Provide members with update on Departmental meeting 4/12 e data modelling Discuss evaluation planning toclarify responsibilities Add agenda item to information session on 15/12 to discuss evaluation and other areas of possible duplication (training, afety) ancel remaining Exec meetings for 2020 Advise Secretariat of leave arrangements over Christmas/New (ear Circulate latest information from TGA on its pharmacovigilance plan for COVID-19 vaccines Send invitations for next combined info session (2 February) Prepare the first tranche of provider materials for Pfizer and Az vaccines Advise re any Government decision about consent Draft mud map of COVID-19 Committees and how they ntegrate with one another Provide draft consent documents (currently on Sharepoint) to G2 and Executive for discussion at next meetings Provide further advice to ATAGI Exec on consent issue and deliverables required, including whether standard/consistent nformation should be provided across Australia	Secretariat Lisa Schofield Taskforce Secretariat All Lisa Schofield Secretariat NCIRS Taskforce Secretariat Secretariat	Completed – email 4/12 Completed – email 4/12 Completed Completed Completed Completed Completed Completed Completed Completed week of 11/1/21 Completed - discussed Exec meeting 8/1/21 - ATAGI advice sought re what consent means and how it will work with different populations Taskforce is progressing priority implementation activities and this item has been overtaken by events (Jan 2021) In progress	Y Y Y Y Y Y Y Y Y	
2 2 3		participants Provide draft Subgroup 3 documents to TGA for internal use Meet to consider approvals, additional advice and roles/responsibilities and advise ATAGI re next steps Further consider prioritisation of critical worker and other special risk groups, along with ring fencing Provide two documents to Taskforce – mandatory vaccination policies and workforce training gap analysis Add TSANZ letter to Subgroup 1 agenda Draft letters to vaccine sponsors requesting access to vaccine data Incorporate further feedback from members and forward safety advice to Taskforce Revisit priority populations advice	discussions and consideration within Dept Members Provide comments on H1NI paper Members Provide comments on H1NI paper Members Provide comments on H1NI paper Members Provide H1N1 Lessons Learned document to Subgroups 1 and 3 Secretariat Prepare summary of ATAGI endorsed papers and next steps to assist in tracking documents and share with the Executive Group Secretariat Develop process for approval of key ATAGI WG documents, including outward facing Taskforce Send MDV Guideline paper to ICEG Secretariat for comment Secretariat Secretariat Secretariat Quert proposed incident management team and key participants Subgroup 3 Provide draft Subgroup 3 documents to TGA for internal use Secretariat.s477 Meet to consider approvals, additional advice and roles/responsibilities and advise ATAGI re next steps Taskforce Further consider prioritisation of critical worker and other special risk groups, along with ring fencing Subgroup 1 Provide two documents to Taskforce – mandatory vaccination policies and workforce training gap analysis Secretariat Add TSANZ letter to Subgroup 1 agenda Secretariat molTGA Nicht synchic to Taskforce Secretariat Bride two documents advise afrom members and forward safety advice to Taskforce <td>discussions and consideration within Dept Completed Provide comments on data modelling paper Members Completed Provide comments on HDV Guideline Members Completed Provide thIN1 Lesons Learned document to Subgroups 1 and 3 Secretariat Completed - see SG2 action items 18/11 Provide summary of ATAGI endorsed papers and next steps to assist in tracking documents and share with the Executive Group Secretariat Completed Develop process for approval of key ATAGI WG documents, including outward facing Taskforce Completed 1/12/20 Send MDV Guideline paper to ICEG Secretariat for comment Subgroup 3 Secretariat Completed 1/12/20 Value out proposed incident management team and key participants Subgroup 3 Secretariat Subgroup 3 Completed 2/12/20 Provide draft Subgroup 3 documents to TGA for internal use Secretariat Subgroup 3 Secretariat Subgroup 3 Evertariat Subgroup 3 Provide draft Subgroup 3 documents to TGA for internal use Secretariat Subgroup 1 Completed - discussed SG1 1/12 Provide draft Subgroup 3 documents to TGA for internal use Secretariat Subgroup 1 Completed - discussed SG1 1/12 Provide draft Subgroup 3 documents to TGA for internal use Secretariat Subgroup 1 Completed - discussed SG1 1/12 Provide draft Subgroup 3</td> <td>discussions and consideration within Dept </td>	discussions and consideration within Dept Completed Provide comments on data modelling paper Members Completed Provide comments on HDV Guideline Members Completed Provide thIN1 Lesons Learned document to Subgroups 1 and 3 Secretariat Completed - see SG2 action items 18/11 Provide summary of ATAGI endorsed papers and next steps to assist in tracking documents and share with the Executive Group Secretariat Completed Develop process for approval of key ATAGI WG documents, including outward facing Taskforce Completed 1/12/20 Send MDV Guideline paper to ICEG Secretariat for comment Subgroup 3 Secretariat Completed 1/12/20 Value out proposed incident management team and key participants Subgroup 3 Secretariat Subgroup 3 Completed 2/12/20 Provide draft Subgroup 3 documents to TGA for internal use Secretariat Subgroup 3 Secretariat Subgroup 3 Evertariat Subgroup 3 Provide draft Subgroup 3 documents to TGA for internal use Secretariat Subgroup 1 Completed - discussed SG1 1/12 Provide draft Subgroup 3 documents to TGA for internal use Secretariat Subgroup 1 Completed - discussed SG1 1/12 Provide draft Subgroup 3 documents to TGA for internal use Secretariat Subgroup 1 Completed - discussed SG1 1/12 Provide draft Subgroup 3	discussions and consideration within Dept

		ATAGI COVID-19 Subgroup 1 Vaccino ut	• •		
		Subgroup 1. Vaccine ut Record of meet	lisation and prioritisation		
Meeting date	Action item	Action	Responsible officer/s	Progress / Comments	Complete
15-Sep-20	6.1	Update and finalise ATAGI COVID Vaccine Preliminary Advice document and Prioritisation Matrix in line with the Preliminary COVID-19 vaccination priority Review and edit preliminary advice document groups List prioritisation principles with no reference to ranking Map cohorts to the prioritisation principles Remove colour coding. Insert caveat for all principles where information is not available	* Sub Group Members * NCIRS * Co-chairs	Complete	Y/N Y
22-Sep-20	3.1	Gather data on numbers of aged care workers, health care workers and people in at-risk occupations in states/territories to guide decision making	NCIRS	Prioritisation matrix has estimates for occupation groups nationally (may need Dept to source population numbers for occupation groups at jurisdictional level if required)	Y
22-Sep-20	3.2	Develop a request for consideration by the Taskforce outlining key input and expertise required by this Subgroup	s47F in consultation with members	Completed - new members agreed at Exec meeting 24/9	Y
22-Sep-20	4.1	4.1 Circulate data on at-risk groups to members	NCIRS	Completed - see 14/12, item 4	Y
44096	4.2	4.2 Gather data on specific populations to understand the landsca	NCIRS	Completed - see 14/12, item 4	Y
22-Sep-20	4.3	4.3 Contact NIR and request presentation on latest data eg NSW data on health care workers and VIC data	Secretariat	Completed, presentation on 6/10	Y
22-Sep-20	5.1	5.1 Circulate questions for AstraZeneca to members for comment	Secretariat	Completed -questions provided to AZ Sept 2020	Y
22-Sep-20	6.1	6.1 Prepare a summary list of documents under development by NCIRS for the sharepoint site to assist with tracking and identifying gaps	Secretariat	Completed 3/11 - currently populating with appropriate content 17/11	Y
6-Oct-20	5	Provide further questions and answers following meeting	Members/Martyn Kirk	Completed	Y
6-Oct-20	6.1	Further discussion to define aims of program	Secretariat	Completed – on Executive meeting agenda for 9/10	Y
6-Oct-20 6-Oct-20	6.2 6.3	Summarise issues and continue discussion by email Complete prioritisation framework by 30 October	S47F and members Members and NCIRS	Completed Completed - to Exec 23/10	Y Y
6-Oct-20	7	Place all Subgroup agenda papers on Sharepoint	Secretariat	Completed	Y
13-Oct-20	3	Seek confirmation from members to publish names website	Secretariat	Completed	Y
13-Oct-20	6.1	Provide comments via email or Sharepoint on preliminary advice document by Friday 16/9 and prioritisation framework by Monday 19/10	Members	Completed	Y
13-Oct-20	6.2	Collate comments and provide revised abcuments for next meeting	s47F and NCIRS	Completed - agenda for 20/10	Y
20-Oct-20 20-Oct-20	4.1 4.2	Amend and finalise preliminary advice document Submit to Taskforce following Co-Chair Executive endorsement	NCIRS and S47F	Completed 21/10/20 Completed 21/10/20	Y Y
20-Oct-20	c	Submit to Taskforce following endorsement by Executive	Secretariat	Completed 26/10/20	Y
20-Oct-20	6	Invite Department's data modellers to provide a half hour presentation on data modelling relevant to this group	Secretariat	Presentation for 27/10	Y
20-Oct-20	7.1	Invite TGA representative to present on TGA approval process	Secretariat	$\begin{array}{l} \mbox{Completed (update provided to Exec} \\ \mbox{Team by email and} {}^{s47E}_{s47E(c)} & \mbox{invited to Exec} \\ \mbox{following return from leave early Nov} \end{array}$	Y
20-Oct-20	7.2	Liaise with S47F regarding sharing of information with the COVID-19 Aboriginal Taskforce	Secretariat	Completed	Y
27-Oct-20	4.1	Allyson Essex to consider further information to be provided to Subgroup 1 and liaise with members on data modelling work, including feasibility of sandpit approach	Allyson Essex	Completed - meeting 5/11	Y
27-Oct-20	5.1	Email Allyson Essex outlining Subgroup's thinking and offering to collaborate and provide input	s47F	Completed	Y
27-Oct-20	5.2	Continue discussions at Executive meeting and Subgroup 1 meetings	Secretariat	Completed - initial meeting with data modelling branch 5/11	Y
27-Oct-20	5.3	Prepare brief paper on data modelling requirements	Subgroup 1/ NCIRS	Completed - meeting of 17/11	Y
3-Nov-20	5.1	Provide Allison Essex with the group's prioritisation document as p	Secretariat	Completed	Y
3-Nov-20	5.2	Organise modelling sandpit session with Allison Essex	Secretariat	Completed	Y
17-Nov-20	3.1	Invite TGA to update at next SG1 meeting	Secretariat	Complete	Y
17-Nov-20	6.1	All interested SG1 members to review modelling advice and provide edits and comments by Wednesday morning	SG1	Complete	Y
17-Nov-20	6.2	Submit data modelling recommendations to Executive Group for consideration	NCIRS/Secretariat	Complete	Y
24-Nov-20	6.1	Prepare a detailed presentation on the Oxford Vaccine for discussion at the next meeting	NCIRS	Completed	Y
1-Dec-20 8-Dec-20	4	Upload NCIRS draft document re critical workers on Sharepoint Provide a more detailed breakdown of priority populations and	NCIRS	Completed	Y
		staged rollout by month or quarter according to predicted vaccine doses available	NCIRS/Subgroup 1	Completed - see 14/12 item 4	Y
8-Dec-20		Recommend how next year's flu vaccine program will interface with COVID vaccine rollout	NCIRS	Completed - see 5/1/21	Y

8-Dec-20	6	Add questions for meeting with Pfizer	NCIRS	Completed	Y
14-Dec-20	4.1	Provide a more nuanced prioritisation and month by month phase by number of available doses	Subgroup 1/NCIRS	Completed - revised prioritisation advice provided to Taskforce 24/12/20	Y
14-Dec-20	4.2	Discuss logistics and delivery issues with subgroup 2	Subgroup 1	Completed - share session 15/12/20, Exec meetings etc	Y
14-Dec-20	4.3	Finalise documents that detail/map at risk groups	NCIRS	Completed Dec 2020	Y
14-Dec-20	4.4	Provide jurisdictional data on priority population numbers to subgroup 1	s47F, s47E(c) /Secretariat	Completed	Y
22-Dec-20	3	Provide further feedback on draft prioritisation advice in next 24 hours	Members	Completed	Y
22-Dec-20	3	Provide input in relation to GPs and prioritisation	s47F	Completed	Y
22-Dec-20	3	Incorporate member comments to enable revised version to be circulated to Subgroup 1	NCIRS/S47F	Completed	Y
22-Dec-20	3	Provide prioritisation advice to Executive Group for endorsement by 24 December	Secretariat	Completed	Y
5-Jan-21	5	Incorporate Subgroup 1 comments and put revised draft Clinical Advice Statement on sharepoint	NCIRS	In progress	Y
5-Jan-21	5	Refer revised version of Clinical Advice Statement to Subgroups 2 and 3 for input/comment	s47F	In progress	
5-Jan-21	5	Finalise revised Clinical Advice Statement next week for consideration by Exec on 15 January	All	In progress	
5-Jan-21	5	Seek Product Information for Pfizer vaccine	Secretariat	Completed - publicly available info put on sharepoint 8/1/21	Y
5-Jan-21	6	Provide comment on draft flu document for discussion at next SG1 meeting on 12 January and finalisation for consideration by Exec on 15 January	All	In progress	
12-Jan-21	4	Include agenda item for Exec meeting re ATAGI meetings with Janssen and Moderna	Secretariat	Completed	Y

retariat complete retariation re

			OVID-19 Working Group istribution and program impler	nentation				
Record of meeting outcomes								
Meeting date	Action item	Action	Responsible officer/s	Progress / Comments	Complete Y/N			
16-Sep-20	4.1	Prepare discussion paper on logistics and issues of distributing frozen COVID-19 Vaccines	NCIRS technical support	Completed	Y			
44090	4.2	Review learnings from 2009 PanVax Program	NCIRS	Completed (on SG2 agenda 4/11 and held over to next meeting)	Y			
16-Sep-20	4.3	Prepare discussion paper on immunisation workforce- capacity, competencies and training needs.	NCIRS technical support	Completed	Y			
16-Sep-20	4.4	Prepare discussion paper on information systems to track distribution and coverage of COVID-19 vaccines	NCIRS technical support	NFA - referred to Commonwealth/ Taskforce	Y			
23-Sep-20	2.1	Update membership list and circulate	Secretariat	Completed	Y			
23-Sep-20	3.1.1	Finalise paper on frozen vaccines following further input from members and consideration at next Subgroup meeting - include high level summary at beginning; clear recommendations and conclusions; and reference to Commonwealth Request for Tender (RFT) to review system readiness	s47F	Completed following SG2 meeting on 30 September 2020	Y			
23-Sep-20	3.1.2	Develop another piece of work	NCIRS	Now part of paper at 3.1.1	Y			
23-Sep-20	3.1.3	incorporating different scenarios Consider availability and cost of freezers and transporting of vaccines	Sarah Sinclair	Referred to Taskforce	Y			
23-Sep-20	3.1.4	Circulate public information on RFT to members	Secretariat	Completed	Y			
23-Sep-20	3.2.1	incorporating different scenarios Consider availability and cost of freezers and transporting of vaccines Circulate public information on RFT to members Finalise paper on workforce competencies following further input from members and consideration at next Subgroup meeting Report back to members at next meeting regarding JIC discussions, intersect with this Subgroup and respective roles Develop list of other pieces of work to be undertaken Update workplan in Sharepoint as required	s47F rele AC and	Completed following SG2 meeting on 30 September 2020	Y			
23-Sep-20	3.3.1	Report back to members at next meeting regarding JIC discussions, intersect with this Subgroup and respective roles	s475th the	On agenda for 30/9 meeting	Y			
23-Sep-20	4.1	Develop list of other pieces of work to be undertaken	NCIRS	On agenda for 30/9 meeting	Y			
23-Sep-20	4.2	Update workplan in Sharepoint as required	NCIRS	Updated late September and ongoing	Y			
23-Sep-20	5.1	Organise a test of videoconferencing with members	Secretariat	Completed	Y			
30-Sep	3	Members to send comments to Secretariat in relation to possible publication of pames	Members	Completed - no further comments received	Y			
30-Sep	4	Place item on Exec agenda re possible TGA rep on Subgroup 2	Secretariat	Completed for Exec meeting 9/10	Y			
30-Sep	5.1	Finalise paper on frozen vaccines following further input from members, for consideration at Exec meeting 9/10	s47F	Completed	Y			
30-Sep	5.2	Finalise paper on workforce competencies following further input from members for consideration at Exec meeting 9/10	s47F	Completed	Y			
30-Sep	6	Place item on Exec agenda re Subgroup 2 proposed work	Secretariat	Completed for Exec meeting 9/10	Y			
30-Sep	8.1	8.1 Move meeting times to Wednesdays from 12-1pm	Secretariat	Completed	Y			
30-Sep	8.2	8.2 Consolidate information already gathered on AIR data quality and present at next meeting	NCIRS	Completed - on agenda for SG2 meeting 7/10	Y			
30-Sep	8.3	8.3 Provide draft points on multidose vials at next meeting	NCIRS	Completed - on agenda for SG2 meeting 7/10	Y			
7-Oct	3.1	3.1 Executive Group to discuss TGA representative	Executive Group	Not discussed on 9/10 and now on hold	Y			
7-Oct	3.2	3.2 Executive Group to discuss publication of member names online	Executive Group	Completed – discussed on 9/10, proceed subject to written confirmation from members	Y			
7-Oct	3.3	3.3 Executive Group to endorse workforce and frozen vaccine discussion papers	Executive Group	Completed	Y			

	<u>.</u>				
7-Oct	4.1	4.1 WG 2 to develop list of consumables, both a 'minimum requirements' list and more detailed version.	NCIRS	Completed	Y
7-Oct	5.1	5.1 Members to send through any further comments or questions on MDV in writing.	Members	Completed	Y
7-Oct	5.2	5.2 NCIRS to update MDV paper following discussion, including addition of section on implications for different clinical settings	NCIRS	Completed	Y
7-Oct	5.3	5.3 Discuss at Executive meeting this group developing a checklist for site requirements necessary to deliver COVID vaccines	Secretariat	Completed – discussed at Exec meeting 9/10	Y
7-Oct	5.4	5.4 NCIRS to discuss AIR paper with Tracie Hibbard	NCIRS	Completed	Y
14-Oct	4.1	4.1 Invite S47F, S47E(C) from the Gene Technology Policy Section to the next meeting to discuss: • whether the proposed vaccines are considered GMO, and • if so, what are the disposal requirements?	Secretariat	Update provided 28/10	Y
14-Oct	5.3	5.3 Will the vaccines have serial numbers?	Taskforce	Completed, dicussed with taskforce.	Y
14-Oct	5.4	5.4 Raise issue of implementation / track and trace software at the Executive Working Group and report back	Secretariat	to be discussed at SG #3 with AIR Representative 30 October	Y
14-Oct	5.5	5.5 Develop a Discussion Paper on consent	NCIRS	Completed	Y
14-Oct	5.6	5.6 Members to review both checklists and updated MDV paper on SharePoint prior to seeking endorsement at the next meeting	Members	Email reminder sent from Secretariat on 19 October, for discussion 28/10	Y
21-Oct	3.1	3.1 Seek an update from the Taskforce at the next meeting about the AstraZeneca & Seqirus information and implementation.	Taskforde	Discussions ongoing at Exec WG and JIC. Completed.	Y
21-Oct	3.2	3.2 Executive WG meeting Friday 23/10: add item for discussion (following meetings with Sponsors this week) regarding the regulatory pathway timing for both AstraZeneca & Seqirus and how this impacts implementation timelines.	NCIRS Members Taskforce	Discussions ongoing at Exec WG and JIC. Completed.	Y
21-Oct	4.1	4.1 Secretariat to raise issue of training at JIC either Thursday 22/10 or the following week.	Secretariat	Complete. Added to agenda for 19/11.	Y
21-Oct	4.2	 Week. 4.2 • Update MDV paper to include a recommendation that nationally consistent training on use of MDVs is required (both for routine providers and new immunisation providers). • Review updated MDV paper out of session, ahead of endorsement at the next meeting. 	NCIRS, Members	Endorsed 28/10	Y
21-Oct	4.3	4.3 Taskforce to provide an update on PPE being purchased at the next meeting.	Taskforce	Update provided 28/10	Y
21-Oct	5.1	5.1 Review and comment on the following documents on SharePoint by Monday 26 October, for endorsement at next meeting: o Checklists; o Consent discussion paper; o AIR discussion paper; and o Clinical guidance.	Members	Complete.	
21-Oct	6.1	6.1 NCIRS to produce a list of 'outward facing' ATAGI advice / actions for program implementation, for consideration by the Executive WG & Taskforce	NCIRS	Completed	Y
28-Oct	2.1	2.1 Taskforce to follow up what level discussions have been held on the proposed implementation approach.	Taskforce	Completed – discussed at Executive Meeting 30/10	Y
28-Oct	2.2	2.2 S47F to follow up discussion regarding the rationale for these decisions	s47F	Completed – discussed at Executive Meeting 30/10	Y

4-Nov	3.1	3.1 Seek list of consumables to be shared	Cocrotoriat	Complete upleaded to ChareDeint	
4-1107	5.1	with SG#2	Secretariat	Complete, uploaded to SharePoint.	
4-Nov	3.2	3.2 S47F to follow up the pathway for key documents (e.g. NHMRC and other groups e.g. RACGP).	s47F	Complete.	
4-Nov	3.3	3.3 Discuss H1N1 paper at next meeting	Secretariat	Complete (added to agenda for 11/11).	Y
44146	2.1	2.1 Revise the MDV Clinical Guidance to incorporate group comments	Subgroup 2/NCIRS	Complete	Y
44146	2.2	2.2 Early engagement with the Infection Control Expert Group	Subgroup 2/ <mark>S47F</mark>	Completed - raised by S47F at ICEG meeting on 11/11 and to be discussed at Exec meeting on 13/11	Y
11-Nov	2.3	2.3 Consult with the Executive on consultation procedures for outward facing documents	Subgroup 2 /Secretariat	Completed	Y
11-Nov	2.4	2.4 Recall the Checklist for Equipment, make revisions, and resubmit to Executive for endorsement	NCIRS/Secretariat	Completed – for Exec meeting 13/11	Y
11-Nov	3.1	3.1 Track progress of PRODA transition and continue discussions at Executive meetings	Subgroup 2/Secretariat	Completd - ongoing	Y
18-Nov-20	2.1	 2.1 NCIRS to update H1N1 paper to include: a statement noting need to consider safety; and add recommomendation on uptake 	NCIRS	Completed - for Exec meeting 20/11	Y
18-Nov-20	2.2	2.2 Provide H1N1 paper to Executive Group for endorsement Friday 21/11	Secretariat Secretariat Secretariat	Complete, on agenda for Executive Group Friday 20/11	Y
18-Nov-20	2.3	2.3 Provide a copy of the H1N1 paper to WG#3 (and #1) once endorsed by the Executive Group	Secretariat	completed (on SharePoint)	Y
18-Nov-20	2.4	2.4 Follow up sharing of papers with JIC and more broadly in jurisdictions	Secretariat	Completed - for Exec meeting 20/11	Y
18-Nov-20	3.1	3.1. Provide updated MDV Clinical Guidance to Executive Group for endorsement Friday 20/11	Secretariat	Complete, on agenda for Executive Group Friday 20/11.	Y
18-Nov-20	3.2	3.2 Members agreed to review the Overview of mandatory vaccination policies the paper on SharePoint and provide any comments by Monday 23 November 2020	Members	Complete	Y
25-Nov-20	3.1	Draft a surge workforce plan	NCIRS	In progress	
13-Jan-21	2	Finalise Multidose vials paper, incorperative ICEG edits as agreed by members, for Executive endoresment on 15 January	SG2/NCIRS	In progress	
13-Jan-21	2.2	Finalise suite of consect upcuments for SG2 endoisement 20 January, review by SG3 chair, and Edecutive endorsement on 22 January	SG2/NCIRS	In progress	

		ATAGI COVID-19 Worki	ng Group		
		Subgroup 3. Vaccine safety, evaluation	, monitoring and confider	nce	
		Record of meeting out	comes		
Meeting date	Action item	Action	Responsible officer/s	Progress / Comments	Complete Y/N
18-Sep-20	4.1	Sub Group 3 to review the Communications Strategy being developed by the Department of Health	COVID-19 Vaccine Taskforce	Discussed at meeting 2/10	Y
18-Sep-20	5.1	Small working group to be established to develop a framework regarding 'vaccine confidence' as part of the COVID-19 readiness planning	s47F s47F	Held first meeting 29/9	Y
18-Sep-20	6.1	Schedule fortnightly meetings for Subgroup 3 - Friday 1.30-2.30pm using videoconference platform	COVID-19 Vaccine Support Section	Completed	Y
2-Oct-20	2	Send Secretariat suggested revised wording for workplan from 'Covid vaccine' to 'effective and safe Covid vaccine'	s47F	Completed	Y
2-Oct-20	3	Subgroup members to send comments to Secretariat in relation to possible publication of names	Members	Completed - no comments received at 11 October	Y
2-Oct-20	4.1.1	Fortnightly agenda item – key themes/updates on Commonwealth communication strategy	Jodie Grieve/ ^{\$47F, \$47E(c)}	Completed - standing agenda item	Y
44106	4.1.2	Use Sharepoint page as a central repository for resources and communication pieces	Secretariat	Completed - separate section created on Sharepoint	Y
2-Oct-20	4.1.3	Agenda for next meeting to include item on community resources that car be shared, including regional components	Secretariat	Completed - on agenda for 16/10	Y
	4.2.1	Share COSSI strategy with members	s47F	Completed	
2-Oct-20	5	More information on the ATAGI subgroup#3 Confidence & Communication framework to be provided for next meeting	s47F /NCIRS	Completed - on agenda for 16/10	Y
16-Oct-20	3.1	Seek written consent to publish member names on website.	ATAGI COVID-19 Working Group Secretariat	Completed	Y
16-Oct-20	3.2	Half day information sharing meeting for Subgroups: 1-5pm AEDT, Tuesday 10 November 2020.	ATAGI COVID-19 Working Group Secretariat	Members notified by email 23/10	Y
16-Oct-20	4.1	Draft high level list of communication activities to be placed on SharePoint	COVID-19 Taskforce	Completed - ^{\$47F, \$47E(c)} provides fortnightly comms updates at SG3 meetings	Y
16-Oct-20	5.1	TGA to establish COVID Standing Committee and draft Terms of Reference	TGA INC	Completed FICA issue and not for ATAGI (discussed with ^{\$47F, \$47E(c)} 13/11)	Y
16-Oct-20	6.1	Members to provide feedback on AESI discussion paper	Subgroup 3 Members	Completed	Y
16-Oct-20	6.2	Members to provide feedback on the SARS-CoV-1 / MERS-CoV Vaccine- associated Enhanced Disease discussion paper	Subgroup 3 Members	Completed	Y
30-Oct-20	2.1	Finalise preliminary advice on safety including AESI	Subgroup 3	Completed - taking to Exec for endorsement 4/12/20	Y
30-Oct-20	3.1	Invite Government agency working with linked data to Subgroup 3 meeting to discuss linking to the AIR	Secretariat	In progress	N
30-Oct-20	3.2	Prepare brief document outlining a range of evaluation options and timings	NCIRS IS47F	Completed (see 17/12 item 4.1)	Y
30-Oct-20	5.1	Bring ATAGI communications advice to next Subgroup 3 meeting for endorsement	NCIRS/Secretariat	Completed	Y
26-Nov-20	4.1	Forward Comms advice to Executive for endorsement	Secretariat	Completed	Y
26-Nov-20	5.1	Incorporate changes to draft safety advice and circulate to members for comment by next week	NCIRS/Secretariat/Members	Completed	Y
26-Nov-20	7.1	Conduct scenario planning next week, 3 December 2020	Subgroup 3	Completed	Y
3-Dec-20	4.1	Forward safety advice to Executive for endorsement	Secretariat	Completed	Y
10-Dec-20	4.1	Circulate information on how and when to contact the news team	Secretariat/ ^{\$47F, \$47E(c)}	To progress	N
17-Dec-20	4.1	Provide high level evaluation framework by mid-January 2021	Subgroup 3/NCIRS	In progress	N
17-Dec-20	4.2	Circulate link to Canada's playbook	Secretariat	Completed	Y
17-Dec-20	5	Seek members' availability and topic interests for smaller group evaluation workshop	Secretariat	Completed	Y

THIS FICE DEP the the by

Record of meeting outcomes							
Meeting date	Action item	Action	Responsible officer/s	Progress / Comments	Complete Y/N		
10-Nov-20	2.1	Develop a list of issues/threats for scenario planning and proposed responses	s47F, s47E(c) and Subgroup 3	Completed	Y		
10-Nov-20	2.2	Provide feedback to Jodie Grieve on Commonwealth Communications plan and activities	All members	Ongoing/Completed	Y		
10-Nov-20	2.3	Provide information to Secretariat on COVID-19 vaccine misinformation to assist Comms to respond	All members	Ongoing/completed	Y		
10-Nov-20	2.4	Publish information on ATAGI webpage about Working Group activities	Taskforce/Secretariat	Ongoing/Completed	Y		
10-Nov-20	3.1	Develop a list of products endorsed by the ATAGI COVID-19 Working Group for consideration by the Taskforce re next steps	Secretariat/Taskforce	Completed	Y		
10-Nov-20	3.2	Develop a holistic view of work underway through ATAGI and the Taskforce and approval pathways	^{s47F} /Taskforce	Completed	Y		
10-Nov-20	3.3	Provide feedback on stakeholders to Secretariat	All members	Completed	Y		
10-Nov-20	4.1	Outline the scope of work required to develop a more comprehensive modelling strategy for consideration by the Department	s47F and SG1 members with modelling expertise	Completed	Y		
10-Nov-20	5.1	Develop roles and responsibilities summary with clear workflows and reporting lines	Chairs, Subgroup leads, NCISS and Taskforce	Completed (implementation plan under development)	Y		
10-Nov-20	6.1	Raise indemnity issues with Taskforce	Hope Peisley	Raised at Exec meeting on 13/11	Y		

the the by

Australian Technical Advisory Group on Immunisation (ATAGI) COVID-19 Working Group Information Sharing Session 10 November 2020, 1-5pm Outcomes

In attendance:		1
Executive members	Subgroup 3 members	Department of Health
Chris Blyth (Co-Chair)	Nigel Crawford (Lead)	s47E(c), s47F
Allen Cheng (Co-Chair)	Tony Korman	Sarah Sinclair
Katie Flanagan	Margie Danchin	s47E(c), s47F
Robyn Gibbs	Deb Petrys	Jodie Grieve
Nigel Crawford	Diane Walsh	s47E(c), s47F
s11C	Alan Leeb	
Lisa Schofield	s47E(c), s47F	
Nick Henderson	John Kaldor	
Hope Peisley	Paul Effler	
Subgroup 1 members	Cheryl Jones	ĸ
Katie Flanagan (Lead)	NCIRS technical support	S &
Bette Liu	s11C	
Tom Snelling		
Jodie McVernon		Secretariat
Penny Burns	and the second sec	and the second s
Angus Dawson		
Kanta Subbarao		
James Wood	Chi i Ohi i O	
Kirsten Howard	Do all all	
Subgroup 2 members	S Mr. Los	
Robyn Gibbs (Lead)	A KO K K	Apologies
Annaliese van Diemen		Michelle Giles
Madeline Hall		Christine Selvey
Madeline Hall Karen Bellamy Katherine Gibney Nick Silberstein Lena Sanci	As been released of a ct and a	James Ward
Katherine Gibner		David Durrheim
Nick Silberstein	Q	Christopher Etherton-Beer
Lena Sanci		
Scott Brown		

1. Meeting Opened

Members:

- NOTED attendees and apologies
- DECLARED no conflicts of interest

Co-chairs thanked all participants for their contribution to this work

2. Commonwealth Communications activities

- NOTED an update from Jodie Grieve on Commonwealth Communications activities including regular:
 - Website updates (health.gov.au)
 - $\circ \quad \text{Social media}$
 - GP webinars and newsletters
 - o Media engagement
 - Engagement with Subgroup 3 on vaccine confidence and communications

- NOTED work underway including:
 - consumer research to inform the development of targeted communications in 2021 0
 - development of a searchable COVID-19 vaccine hub to provide quick and easy access 0 to information
 - o plans to publish information on the ATAGI webpage
- DISCUSSED the importance of early engagement with jurisdictions and the immunisation workforce
- AGREED to undertake scenario planning to assist with addressing vaccine implementation issues quickly

Action	Responsible	e officer/s	Progress
Develop a list of issues/threats for scenario planning	s47E(c), s47F	and	In progress
and proposed responses	Subgroup 3		
Provide feedback to Jodie Grieve on Commonwealth	All member	S	In progress
Communications plan and activities			
Provide information to Secretariat on COVID-19	All member	'S	In progress
vaccine misinformation to assist Comms to respond			
Publish information on ATAGI webpage about	Taskforce/S	ecretariat	In progress
Working Group activities		0	NO NO
OVID-19 Vaccine Strategy Taskforce update Members: • NOTED an update from Lisa Schofield including:	2580,09	Aged	<i>.</i>

3. COVID-19 Vaccine Strategy Taskforce update

- NOTED an update from Lisa Schofield including:
 - Government announcement on 5 November 2020 about two new purchase agreements with Novavax and Pfizer
 - Government consideration of Subgroup 1 advice on priority populations
 - Engagement with Health CEOs, Australian Health Protection Principal Committee, 0 Jurisdictional Immunisation Coordinators, Communicable Diseases Network Australia and others
 - Plans to commence bilateral meetings with jurisdictions on implementation 0
- NOTED the audience and approval pathway for ATAGI Working Group advice will depend on • the product and that the and scape for program related materials needs to be defined
- NOTED consumer perspectives including the need to: •
 - o expand the stakeholder list and utilise relationships with Primary Health Networks
 - provide clear information, including on TGA processes and priority populations 0

Action 🔗	Responsible officer/s	Progress
Develop a list of products endorsed by the ATAGI	Secretariat/Taskforce	In progress
COVID-19 Working Group for consideration by the		
Taskforce re next steps		
Develop a holistic view of work underway through	^{s47F} /Taskforce	In progress
ATAGI and the Taskforce and approval pathways		
Provide feedback on stakeholders to Secretariat	All members	In progress

4. Subgroup 1 update - Priority populations and scenario modelling

- NOTED a presentation by ^{\$47F} covering:
 - Preliminary advice on general principles to guide the prioritisation of target populations in a COVID-19 vaccination program
 - Preliminary advice on suitability of the Oxford/AstraZeneca vaccine for possible priority populations

- Modelling requirements for an Australian COVID-19 Vaccine Program 0
- NOTED the Department is developing two models Economic cost and Distribution •
- DISCUSSED the need for a model with various epidemiological and health outcomes (that links to the two existing models) which requires a distinct and specialist skillset

Action	Responsible of	fficer/s	Progress
Outline the scope of work required to develop a	s47F	and SG1	In progress
more comprehensive modelling strategy for	members with	modelling	
consideration by the Department	expertise		

5. Subgroup 2 update – Program implementation issues

Members:

- NOTED a presentation by^{s47F} covering program implementation issues including:
 - Multidose vials 0
 - Workforce
 - Australian Immunisation Register 0
- DISCUSSED the importance of clear roles, responsibilities and reporting lines for the • Commonwealth, states and territories including better definition of ATAGI and NCIRS roles
- DISCUSSED workforce issues including the need for clarity around development of training

Action	Responsible officer/s Progress
Develop roles and responsibilities summary	Chairs, Subgroup leads, In progress
with clear workflows and reporting lines	NCIRS and Taskforce

6. Subgroup 3 update - Vaccine safety, confidence, communication and education

Members:

- NOTED a presentation by Nigel Crawford covering: Education and training Safety Indemnity

 - Indemnity 0
 - Evaluation 0
- NOTED the Commonwealth is undertaking consultations on proposed mandatory reporting • to the Australian Immunisation Register (AIR), with a proposed implementation date of 1 March 202 Ø

0

AGREED that Subgroup 3 would prepare advice regarding evaluation of a COVID-19 • immunisation program

Action	Responsible officer/s	Progress
Raise indemnity issues with Taskforce	Hope Peisley	Raised at Exec
		meeting on 13/11

7. Gaps, key issues and draft recommendations

- NOTED key issues/recommendations covered in this session included:
 - Need to develop advice on data modelling
 - Workforce training and model of vaccine delivery
 - Clarity in relation to indemnity
 - Incident management strategy (roles and reporting) 0
 - AIR 0
 - 0 Communications strategy

- Meetings with vaccine sponsors
- TGA information sharing

8. Next steps

- Members thanked NCIRS staff for preparing papers for this session and:
- AGREED on the following priorities for the Working Group:
 - Advice on roles, responsibilities and reporting lines
 - o Plan potential incidences and develop incident management strategies
 - Epidemiological modelling
 - o Communications including the Department's COVID-19 hub
- AGREED to hold another information sharing session in mid-December and include Aboriginal and Torres Strait Islander vaccination issues on the agenda